lab_id,phase,challengeVitalStatus,challengeOverallSurvival,dbgap_dnaseq_sample,dbgap_rnaseq_sample,dbgap_subject_id,patientId,cohort.x,cohort.y,used_manuscript_analyses,manuscript_dnaseq,manuscript_rnaseq,manuscript_inhibitor,consensus_sex,inferred_sex,reportedRace,reportedEthnicity,inferred_ethnicity,centerID,CEBPA_Biallelic,consensusAMLFusions,ageAtDiagnosis,isRelapse,isDenovo,isTransformed,specificDxAtAcquisition_MDSMPN,nonAML_MDSMPN_specificDxAtAcquisition,priorMalignancyNonMyeloid,priorMalignancyType,cumulativeChemo,priorMalignancyRadiationTx,priorMDS,priorMDSMoreThanTwoMths,priorMDSMPN,priorMDSMPNMoreThanTwoMths,priorMPN,priorMPNMoreThanTwoMths,dxAtInclusion,specificDxAtInclusion,ELN2017,dxAtSpecimenAcquisition,specificDxAtAcquisition,ageAtSpecimenAcquisition,timeOfSampleCollectionRelativeToInclusion,specimenGroups,diseaseStageAtSpecimenCollection,specimenType,rnaSeq,exomeSeq,totalDrug,analysisRnaSeq,analysisExomeSeq,analysisDrug,cumulativeTreatmentTypeCount,cumulativeTreatmentTypes,cumulativeTreatmentRegimenCount,cumulativeTreatmentRegimens,cumulativeTreatmentStageCount,cumulativeTreatmentStages,responseToInductionTx,typeInductionTx,responseDurationToInductionTx,mostRecentTreatmentType,currentRegimen,currentStage,mostRecentTreatmentDuration,vitalStatus,overallSurvival,causeOfDeath,X..Basophils.in.PB,X..Blasts.in.BM,X..Blasts.in.PB,X..Eosinophils.in.PB,X..Immature.Granulocytes.in.PB,X..Lymphocytes.in.PB,X..Monocytes.in.PB,X..Neutrophils.in.PB,X..Nucleated.RBCs.in.PB,ALT,AST,albumin,creatinine,fabBlastMorphology,hematocrit,hemoglobin,karyotype,LDH,MCV,otherCytogenetics,plateletCount,surfaceAntigensImmunohistochemicalStains,totalProtein,wbcCount,FLT3.ITD,allelic_ratio,NPM1,RUNX1,ASXL1,TP53,variantSummary
13-00118,training,Dead,1378,BA2236D,BA2236R,2446,685,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,54,TRUE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,57,349,Relapse|Post-Chemotherapy,Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,7,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",5,Consolidation|Salvage|Induction|Re-induction|Maintenance,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,Decitabine,Re-induction,160,Dead,1378,Dead-Disease,3,71,83,2,,5,10,4,,35,31,3.9,0.81,M4,33.7,11.7,"47,XY,+21[17]/47,idem,t(10;22)(q22;q13)[cp3]/46,XY[1]",438,100.6,80% Trisomy 21,119,"CD13, CD33, CD38, CD58, dim CD64, CD117, and CD123",7.1,33.8,negative,0,positive,,,,
13-00149,training,Dead,267,BA2360D,BA2360R,2298,1049,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Female,White,NON-HISPANIC,White,1,bi,,78,FALSE,FALSE,FALSE,FALSE,FALSE,y,Bladder Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,79,0,Post-Chemotherapy|Residual Disease,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,Decitabine,Induction,-1,Dead,267,Dead-Disease,0,87,72,1,,17,4,1,,19,41,3.4,0.75,,32.3,10.6,"45,X,-Y[19]/46,XY[1]",460,103.6,Normal,15,"CD7, CD13, CD33, partial CD34, CD117, CD123, HLA-DR, MPO +",6.2,8.5,negative,0,negative,,,,CEBPA (1031?1032 ins AAC; MAF 50%)|CEBPA (347?348 del GACCTGT; MAF 50%)|WT1 (p.R369R; MAF 50%)
13-00157,training,Alive,1379,BA2235D,BA2235R,2407,1054,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,60,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,60,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,MiDAC,Consolidation,104,Alive,2801,Alive,0,80,,0,,11,13,23,,32,50,2.9,0.64,M2,41.1,13.4,"46,XX[20]",660,86.1,normal,228,"partial CD7, partial CD11b, CD13, CD33, dim CD45, CD58,     partial CD64, partial CD117, CD123, dimHLA-DR,  MPO positive",7.4,53.9,negative,0,positive,,,,DNMT3A (p.Q696fs*9; MAF 40% )|IDH1 (p.R132H; MAF 40%)|NPM1 (p.W288fs*12; MAF ~40%)|PTPN11 (p.G503A; MAF 40%)
13-00160,training,Dead,1165,BA2858D,BA2858R,2087,967,Waves1+2,Waves1+2,no,no,no,no,Male,Male,White,NON-HISPANIC,White,1,,,70,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,73,93,Post-Chemotherapy,Remission,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|Azacitidine",2,Induction|Maintenance,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,Azacitidine,Maintenance,-1,Dead,1165,Dead-Unknown,,,,,,,,,,,,,,,,,"46,XY[19]",,,Normal,,,,,negative,0,negative,,,,
13-00163,leaderboard,Alive,400,BA3038D,BA3038R,2278,1058,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,Multiracial,HISPANIC,HispNative,1,,CBFB-MYH11,24,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,24,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine, Methotrexate|Busulfan, Cyclophosphamide",3,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1,Alive,3041,Alive,0,50,,0,,19,52,16,,,,,,M4,26.3,9.2,"47,XY,inv(16)(p13q22),+22[20]",,91.5,62.5% CBFB rearrangement|74% BCR/ABL/ASS,53,"- 14% Myeloid blasts: CD13, CD34, CD38, CD58, partial CD64,     CD117, CD123,          HLA-DR, and MPO positive     - 30% Monoblasts/promonocytes: CD11b, CD13, CD14, CD38, CD58, bright CD64,     HLA-DR, and MPO",,13.8,negative,0,negative,,,,KIT (p.D816H; MAF ~50%)|WT1 (rs16754; MAF ~50%)
13-00165,training,Dead,439,BA3006D,BA3006R,2239,1060,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,3,,,33,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,33,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|HAM (Cytarabine, Mitoxantrone)",4,Allogeneic - Sibling|Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Sibling,-1,Dead,439,Dead-Treatment,,70.8,,,,,,,,,,,,M2,,,"46,XX[7] ",,,,,"increased CD117 positive, partial CD34 positive myeloblasts,   representing approximately 91% of the leukocytes, consistent with acute myeloid leukemia",,,positive,4,positive,,,,FLT3-ITD|NPM1
13-00166,training,Dead,1020,BA2245D,BA2245R,2173,1061,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,65,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,67,0,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,8,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cladribine",6,Hypomethylating/Low Dose Cytarabine|Salvage|Consolidation|Unknown|Induction|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,Cladribine,Unknown,5,Dead,1020,Dead-Unknown,0,,77,0,,15,1,3,,18,10,3.6,1.01,M2,28.1,9.3,,132,93.5,,22,,6.3,19.5,negative,0,negative,,,,
13-00186,training,Dead,126,BA2667D,BA2667R,2286,1072,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,Unknown,UNKNOWN,White,1,,,74,FALSE,FALSE,TRUE,FALSE,FALSE,n,,n,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,74,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,126,Dead-Unknown,0,60,,1,,26,18,24,,250,160,3.2,0.59,M2,22,7.1,"46,XY[20]",399,87.4,,107,"partial CD7, CD13, CD33, CD34, CD38, CD58, CD117, CD123, TdT, and HLA-DR positive",7,11.8,negative,0,negative,RUNX1 (p.A142Gfs*4; 32.2%),,,RUNX1 (p.A142Gfs*4; MAF 30% )|SRSF2 (p.P95L; MAF 48%)
13-00195,training,Alive,972,BA2239D,BA2239R,2326,1078,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,66,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,66,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,MiDAC,Consolidation,74,Alive,2756,Alive,0,90,,0,,14,61,1,,19,14,2.4,1.13,M5,23.9,7.9,"46,XY[20]",387,103.6,normal,122,"CD11b, dim/partial CD13, CD14, CD33, CD38, CD58, CD64,     partial CD117, dim/partial CD123, and HLA-DR positive",6.3,28,negative,0,positive,,,,CREBBP (p.Q2208H; MAF 50%)|DNMT3A (p.R882H; MAF 50%)|NPM1 (W288fs*>9; MAF 50%)|WT1 (rs16754; MAF 50%)
13-00204,training,Dead,7,BA2649D,BA2649R,2097,1088,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,PML-RARA,65,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,65,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"ATRA (Tretinoin)|3+7 (Cytarabine, Daunorubicin)",1,Induction,Unknown,Standard Chemotherapy,5,Standard Chemotherapy,"3+7 (Cytarabine, Daunorubicin)",Induction,3,Dead,7,Dead-Other,0,72,57,0,,36,1,8,,24,33,2.9,0.6,M3,20.7,6.8,"46,X,der(X)add(X)(p22.1)add(X)(q22~24),add(7)(p15),der(15)t(15;17)(q22;q21),der(17)t(15;17)(q22;q21)inv(17)(q21q21)del(17)(q21)[17]/46,XX[3] (unusual PML-RARA translocation)",398,90.2,"76% Unusual t(15;17), with the fusion signal on the derivative chromosome 15",10,"partial CD2, CD13, CD33, partial CD34, CD117, CD123, MPO-positive",5.6,9.8,positive,,negative,,,,FLT3-ITD (MAF 40%)|SF3B1 (p.K66N; MAF 40%)|WT1 (rs16754; MAF 50%)
13-00226,training,Alive,1429,BA2488D,BA2488R,2489,928,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,PML-RARA,83,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,83,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),3,"Ruxolitinib|ATRA, Arsenic Trioxide|Idarubicin",3,Induction|Maintenance|Symptom Control,Complete Response,Standard Chemotherapy,253,Standard Chemotherapy,Idarubicin,Symptom Control,0,Alive,2806,Alive,0,75,70,0,,17,2,23,,14,9,3.7,0.7,M3,23.4,8.1,"46,XX,t(15;17)(q24;q21)[12]/46,XX,idem,del(16)(q12.1q24)[3]/46,XX[5]",367,86.2,7% 16q deletion,,"CD13, CD33, partial CD34, CD64, CD117, CD123, and MPO-positive",6.8,6,negative,0,negative,,,,FLT3-D835 (D835H; MAF Unlisted)|JAK2 (p.V617F; MAF 90%)
13-00232,leaderboard,Alive,1001,BA2861D,BA2861R,2015,1101,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,mono,,22,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,22,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Matched Unrelated Donor,-1,Alive,2729,Alive,0,56,55,2,,7,33,24,,67,16,2.2,0.64,M4,24,8,"46,XX[24]",373,95.2,normal,34,"partial CD7 ,dim/partial CD10 , CD13 , CD33 , CD34 , CD38 , CD56 , CD64 , dim CD123 , HLA-DR , and MPO positive",6.5,29.4,negative,0,negative,,,,CEBPA (p.D107fs*; MAF ~50%)|WT1 (p.Y385*; MAF 20%)|WT1 (rs16754; MAF ~50%)
13-00245,training,Alive,857,BA2909D,BA2909R,2509,1108,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,Asian,NON-HISPANIC,Asian,1,,RUNX1-RUNX1T1,8,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,8,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",2,Induction|Intensification,Complete Response,Standard Chemotherapy,11,Standard Chemotherapy,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)",Intensification,62,Alive,2662,Alive,0,30,,0,,33,17,20,,,,,0.53,M2,29.3,10.3,"46,XY,t(8;21)(q22;q22)[5]/46,idem,der(7)t(7;8)(q22;q11.2)[13]/46,XY[2]",,93.5,t(8;21) (34%) | t(8;21) and der(7)t(7;8) (56%) | Missing D7S486 signal (70%),109,"dim CD7, CD13, CD33, CD34, CD38, partial CD56,CD58, CD117, CD123, dim HLA-DR, and MPO",,19.5,negative,0,negative,,,,
13-00262,training,Dead,455,BA2032D,BA2032R,2022,1118,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,2,,,64,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65,0,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),5,"Crenolanib|MEC, plexifor, GCSF|Sorafenib|7+3 (Cytarabine, Idarubicin) plus LBH|Clofarabine, Cytarabine",4,Salvage|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,21,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,124,Dead,455,Dead-Disease,,81,94,,,6,,,,87,47,2.8,0.53,,27.2,9.7,"46,XX,t(3;11)(q21;p11.2),t(15;15)(q15;q22)[19]/46,XX,t(2;14)(q21;q11.2)[2]",743,,"nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2 (5'MLL con 3'MLLx2)[198],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",11,"CD7(partial +), CD15(partial +), CD33(bright +), CD34(partial +), CD45(+), and CD117(variably +). (80% population of variably-sized cells)",5.2,26,positive,15.6666666666667,positive,,,,
13-00281,training,Dead,189,BA2597D,BA2597R,2290,1131,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,4,,,79,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,79,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"Azacitidine, Lenalidomide",1,Induction,Refractory,Standard Chemotherapy,137,Standard Chemotherapy,"Azacitidine, Lenalidomide",Induction,137,Dead,189,Dead-Disease,,73,56,,,,1,,,,,,,,,,"46,XX,del(16)(p11.2)[3]/46,XX[2]",,,,,"CD34, CD4(dim), CD7, CD11c(dim), CD13, CD33(dim),CD38, CD117, and HLA-DR",,8.7,negative,0,negative,,ASXL1 (p.G645Vfs*58; 12.5%),,IDH2 (R140Q)
13-00331,training,Dead,761,BA2106D,BA2106R,2055,1153,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,4,,,35,TRUE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,37,1,Post-Chemotherapy|Relapse,Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cyclophosphamide, Etoposide, TBI",5,Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Re-induction,53,Dead,761,Dead-Disease,,92,97,,,,,,,,,,,M5,,,"46,XX[5]",,,,,"CD45, DIM CD64, DIM CD13, DIM CD33, CD15, CD38, MPO, CD11C, DIM CD4, DIM PARTIAL CD19, CD117, AND HLA-DR",,140,negative,0,positive,,,,FLT3-D835|IDH1|NPM1
13-00353,training,Dead,270,BA2446D,BA2446R,2429,1161,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,Pacific Islander,NON-HISPANIC,Asian,1,,MLLT3-KMT2A,30,FALSE,FALSE,FALSE,FALSE,FALSE,y,Acute Promyelocytic Leukemia,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,30,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,4,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine",4,Consolidation|Salvage|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,6,Supportive/Palliative Care,Decitabine,Supportive/Palliative Care,31,Dead,270,Dead-Disease,0,64,65,0,,28.9,25.4,19.3,1.7,48,33,3.6,0.64,M1,21.8,7.5,"46,XX,t(9;11)(p11;q34)[19]/46,XX[1]",,111.8,Disruption of MLL signal and t(9;11) (65%),29,"CD11b, CD13, CD14,  CD33, CD64, CD56, CD123 and HLA-DR positive",6.1,29.25,negative,0,negative,,,,CREBBP (p.A254T; MAF 50%)|CREBBP (p.T910S; MAF 40%)|FLT3-D835 (p.D835; MAF 35%)
13-00354,training,Dead,330,BA2645D,BA2645R,2230,1163,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,Asian,4,,,73,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,73,0,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Decitabine|Stanford Protocol 9153 (TLI, ATG)",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Stanford Protocol 9153 (TLI, ATG)",Allogeneic - Mismatched Unrelated Donor,-1,Dead,330,Dead-Disease,,84,71,,,,6,,,,,,,M5,,,"46,XY[20]",,,,,""" CD4(subset), CD11c(partial), CD13(partial), CD14(partial), CD15(partial), CD33(subset), CD34(subset), CD38, CD64(subset), CD117(subset), HLA-DR and MPO""",,16.2,negative,0,negative,,,,
13-00365,leaderboard,Dead,420,BA2525D,BA2525R,2543,1171,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,4,,,72,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,72,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"Azacitidine, Lenalidomide|Temozolomide, Vorinostat",2,Induction|Re-induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,"Temozolomide, Vorinostat",Re-induction,-1,Dead,420,Dead-Disease,,,,,,,,,,,,,,,,,"46,XX,del(5)(q31q35),inv(7)(p15q32),del(12)(q?15)[2]/45~46,idem,add(3)(q27),-9,-del(12)(q?15),+add(12)(q13),-16,-17,+mar1,+mar2x2[cp16]/46,XX[2]",,,,,,,,positive,0.538461538461538,positive,,,TP53,TP53
13-00393,leaderboard,Dead,1237,BA2357D,BA2357R,2245,1184,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,Unknown,,HispNative,2,,,52,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,52,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,5,"7+3 (Cytarabine, Idarubicin)|HiDAC|AG-221|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Fludarabine, Melphalan, ATG",5,Consolidation|Salvage|Induction|Experimental|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,15,Bone Marrow Transplant,"Fludarabine, Melphalan, ATG",Allogeneic - Matched Unrelated Donor,-1,Dead,1237,Dead-Disease,,21,5,,,68,4,23,,17,23,3.6,0.89,,28.3,8.5,"89<4n>,XXY,-Y,-7,-12,+13,+13,-17,-21[2]/46,XY[18]",183,,"nuc ish(RUNX1T1x4,RUNX1x3)[33/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[41/200],(PMLx4,RARAx3~4)[31/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[27/200]",22,"partialCD4, partialCD15, dimCD33, CD34, CD38, dimCD45, CD117, HLA-DR, TdT, MPO",7.5,3.42,negative,0,negative,RUNX1 (p.R201Q; 33.9%),,,
13-00396,training,Dead,228,BA2546D,BA2546R,2259,1187,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,63,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,Decitabine,Consolidation,-1,Dead,228,Dead-Treatment,1.8,51,,0.9,,41.2,37.7,11.4,0,20,20,3.2,1.37,M4,33.7,11,"42~45,XY,del(4)(q31q35),del(5)(q13q35),add(9)(q21),add(13)(p11.2),-16,-21[cp15]/40~46,sl,+9,-add(9)(q21),-15,+der(16)t(15;16)(q11.1;p13.3),-18,+mar[cp5]",,92.6,Extra MLL signal (5%) | 5q deletion (95%) | Abnormal 9q (33%) | Partial deletion of RUNX1 (34%),24,"CD13, CD33, CD34, CD56, CD58, dim CD64, CD117 and partial HLA-DR.",7.1,5.23,negative,0,negative,,,TP53 (p.X307_splice; 46.6%)|TP53 (p.R273S; 40.4%),"TP53 (Intron 7, 5' splice site mutation; MAF 40%)|TP53 (p.R273S; MAF 40%)"
13-00406,training,Dead,2,BA2742D,BA2742R,2403,1190,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,62,FALSE,TRUE,FALSE,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,62,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Leukapheresis,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,2,Dead-Disease,0,95,95,0,,9.5,1.9,4.8,0.2,93,104,3.2,1.85,M5,26.2,8.5,"46,XY[20]",2941,104.8,Normal,92,"CD4, CD11b, CD13, CD14, partial CD16, CD33, CD38,      partial CD56, CD58, CD64, CD123, and HLA-DR positive",6.5,250.23,positive,15.6666666666667,negative,RUNX1 (p.X205_splice; 56.7%),,,"DNMT3A (p. R882C; MAF 50%)|DNMT3A (p.R882C; MAF 50%)|FLT3-ITD (MAF 90%)|RUNX1 (Intron 5, 3' splice site mutation; MAF 50%)"
13-00420,training,Dead,383,BA2421D,BA2421R,2195,1194,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,Unknown,,White,2,,,75,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",75,0,Residual Disease|Post-Chemotherapy,Residual,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,5,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",4,Consolidation|Induction|Re-induction|Maintenance,Refractory,Standard Chemotherapy,56,Standard Chemotherapy,Azacitidine,Maintenance,34,Dead,383,Dead-Disease,,,,,,,,,,,,,,,,,"47,XY,+8,inv(9)(p11q12)c[1]/48,idem,+3[5]/49,idem,+3,+15[1]/50,idem,+3,+8,+mar(8]/46,XY,inv(9}(p11q12)c[5]",,,"nuc ish (D8Z2x3~4)[134/200],(D15Z4x3)[114/200]",,,,,negative,0,negative,,,,
13-00425,training,Alive,486,BA2087D,BA2087R,2221,1197,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,Unknown,,White,2,,MLLT3-KMT2A,40,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,40,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide",3,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1,Alive,1435,Alive,,84,29,,,63,3,5,,21,23,3.7,0.65,,35,12,"46,XX,t(9;11)(p22;q23)[20]",613,,"nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1) [179/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",34,"brightCD4, partialCD11b, brightCD15, brightCD33, partialCD36, partialCD38, CD45, brightCD64, partialCD117, HLA-DR (86% population of cells)",6.5,9.1,negative,0,negative,,,,
13-00450,training,Dead,124,BA2910D,BA2910R,2261,1224,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,2,,,79,TRUE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,79,0,Post-Chemotherapy|Relapse,Relapse,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),2,"7+3 (Cytarabine, Idarubicin)|Crenolanib",2,Induction|Experimental,Complete Response,Standard Chemotherapy,4,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,14,Dead,124,Dead-Disease,,,,,,,,,,,,,,,,,,,,,,,,,positive,0.470588235294118,positive,,,,FLT3-ITD (High level (>50%))|NPM1 (Positive for insertion mutation in exon 12)
13-00468,training,Dead,370,BA2329D,BA2329R,2186,1233,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,61,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,61,0,Post-Chemotherapy|Residual Disease,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",3,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,Decitabine,Salvage,126,Dead,370,Dead-Disease,,19,10,,,27.7,,39.2,,47,22,3.8,0.5,M5,25.8,8.5,"47~49,XY,-21,+1~4mar[cp21]/46,XY[2]",,86.6,Monosomy 21 (30%),40,"Blasts (15-20%): CD11b, CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, and HLA-DR, and partial TdT positive - Aberrant monocytic population (20%): CD11b, CD13, CD14, bright CD33, dim CD56, CD64, and HLA-DR positive",7.6,5.5,negative,0,negative,,,,CSF3R (p. T618I; MAF: 50%)|WT1 (benign SNP rs16754 (R369R: no amino acid change); MAF: 50%)
13-00487,training,Alive,358,BA2072D,BA2072R,2115,1243,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,CBFB-MYH11,35,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,35,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,HiDAC,Consolidation,94,Alive,1848,Alive,0,70,27,1.8,,19.6,37.5,7.1,0,20,17,3.1,0.88,M4,14.3,4.8,"46,XX,t(16;16)(p13.1;q22)[16]/47,idem,+22[4]",505,100.7,Trisomy 22 (16%) | t(16;16) (90%),36,"Myeloid blasts (21%): CD13, CD33, CD34, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive. Promonocytic/monocytic cells (55%): CD11b, CD13, CD14, CD33, dim/partial CD34, CD38, CD58, CD64, variable CD123, HLA-DR, and MPO-positive. (Included both populations of cells)",7.8,49.4,negative,0,negative,,,,CREBBP (P552S; MAF 50%)|KDM6A (K395N; MAF 50%)|KIT (D816V; MAF 1%)|NRAS (G13D; MAF 6%)
13-00500,training,Dead,156,BA2995D,BA2995R,2281,1248,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,2,,,71,FALSE,FALSE,FALSE,FALSE,FALSE,y,Prostate Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",71,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,55,Dead,156,Dead-Unknown,0,76,58,2,,38,6,14,,27,25,3.1,,,25,8.5,"46,XY",,,"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[29/200],(D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[11/200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",93,"CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial +), CD13(partial +), CD15(-), CD19(-), CD22(partial +), CD33(partial and variably +), CD34(variably +), CD36(partial +), CD38(variably +), CD45(partial +), CD56(-), CD64(partial +), CD117 (partial +), HLA-DR(+), TdT(partial +), MPO(-)",5.8,7.5,negative,0,negative,RUNX1 (p.P333Rfs*261; 48.9%)|RUNX1 (p.D332G; 51.1%)|RUNX1 (p.R162G; 47.3%),,,
13-00513,training,Dead,246,BA2069D,BA2069R,2179,1255,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,MLLT3-KMT2A,55,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,55,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",3,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Salvage,4,Dead,246,Dead-Disease,1.4,75,23,8.5,,11.4,8.5,34,0.2,62,31,3.8,1.44,M5,38.1,12.2,"46,XY,t(9;11)(p22;q23)[20]",497,87.6,MLL rearrangement and t(9;11) (86%),32,"CD11b, partial CD13, CD33, CD38, CD56, CD58, CD64, partial CD117, CD123, and HLA-DR+ ",7.9,10.21,positive,1.08333333333333,positive,,,,No gene mutations found in the 43 genes tested
13-00515,training,Dead,658,BA2100D,BA2100R,2485,1257,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,Unknown,,White,2,,,73,FALSE,FALSE,TRUE,FALSE,FALSE,y,Prostate Cancer,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,74,0,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),7,"Cytarabine, Fludarabine, Sorafenib|Crenolanib|Azacitidine|Sorafenib|Decitabine, Sorafenib |Clofarabine, Cytarabine|Sapacitabine (CYC682-06)",6,Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,39,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,33,Dead,658,Dead-Unknown,1,32,67,2,,8,3,14,,15,30,4.1,,,32.8,11,"46,XY,+1,dic(1;15)(q12;p11.2)[2]/46,XY[18] ",,,"18].nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2 [200],(RUNX1T1,RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",90,"CD4(partial dim +), CD7(-), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variably +), CD34(+), CD36(-), CD38(variably +), CD45 (variably +), CD56(-), CD64(-), CD79a(-) | CD117(variably +), HLA-DR (variably +), MPO(predominantly -), TdT(-)",5.8,24.2,positive,1.22222222222222,negative,RUNX1 (p.R201Q; 47.2%),,,FLT3-ITD (NOT FOUNDATION NO MAF AVAILABLE)
13-00545,training,Dead,555,BA2308D,BA2308R,2248,1286,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,4,,GATA2-MECOM,71,FALSE,FALSE,FALSE,FALSE,FALSE,y,Prostate Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,72,0,Residual Disease|Post-Chemotherapy,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4,"Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine",4,Hypomethylating/Low Dose Cytarabine|Induction|Experimental|Maintenance,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1,Dead,555,Dead-Disease,,82,,,,,,,,,,,,,,,"45,XY,-7,t(3;3)[20]",,,,,"CD34+ CD38, CD13,CD33, CD117, HLA-DR, DIM CD7, PARTIAL CD11C, CD2(SUBSET), CD15(MINOR SUBSET), DIM cCD79a(MINOR SUBSET), AND PARTIAL CD4",,,positive,5.25,negative,,,,FLT3-D835
13-00551,leaderboard,Alive,1487,BA2701D,BA2701R,2419,1314,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,Black,2,,,51,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",51,0,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide",3,Allogeneic - Sibling|Induction|Re-induction,Refractory,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1,Alive,1487,Alive,,82,1,,,17,35,23,,16,14,3.7,0.8,,25,8.7,"46,XY[20]",,83.8,,16,"CD1a(-), CD2(-), surface CD3(-), cytoplasmic CD3(partial dim +), CD4(partial dim +), CD5(dim +), CD7(+), CD8(-), CD10(-), CD11b(partial +), CD13(+), CD14(-), CD15(-), CD16 (-), CD22(partial dim +), CD33(variably +), CD34(+), CD36(-), CD38(partial +), CD45(variably +), CD56(variably +), CD64(-), | CD117(variably +), HLA-DR(partial +), MPO(-), and TdT(+)",6.8,3.2,negative,0,negative,,,,
13-00552,leaderboard,Dead,415,BA2634D,BA2634R,2047,1315,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,3,,,74,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,75,0,Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Etoposide, Mitoxantrone",3,Hypomethylating/Low Dose Cytarabine|Salvage|Induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Salvage,-1,Dead,415,Dead-Disease,,60.1,,,,,,,,,,,,M2,,,"46,XY,add(1)(p34),del(7)(q22),del(20)(q11.2)[20]",,,"normal, no evidence of RUNX1T1/RUNX1 transloc or 11q23 or 16q22",,"Increased CD34 positive myeloblasts, representing approximately 55% of the leukocytes",,,positive,1.94117647058824,negative,,,,
13-00557,training,Dead,370,BA2677D,BA2677R,2186,1233,Waves1+2,Waves1+2,no,no,no,no,Male,Male,White,NON-HISPANIC,White,1,,,61,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,62,43,Residual Disease,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine",3,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,Decitabine,Salvage,126,Dead,370,Dead-Disease,,17,2,,,32.2,,34.2,,34,15,3.7,0.3,M5,32.4,10.4,"46~49,XY,-21,+1~4mar[cp20]",,87.2,Monosomy 21 (45%),21,"Myeloid blasts:CD13, CD33, CD34, CD38, CD58, dimCD64, CD117, and HLA-DR+    Promonocytes/immature monocytes:CD11b, CD13, CD14, CD33, CD64, and HLA-DR+",7,7.2,negative,0,negative,,,,
13-00558,training,Dead,213,BA2937D,BA2937R,2212,1341,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,61,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,61,0,Residual Disease|Post-Chemotherapy,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Hydroxyurea|Busulfan, Cyclophosphamide",5,Allogeneic - Sibling|Salvage|Induction|Re-induction|Symptom Control,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1,Dead,213,Dead-Treatment,0,25,20,13,,6,12,55,0.9,45,34,3.1,0.8,,31.1,9.8,"42~44,XY,t(1;10)(q12;q21),-5,-7,-11,add(13)(p11.1),der(18)t(11;18)(q14;q21.1),add(20)(q12),+1~3mar[cp4]/41~44,sl,add(4)(q23)[cp9]/41~44,sl,del(4)(q21q?27)[cp5]/41~42,",,88.9,Monosomy 5 (52%) | 5p deletion (39%) | Monosomy 7 (48%) | Abnormal 7q arm (48%),243,"CD13, CD33,CD34, CD38, dimCD56, CD58, CD117, and HLA-DR+",6.4,96.64,negative,0,negative,,,TP53 (p.R248Q; 96.4%),
13-00573,training,Dead,333,BA2412D,BA2412R,2260,1349,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,85,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,86,0,Residual Disease|Post-Chemotherapy,Residual,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Supportive/Palliative Care,,,,Standard Chemotherapy,Decitabine,Supportive/Palliative Care,169,Dead,333,Dead-Disease,0,,,0,,17,44,39,0,15,9,3.5,0.9,M5,25.7,8.2,,175,88,,18,,6.9,13.22,negative,0,negative,,,TP53 (p.R248W; 72.2%),
13-00578,training,Dead,568,BA2334D,BA2334R,2270,1353,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,2,,DEK-NUP214,30,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(6;9)(p23;q34); DEK-NUP214,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(6;9)(p23;q34); DEK-NUP214,31,0,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),6,"7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine, Sorafenib |Quizartinib",3,Salvage|Induction|Experimental,Refractory,Standard Chemotherapy,-1,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,52,Dead,568,Dead-Disease,,65,47,,,,,,,49,31,4.2,0.85,,,,"47~49,XX,t(6;9)(p23;q24),+8,+13,+15[cp8]/47~49,idem,+del(13)(q12q22)[cp12]",329,,,10,"CD34(partial +), CD13(+), CD14(-), CD15(few +), CD30(-), CD33(+), CD38(variably +), CD45 (moderately +), CD64(variably +), CD4(partial +), CD117(+), CD123(variably +), HLA-DR(+), CD79a(-), CD22(-), intracellular CD3(-), TdT(-), MPO(partial +), other myeloid and lymphoid antigens(-).",6.3,20.2,positive,2.125,negative,,,,FLT3-D835|FLT3-ITD
13-00593,training,Dead,658,BA2953D,BA2953R,2485,1257,Waves1+2,Waves1+2,no,no,no,no,Male,Male,Unknown,,White,2,,,73,FALSE,FALSE,TRUE,FALSE,FALSE,y,Prostate Cancer,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,74,37,Post-Chemotherapy|Residual Disease,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),7,"Cytarabine, Fludarabine, Sorafenib|Crenolanib|Azacitidine|Sorafenib|Decitabine, Sorafenib |Clofarabine, Cytarabine|Sapacitabine (CYC682-06)",6,Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,39,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,33,Dead,658,Dead-Unknown,6,66,40,2,,19,20,8,,22,36,4.3,,,34.7,11.6,"46,XY",,,"nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]",67,"CD2(-), CD4(-), CD7(-), CD8(-), CD10(-), CD11b(partial +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variable and bright +), CD34(variably +) (Within this population, there is a small subset of cells (1.7% of total events) that is CD10(partial +), CD13(partial +), CD19(+), CD20(partial +), CD22(partial +), CD33(+), CD34(variably +), CD38(+), CD45(+), CD79a(+), CD117(partial +), HLA-DR(+) and TdT(partial +).) | CD36(-), CD38(variably +), CD45(moderately +), CD56(-), CD64(partial +), CD117(variably +), HLA-DR(variably +).",6.2,13.9,positive,3,negative,RUNX1 (p.R201Q; 51.8%),,,
13-00601,leaderboard,Dead,116,BA2481D,BA2481R,2159,1369,Waves1+2,Waves1+2,no,no,no,no,Male,Male,,,White,2,,,,FALSE,FALSE,FALSE,TRUE,FALSE,n,,y,n,y,n,n,n,n,n,MYELODYSPLASTIC SYNDROMES,Refractory anaemia with excess blasts,NonAML,MYELODYSPLASTIC SYNDROMES,Refractory anaemia with excess blasts,,4,Unknown,,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Induction,Unknown,Standard Chemotherapy,60,Standard Chemotherapy,Decitabine,Induction,60,Dead,116,Dead-Unknown,,3,,,,,,,,,,,,,,,"46,XY[20]",,,"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",,The findings reveal a slightly expanded population of myeloblasts with an essentially unremarkable immunophenotype. There is no definitive immunophenotypic evidence of a hematolymphoid malignancy.,,,negative,,negative,,,,
13-00602,training,Alive,1433,BA2731D,BA2731R,2036,1370,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,2,bi,,63,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,63,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,5,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1,Alive,1346,Alive,,86,85,0,,9,3,3,,16,27,2.9,0.75,,,,"46,XY,del(11)(q14q23)[13]/46,XY[7].ishdel(11)(5'MLL-,3'MLL+)[2].",682,,"nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(5'MLLx1,3'MLLx2)(5'MLL con 3'MLLx1)[118/200]",,"CD7(+), CD11b(-), CD13(dim +), CD14(-), CD15(partial +), CD16(-), CD33(variably +/subset bright +), CD34(+), CD36(-), CD38(+), CD45(+), CD56(partial +), CD64(partial +), CD117(+), HLA-DR(+), MPO(+), TdT(-).",6.6,33,negative,0,negative,,,,
13-00615,training,Alive,239,BA2294D,BA2294R,2499,1375,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Male,,,HispNative,4,,RUNX1-RUNX1T1,62,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,62,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",1,Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Induction,-1,Alive,239,Alive,,52,57,,,,6,,,,,,,,,,"46,XY,t(8;21)(q22;q22)[14]",,,,,"CD34, PARTIAL CD38, CD33, CD13, CD64, PARTIAL CD11C, PARTIAL CD19, HLA-DR, PARTIAL CD15, CD117, AND MPO",,12.9,negative,0,negative,,,,NRAS
13-00655,training,Dead,979,BA2814D,BA2814R,2539,1394,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,3,,MLLT3-KMT2A,62,FALSE,FALSE,FALSE,FALSE,FALSE,y,Prostate Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,62,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"7+3 (Cytarabine, Idarubicin)|Fludarabine, TBI|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |ODSH (2 O, 3-O Desulfated Heparin) ",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Fludarabine, TBI",Allogeneic - Matched Unrelated Donor,-1,Dead,979,Dead-Disease,,93,58,,,,,,,,,,,M5a,,,"47,XY,+8,t(9;11)(p21;q23)[9]/46,XY[11]",,,"8q22 (RUNX1T1): gain present  11q23 (MLL): rearrangement present (83.5% 11q23, 84.5% 8q22)",,"Large population of promonocytes/monoblasts that represent approximately 88% of the leukocytes, consider acute monoblastic leukemia.",,14.66,negative,0,negative,,,,
13-00658,training,Alive,201,BA2631D,BA2631R,2369,1396,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,60,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,60,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,MiDAC,Consolidation,114,Alive,2769,Alive,0.8,30,55,4.5,,19.7,8.3,15.9,0.3,49,23,3.5,1.22,M2,30.6,10.6,"46,XY[21]",536,95.6,Normal,141,"CD7, CD13, CD33, partial CD34, CD38, CD58, CD117, CD123,HLA-DR, and MPO positive",7.2,11.93,negative,0,positive,,,,CEBPA (p. Q83fs*27 (c.245?246insTGTTCCA); MAF 50%)|FLT3 ( p.N841I; MAF 12%)|FLT3 (p.I836delI; MAF 25%)|NPM1 (p.W288fs*>9; MAF 40%)
14-00015,leaderboard,Dead,270,BA2025D,BA2025R,2429,1161,Waves1+2,Waves1+2,no,no,no,no,Female,Female,Pacific Islander,NON-HISPANIC,Asian,1,,MLLT3-KMT2A,30,TRUE,FALSE,FALSE,FALSE,FALSE,y,Acute Promyelocytic Leukemia,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,31,147,Relapse|Post-Chemotherapy,Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,4,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine",4,Consolidation|Salvage|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,6,Supportive/Palliative Care,Decitabine,Supportive/Palliative Care,31,Dead,270,Dead-Disease,0,75,35,0,,9.9,9.9,37.2,0.8,37,39,3.1,0.56,M1,22.1,7.7,"46,XX,t(9;11)(p22;q23)[20]/46,XX[1]",,89.8,MLL disruption and t(9;11) (70%),39,"dim/partial CD13, CD33, CD38, CD56, CD58, CD64, partialCD117, CD123 and HLA-DR positive",6,43.72,negative,0,negative,,,,FLT3-D835 (MAF 70%)
14-00021,training,Dead,357,BA2636D,BA2636R,2576,1408,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,4,,,74,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,74,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,4,"Hydroxyurea|Decitabine|Temozolomide, Vorinostat|Azacitidine, MLN4924",4,Salvage|Induction|Re-induction|Symptom Control,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,Decitabine,Salvage,-1,Dead,357,Dead-Disease,,,,,,,,,,,,,,,,,"46,XY",,,,,,,,negative,0,negative,,ASXL1 (p.G645Vfs*58; 43.8%),,
14-00034,training,Alive,906,BA2156D,BA2156R,2017,1431,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,bi,,55,FALSE,FALSE,FALSE,FALSE,FALSE,y,Other malignant neoplasm without specification of site,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,55,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Busulfan, Cyclophosphamide",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Matched Unrelated Donor,-1,Alive,2733,Alive,0,50,25,0,,45.3,19.6,9.3,6,27,20,3.7,1.01,M2,30.6,10.1,"46,XY[20]",,98.4,Normal,15,"CD7, CD13, CD33, CD34, CD38, CD64, CD123, HLA-DR, and MPO",6.3,3.85,negative,0,negative,,,,CEBPA (c.242?243insCTTGGTT (7bp out-of-frame insertion); MAF 50%)|CEBPA (c.912?913insTTG (3 bp in-frame insertion); MAF 50%)
14-00041,training,Alive,952,BA2511D,BA2511R,2567,1434,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,4,,GATA2-MECOM,71,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,71,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,AG-221,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,AG-221,Hypomethylating/Low Dose Cytarabine,-1,Alive,1008,Alive,,22,8,,,,10,,,,,,,M4,,,"46,XX,inv(3)?(q21q25)[21]",,,,,"CD34, CD117, CD38, CD56 (minor subset), partial CD13, partial CD33, CD11c, and HLA-DR",,2.6,negative,0,negative,,,,IDH2
14-00092,training,Alive,566,BA2603D,BA2603R,2314,1461,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,63,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,63,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1,Alive,2438,Alive,1.7,29,14,0.8,,9.4,28.2,49.6,1.6,18,26,2.8,0.74,M4,21.2,7.3,"46,XX[20]",514,101.4,Normal,57,"CD13, CD33, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive (Myeloid blast phenotype) | CD11b, variable CD13, CD14, CD33, dimCD56, CD64, HLA-DR-positive (Monocytic phenotype)",6.1,63.75,negative,0,positive,,,,CREBBP (p.V319I; MAF 50%)|DNMT3A (p.R882H; MAF 50%)|DNMT3A (p.T138I; MAF 50%)|NPM1 (p.W288fs*12; MAF 50%)|NRAS (p.Q61H; MAF 40%)
14-00126,training,Alive,0,BA2812D,BA2812R,2563,1451,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,3,,,46,FALSE,TRUE,FALSE,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE,"Mixed phenotype acute leukaemia, T/myeloid, NOS",MissingKaryo,ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE,"Mixed phenotype acute leukaemia, T/myeloid, NOS",46,14,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Unknown,0,,,,,,,,,,,,,,,,,,,,,,,,,,negative,0,negative,,,,
14-00127,training,Dead,207,BA2822D,BA2822R,2227,1481,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,37,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,38,0,Residual Disease|Post-Chemotherapy,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,2,"7+3 (Cytarabine, Idarubicin)|Azacitidine",2,Induction|Maintenance,Refractory,Standard Chemotherapy,6,Supportive/Palliative Care,Azacitidine,Maintenance,-1,Dead,207,Dead-Disease,0,,95,0,,0.9,0,0,0.1,17,56,1.8,0.6,,23,7.9,"48~54,XY,add(2)(p13),+5,add(5)(q13),del(5)(q13),+10,+11,+13,+13,del(13)(q32),+14,-15,-16,del(17)(p12),-20,+21,+21,+22,+mar[cp9]/49~52,sl,-del(17)(p12)[cp8]/51~54,sl",,86.8,Extra chromosome 5 (98%) | 5q deletion (98%) | Monosomy 16 (93%) | Extra copies of chromosome 21 (63%) | Monosomy 17 (99%) | Extra chromosome 11 (99%),20,"CD10, CD13, CD33, CD34, CD56 and HLA-DR positive",5.3,38.47,negative,0,negative,,,TP53 (p.R273H; 90.9%),"NRAS (p.G13D, MAF 46%)|TP53 (p.R273H, MAF 96%)"
14-00135,training,Dead,252,BA2594D,BA2594R,2554,1485,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,72,FALSE,FALSE,FALSE,FALSE,FALSE,y,Other malignant neoplasm without specification of site,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,72,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,Azacitidine|Decitabine,3,Consolidation|Induction|Maintenance,Unknown,Standard Chemotherapy,38,Standard Chemotherapy,Azacitidine,Maintenance,36,Dead,252,Dead-Disease,0,55,46,0,,27.8,27,20.6,0,32,31,2.2,1.37,M4,20.6,6.6,"43~44,X,-Y,t(3;11)(p21.3;p11.2),del(5)(q11.1;q31.1),add(12)(p11.2),-21[cp17]/44~45,idem,-t(3;11),+9[cp4]",435,85.8,Previous FISH results were consistent with the deleted 5q and trisomy 9,33,"CD13, CD33, CD34, partial CD56,variable CD117, dim CD123, and dim HLA-DR+",5.9,20.82,negative,0,negative,,,TP53 (p.H193R; 90.7%),TP53 (p.H193R; MAF 92%)
14-00141,training,Dead,357,BA2747D,BA2747R,2205,1488,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,Asian,4,,,85,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,85,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"Decitabine, Midostaurin",1,Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"Decitabine, Midostaurin",Induction,-1,Dead,357,Dead-Disease,,,,,,,,,,,,,,M4,,,"46,XY[14]",,,,,,,,negative,0,negative,,,,FLT3-ITD
14-00193,training,Dead,421,BA2956D,BA2956R,2123,1519,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,2,,CBFB-MYH11,56,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,57,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Unknown,Standard Chemotherapy,3,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,3,Dead,421,Dead-Disease,0,N/A,54,0,,38,8,0,,15,23,3,1.3,,,,"46,XY,del(5)(q15q35),inv(16)(p13.1q22)[20]",409,,"nuc ish(D5S721x2,D5S23x2,EGR1x1)[182/200],(D7Z1,D7S522)x2[199], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[192],(PML,RARA)x2[198],(5'CBFB,3'CBFB)x2(5'CBFB sep 3'CBFBx1)[176/200]",,"CD2(-), CD4(partial dim +), CD7(partial dim +), CD11b(-), CD13(+), CD14(-), CD15(+), CD16(-), CD19(-), CD20(-), CD22(few dim +), CD25(-), CD33(+), CD34(+), CD36 (-), CD38(variably +), CD45(moderately +), CD56(-), CD64(few dim +), CD79a(-), CD117(+), CD123(+) (PB) | HLA-DR(variably +), MPO(+), TdT(+). (PB)",6.6,8.2,negative,0,negative,,,,NRAS (G12D; MAF 16%)|NRAS (G13D; MAF 13%)|NRAS (Q61H; MAF 5%)
14-00228,training,Alive,788,BA2474D,BA2474R,2029,1532,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,46,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,46,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,5,"7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC",3,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Re-induction,4,Dead,1373,Dead-Disease,0,80,,1.6,,9.9,14.9,10.7,0,52,28,2.5,0.77,M4,25.2,8.4,"46,XX[20]",550,88.1,Normal,107,"dim CD11b, CD13, CD33, partial CD34, dim CD45, dim CD64, CD117, CD123, and dim HLA-DR+",6.3,57.23,negative,0,positive,,,,DNMT3A (p.R882C; MAF 46%)|NPM1 (p.W288fs*12; MAF 43%)|PTPN11 (p.E76Q; MAF 40%)
14-00240,leaderboard,Dead,37,BA2006D,BA2006R,2020,1540,Waves1+2,Waves1+2,yes,yes,no,yes,Female,Female,,,Black,2,,,78,FALSE,TRUE,FALSE,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,78,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,n,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,37,Dead-Disease,,,1,,,6,49,35,,9,15,2.9,1.09,,26.1,8.3,"45,XX,+i(5)(p10),psudic(12;5)(p13;q11.2),-16,del(17)(p11.2p13)[5]/44,idem,-i(5)[3]/46,XX[12]",342,,"nuc ish(D5S721x2,D5S23x2,EGR1x1)[57/200]/(D5S721x4,D5S23x4,EGR1x1)[29/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[83/200]",50,,6.7,51.64,negative,0,negative,,ASXL1 (p.G646Wfs*12; 32.6%),TP53 (p.X307_splice; 76.3%),
14-00259,leaderboard,Dead,439,BA2110D,BA2110R,2305,1546,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,65,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Fludarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC",4,Consolidation|Salvage|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,Fludarabine,Consolidation,4,Dead,439,Dead-Disease,0.1,70,,0.1,1.7,8.3,85.2,4.6,0.2,16,13,2.7,0.87,M4,30.4,9.6,"46,XX[20]",506,101.7,Normal,112,"CD11b, partial CD13, partial CD14, dim CD15, partial      CD16, CD33, CD38, CD58, CD64, partial CD123 and HLA-DR positive",7.4,58.86,positive,,positive,,,,DNMT3A ( p.R882H; MAF 50%)|FLT3-ITD (MAF 10%)|FLT3-N676K (MAF 12%)|NPM1 (p.W288fs*12; MAF 50%)|PTPN11 (p.F71L; MAF 14%)
14-00279,training,Alive,36,BA2992D,BA2992R,2348,1558,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,HispNative,4,,CBFB-MYH11,52,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,52,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,SWOG S1203 (7+3 +/- Vorinostat),1,Induction,Complete Response,Standard Chemotherapy,8,Standard Chemotherapy,SWOG S1203 (7+3 +/- Vorinostat),Induction,8,Alive,36,Alive,,91,79,,,,0,,,,,,,,,,"46,XX,inv(16)(p13.1q22)[cp20]",,,,,"CD34, PARTIAL CD117, CD15, CD38, PARTIAL CD13, CD33, CD64, PARTIAL CD14(SUBSET), PARTIAL CD11c, DIM CD4, HLA-DR AND BRIGHT MPO",,28.1,negative,0,negative,,,,
14-00289,training,Dead,318,BA2220D,BA2220R,2394,1561,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,23,FALSE,FALSE,FALSE,FALSE,FALSE,y,Mediastinum mass,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,23,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),2,"Trametinib|HAEP (Cytarabine, Etoposide, Cisplatin) ",3,Consolidation|Induction|Experimental,Complete Response,Standard Chemotherapy,8,Targeted Therapy - Kinase Inhibitor(s),Trametinib,Experimental,197,Dead,318,Dead-Disease,3.2,3,30,2.1,,25.8,1.1,36.6,43.4,32,131,3,0.91,M6b,17.9,5.7,"48,XY,add(6)(p22),der(7)t(7;19)(p11.1;p12),i(13)(q10)x2,add(14)(q24),+mar1,+mar2[cp20]",16499,95.2,Low-level tetraploidy or near-tetraploidy (5%),24,,5.6,40.76,negative,0,negative,,,TP53 (p.G245S; 83.1%),NRAS (p.G12C; MAF 86%)|TP53 (p.G245S; MAF 87%)
14-00359,training,Alive,761,BA2260D,BA2260R,2447,1604,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,3,,CBFB-MYH11,58,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,58,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin) ",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,5,Standard Chemotherapy,HiDAC,Consolidation,210,Alive,1250,Alive,,50.8,,,,,,,,,,,,M4,,,"48,XY,+8,inv(16)(p13.1q22),+22[18]/49,sl,+21[2]",,,"8q22 (RUNX1T1): gain present  16q22 (CBFB): rearrangement present  21q22 (RUNX1): gain or rearrangement present (96%, 71.5%, 11% respectively)",,Relative increase of CD34 positive myeloblasts representing approximately 20% of the leukocytes and increased promonocytes/monoblasts consistent with acute myeloid leukemia with   myelomonocytic differentiation,,,negative,0,negative,,,,
14-00376,leaderboard,Alive,714,BA2676D,BA2676R,2008,1614,Waves1+2,Waves1+2,no,no,no,no,Male,Male,White,NON-HISPANIC,White,1,,,48,FALSE,FALSE,FALSE,TRUE,FALSE,n,,y,n,y,n,n,n,n,n,MYELODYSPLASTIC SYNDROMES,Refractory anaemia with excess blasts,NonAML,MYELODYSPLASTIC SYNDROMES,Refractory anaemia with excess blasts,48,0,Unknown,,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"Decitabine|Busulfan, Cyclophosphamide",2,Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,116,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Matched Unrelated Donor,-1,Alive,2114,Alive,0,17,5.3,0,,67.3,22.1,5.3,0,36,20,3.5,0.82,,32.5,10.2,"47,XY,+8[18]/46,XY[2]",155,83.5,Trisomy 8 (84%),105,"CD13, CD33, CD34, CD38, CD58, CD117, CD123, MPO+",7.9,0.94,negative,,negative,,,,DNMT3A (p.R882C; MAF 45%)|IDH1 (p.R132C; MAF 44%)|TET2 (p.P455R; MAF 45%)
14-00423,training,Alive,795,BA2524D,BA2524R,2134,1644,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,4,,CBFB-MYH11,51,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,51,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Stanford Protocol 9022 (BU/CY)",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,7,Bone Marrow Transplant,Stanford Protocol 9022 (BU/CY),Allogeneic - Matched Unrelated Donor,-1,Alive,839,Alive,,74,61,,,,1,,,,,,,M4eo,,,"46,XX,inv(16)(p13q22)[20]",,,,,"CD34+ EXPRESSING CD38, CD13, CD33, PARTIAL DIM CD2, PARTIAL CD64; DIM PARTIAL CD11C, PARTIAL DIM CD4, COEXPRESSION OF CD117 AND CD15, HLA-DR, MPO, AND PARTIAL DIM TDT",,34.4,negative,0,negative,,,,
14-00434,training,Alive,0,BA2540D,BA2540R,2176,1648,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,4,,MLLT3-KMT2A,69,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,69,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Hydroxyurea,1,Induction,Unknown,Standard Chemotherapy,365,Standard Chemotherapy,Hydroxyurea,Induction,,Unknown,0,,,94,83,,,,0,,,,,,,M5a,,,"46,XX[1]",,,,,"CD38, CD56, slightly dim CD4, CD33, dim CD13, CD64, CD11c, CD15 and partial CD117",,137.6,negative,0,negative,,,,
14-00448,leaderboard,Dead,161,BA2302D,BA2302R,2336,1656,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,4,,,78,FALSE,FALSE,FALSE,FALSE,FALSE,y,Uterine Sarcoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,78,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"Azacitidine, MLN4924",1,Induction,Refractory,Standard Chemotherapy,111,Standard Chemotherapy,"Azacitidine, MLN4924",Induction,111,Dead,161,Dead-Disease,,78,77,,,,1,,,,,,,,,,"46,XX[20]",,,,,"CD34 and MPO, with partial CD38, CD33, CD13, CD11c, CD117 and HLADR",,5.6,negative,0,negative,,,,IDH1
14-00464,leaderboard,Alive,453,BA2651D,BA2651R,2160,1664,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,4,,MLLT3-KMT2A,22,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,22,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,4,"ATRA (Tretinoin)|Cyclophosphamide, TBI|3+7 (Cytarabine, Daunorubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)",4,Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,7,Bone Marrow Transplant,"Cyclophosphamide, TBI",Allogeneic - Matched Unrelated Donor,-1,Alive,826,Alive,,65,90,,,,0.1,,,,,,,M1,,,"46,XX,t(9;11)(p22;q23)[22]",,,,,"CD34, CD38 (dim partial), CD13, CD33 (dim partial), CD11c, CD4 (dim partial), HLA-DR, CD117 and MPO",,40.2,negative,0,negative,,,,FLT3-D835
14-00495,leaderboard,Dead,568,BA2735D,BA2735R,2079,1246,Waves1+2,Waves1+2,no,no,no,no,Male,Male,,,White,2,,,62,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,64,254,Post-Chemotherapy|Post-Transplant|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),6,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Crenolanib|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide",5,Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,24,Targeted Therapy - Kinase Inhibitor(s),Crenolanib,Experimental,141,Dead,568,Dead-Unknown,,,,,,,,,,23,26,2.9,,,27.9,9.6,"45,XY,der(12;16)(q10;p10)[2]/46,XY[18]",,,"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[31/200]",30,,5,27.4,positive,5.66666666666667,positive,,,,CCND3 (P203S; MAF unlisted)|CHEK2 (T367fs*15; MAF unlisted)|DNMT3A (R882H; MAF unlisted)|FLT3-ITD|NPM1 (W288fs*10+; MAF unlisted)
14-00504,leaderboard,Alive,1226,BA2377D,BA2377R,2385,1693,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,2,,MLLT3-KMT2A,35,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,35,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Cyclophosphamide, Thymoglobulin",Allogeneic - Matched Unrelated Donor,-1,Alive,1156,Alive,,86,,,,,,,,,,,,,,,"46,XY,der(4)t(4;9;11)(p14;p22;q23),der(9)del(9)(p13p22)t(4;9;11),der(11)t(4;9;11)[19]/46,XY[1].isht(4;9;11)(5'MLL-,3'MLL+;5'MLL-,3'MLL-;5'MLL+,3'MLL-)[1] ",,,"nuc ish(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1)[189/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]",,"CD2(-), CD4(+), CD7(-), CD11b(+), CD13(partial +), CD14(-), CD15(+), CD16(-), CD33(+), CD34(-), CD36(partial +), CD45(+), CD56(variably +), CD64(+), CD117(partial +), CD79a(-), HLA-DR(+), MPO(-), Tdt(-)",,,positive,2.44827586206897,positive,,ASXL1 (p.D943Qfs*6; 38.5%),,ASXL1 (D943fs*6; MAF 25%)|FLT3-D835 (BMA)|KMT2A (MLL-AF9 fusion)
14-00514,training,Dead,53,BA2499D,BA2499R,2003,1696,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,2,,,71,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,71,0,Post-Chemotherapy|Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,107,Dead,53,Dead-Disease,0,N/A,50,1,,17,1,13,,19,42,3.2,1.83,,23.7,7.7,,766,92.2,,11,,7.1,45.6,negative,0,negative,RUNX1 (p.R320*; 46.2%),,,
14-00537,leaderboard,Alive,74,BA2350D,BA2350R,2112,1708,Waves1+2,Waves1+2,yes,yes,no,yes,Male,Male,,,HispNative,2,,,17,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",17,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,n,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Bu/Cy/ATG|ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC + Midostaurin|Etoposide, Cytarabine",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Unknown,Standard Chemotherapy,-1,Bone Marrow Transplant,Bu/Cy/ATG,Allogeneic - Matched Unrelated Donor,-1,Alive,74,Alive,,,,,,,,,,,,,,,,,"46,XY,t(11;19)(q23;p13.1)[19]/46,XY[1]",,,,,,,,negative,0,negative,,,,
14-00559,training,Alive,976,BA2901D,BA2901R,2529,1721,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,2,,,68,FALSE,FALSE,FALSE,FALSE,FALSE,y,Melanoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,68,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)",4,Consolidation|Induction|Re-induction|Maintenance,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,Azacitidine,Maintenance,-1,Alive,1203,Alive,0,79,54,,,10,42,30,,8,26,4,,,20.8,6.8,"46,XY ",,,IGH-MYEOV and IGH-CCND1 rearrangement; MAF unlisted,61,"CD2(-), CD4(equivocal), CD7(partial +), CD11b (equivocal), CD13(+), CD14(-), CD15(-), CD16(equivocal), CD33(-), CD34(bright +), CD36(-), CD38(dim +), CD45(+), CD56(equivocal), CD64(-), CD117(+), CD123(equivocal), HLA-DR(dim +), MPO(partial +), TdT(-) (Population 1 of 4 (0.02% of total events), consists of small myeloblasts) | CD2(-), CD4(equivocal), CD7(-), CD11b (-), CD13(partial +), CD14(-), CD15(partial +), CD16(-), CD25(-), CD33(variably +), CD34(-), CD36(-), CD38(moderately bright +), CD45(dim +), CD56(-), CD64(-), CD117(+), CD123(+), HLA-DR(partial +), MPO(partial +), TdT(-) (Population 2 of 4 (3.8% of total events), consists of immature myeloid cells) | CD13(partial +), CD14(partial +), CD36(variably +), CD45(variably +), CD56(partial +), HLA-DR(partial +), MPO(partial +) (Population 3 of 4 (61% of total events), consists of monocytes) | CD19(-), CD20(-), CD38(bright +), CD45(-), CD56(+), surface Ig(-), intracellular kappa(+), intracellular lambda(-) (Population 4 of 4 (0.34% of total events), consists of plasma cells)",7.1,41.4,negative,0,positive,,,,DNMT3A (R882C; MAF 50%)|NPM1 (W288fs*10+; MAF 34%)|NRAS (G13D; MAF 44%)
14-00567,training,Dead,462,BA2387D,BA2387R,2454,1723,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,71,FALSE,FALSE,FALSE,FALSE,FALSE,y,Thyroid Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,71,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",3,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",Allogeneic - Mismatched Unrelated Donor,-1,Dead,462,Dead-Treatment,0,95,88,0,0,6.7,5.1,0,0.1,20,20,2.6,0.62,M5,21.4,7,"46,XX,idic(7)(q11.2)[20]",373,93.9,,19,"CD11b, CD13, CD33, partial CD34,      CD38, CD58, CD64, CD117, CD123, partial HLA-DR and cMPO positive",5.8,78.71,negative,0,negative,,,,BCOR (p.T870fs*46 (2 bp deletion); MAF 50%)|IDH1 (p.R132C; MAF 50%)|MLL (PTD)|PTPN11 (p.S502L; MAF 50% )
14-00578,training,Dead,327,BA2962D,BA2962R,2558,1730,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,75,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,IntermediateOrAdverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,75,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|Cytarabine|Fludarabine, TBI|Decitabine",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Refractory,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, TBI",Allogeneic - Mismatched Unrelated Donor,-1,Dead,327,Dead-Disease,0,90,,0,0,6,2.6,0,0.1,18,49,2.6,0.94,M5,26.8,9.1,"46,XY[20]",1173,105.5,Normal,45,"dim partial CD11b, dim variable CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, CD123, HLA-DR, partial TdT, dim MPO positive",6.8,98.9,positive,,negative,,,,DNMT3A (intron 7 splice site (at invariant AG splice donor); MAF 50% )|DNMT3A (p.P777L; MAF 50%)|FLT3-ITD (MAF 40%)|IDH2 (p.R140Q; MAF 45%)|MLL (PTD; no MAF available)|WT1 (Intron 1 splice site (at invariant AG splice donor); MAF 90% )
14-00581,training,Dead,70,BA2195D,BA2195R,2013,1731,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,Black,4,N/A,,68,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,68,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,CPX-351 (Liposomal Cytarabine + Daunorubicin),1,Induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,CPX-351 (Liposomal Cytarabine + Daunorubicin),Induction,-1,Dead,70,Dead-Disease,,33,37,,,,8,,,,,,,,,,"42~45,XX,-18[cp14]/43~45,idem,+2~3mar[cp3]/47,XX,+8[cp2]/45,X,-X[1]",,,,,"CD34+ BLAST POPULATION, 33%, EXPRESSING PARTIAL CD38, PARTIAL CD4, PARTIAL CD11C, HLA-DR, CD117, PARTIAL CD13, PARTIAL CD33, PARTIAL CD15, AND MPO",,29.1,negative,0,negative,RUNX1 (p.S322Nfs*277; 9.7%),,TP53 (p.I195T; 22.2%)|TP53 (p.P151R; 54.8%),CEBPA (Triple positive)|IDH2
14-00608,training,Dead,1134,BA2122D,BA2122R,2026,1749,Waves1+2,Waves1+2,no,no,no,no,Female,Female,,,White,4,,,75,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,77,716,Post-Chemotherapy,Remission,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,1131,Dead,1134,Dead-Disease,,,,,,,,,,,,,,M2,,,"46,XX[8]",,,,,,,,negative,0,negative,RUNX1 (p.R162K; 95.1%),ASXL1 (p.Q512*; 56.3%)|ASXL1 (p.G645Vfs*58; 9.1%),,
14-00643,training,Alive,566,BA2354D,BA2354R,2050,1763,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,Asian,NON-HISPANIC,Asian,1,,RUNX1-RUNX1T1,37,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,37,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Busulfan, Cyclophosphamide",4,Salvage|Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Matched Unrelated Donor,0,Alive,1348,Alive,0.8,,,0,7.5,17.5,0,37.5,0.4,22,13,3,0.89,M2,15.8,5.5,"45,X,-Y,t(8;21)(q22;q22)[20]",411,100.6,"RUNX1T1/RUNX1:   94% of cells had the dual fusion signal pattern consistent with RUNX1T1/RUNX1 fusion and t(8;21), as seen on metaphase analysis.",42,"dim CD7, CD13, dim CD33, CD34, CD38, CD56, dim partial      CD64, CD117, dim CD123, HLA-DR, MPO, dim TdT positive",7,8.15,negative,0,negative,,,,EZH2 (p.F445fs*3; MAF 30% )|KIT (p.N822K (exon 17); MAF 5% )|KIT (p.Y418_D419insFL (exon 8); MAF 29%)|TET2 (p.G1160E; MAF 49% )
14-00658,training,Dead,254,BA2893D,BA2893R,2455,1775,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,3,,,59,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,59,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Azacitidine, Sorafenib|Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"Azacitidine, Sorafenib",Hypomethylating/Low Dose Cytarabine,-1,Dead,254,Dead-Disease,,51.5,72,,,,,,,,,,,,,,"46,XX[20]",,,Normal,,"Large population of CD117 positive myeloblasts (predominantly CD34 negative, HLA-DR negative), representing approximately 71% of the leukocytes consistent with acute myeloid leukemia.",,89.17,positive,1,positive,,,,NPM1
14-00670,leaderboard,Alive,1059,BA2489D,BA2489R,2480,1787,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,Black,2,,,63,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,3,"AG-221|Azacitidine|Fludarabine, Melphalan, TBI, ATG",3,Hypomethylating/Low Dose Cytarabine|Experimental|Allogeneic - Child,,,,Bone Marrow Transplant,"Fludarabine, Melphalan, TBI, ATG",Allogeneic - Child,-1,Alive,1156,Alive,0,20,0,0,,76,0,24,,18,16,4.1,1.24,,24.9,8.3,"46,XY[20]",148,100.4,,72,,7.4,1.8,negative,0,negative,,ASXL1 (p.G646Wfs*12; 31.2%),,ASXL1 (G646fs*12; MAF 30%)|CIITA (Q320fs*41; MAF 51%)|CUX1 (P442fs*16; MAF 38%)|IDH2 (R140Q; MAF 46%)|SRSF2 (P95H; MAF 40%)|STAG2 (R614*; MAF 90%)
14-00672,leaderboard,Alive,5305,BA2309D,BA2309R,2335,1786,Waves1+2,Waves1+2,no,no,no,no,Male,Male,White,NON-HISPANIC,White,7,,,64,FALSE,FALSE,FALSE,TRUE,FALSE,n,,y,n,n,n,n,n,y,n,MYELOPROLIFERATIVE NEOPLASMS,Essential thrombocythaemia,NonAML,MYELOPROLIFERATIVE NEOPLASMS,Essential thrombocythaemia,77,0,Post-Chemotherapy|Residual Disease,,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,Ruxolitinib|Imatinib|Hydroxyurea,2,Induction|Re-induction,,Standard Chemotherapy,4626,Standard Chemotherapy,Ruxolitinib,Re-induction,-1,Alive,5397,Alive,,15,,,,,,,,,,,,,,,"47,XY,+der(1;9)(q10;p10)[17]/94,idemx2[2]/46,XY[1]",,,"Fluorescent in situ hybridization (FISH) was performed with a 9p/CEP 9 probe set. Both probes hybridized to the derivative chromosome. 90/100 (90%) interphase cells scored had a 3 red/ 3 green signal pattern, reflecting the extra derivative. ",,"dimCD7, CD13, dim CD33, CD34, CD71, and CD117 positive",,,negative,,negative,,,,
14-00676,training,Dead,318,BA2720D,BA2720R,2394,1561,Waves1+2,Waves1+2,no,no,no,no,Male,Male,White,NON-HISPANIC,White,1,,,23,FALSE,FALSE,FALSE,FALSE,FALSE,y,Mediastinum mass,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,24,163,Residual Disease|Post-Chemotherapy,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),2,"Trametinib|HAEP (Cytarabine, Etoposide, Cisplatin) ",3,Consolidation|Induction|Experimental,Complete Response,Standard Chemotherapy,8,Targeted Therapy - Kinase Inhibitor(s),Trametinib,Experimental,197,Dead,318,Dead-Disease,0,5,10,0,2.9,36.2,1.5,47.8,,30,146,3.4,0.82,M6b,25.5,7.9,"48,XY,add(6)(p22),der(7)t(7;19)(p11.2;p12),del(9)(p13p22),i(13)(q10)x2,add(14)(q24),+mar1,+mar2[cp2]/46~48,sl,add(17)(p1?3),add(22)(q13)[cp9]/46~48,sl,add(21)(p11.2)[cp6]/47~48,sl,add(1)(p36.1)[cp2]/48,sl,t(2;17)(p21;p11.2)[1]",,98.5,Low-level tetraploidy or near-tetraploidy,48,"A CD34 positive blasts population comprises approximately 4% of cellular gated events. Approximately 3% of cells are lymphocytes composed of 28% B cells, 45% T cells and 27% NK cells. | T cells are present in a CD4:CD8 ratio of about 1.1:1 and do not demonstrate aberrant antigen expression. A monoclonal B cell population is not identified.",6.1,11.28,negative,0,negative,,,TP53 (p.G245S; 89.1%),NRAS (p.G12C; MAF 97%)|TP53 (p.G245S; MAF 96%)
14-00712,leaderboard,Dead,158,BA2872D,BA2872R,2415,1810,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,65,FALSE,FALSE,FALSE,FALSE,FALSE,y,Pancreatic adenocarcinoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,65,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"3+7 (Cytarabine, Daunorubicin)|Decitabine|5+2 (Ara-C, Daunorubicin)",3,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,Decitabine,Salvage,9,Dead,158,Dead-Disease,0,18,12,0.9,32,7.4,35.2,18.5,4.8,44,165,2.9,1.65,M2,20.1,6.7,"46,XY,i(17)(q10)[20]",3923,81,"TP53/CEP17: 85% of cells were missing a signal for TP53, consistent with deletion due to the i(17) seen on metaphase analysis.  PML/RARA: 69% of cells had three signals for RARA (17q21), consistent with three copies of 17q due to the i(17) seen on metaphase analysis.",40,"CD13, CD33, CD34, CD117, and HLA-DR positive",5.7,161.89,negative,0,negative,,,,ASXL1 (p.R693fs*10; MAF 49% )|CREBBP (p.S893L; MAF 52% )|NRAS (p.G12D; MAF 46% )
14-00739,training,Dead,216,BA2541D,BA2541R,2484,1820,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,KMT2A_re,39,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,39,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Intrathecal,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Methotrexate",3,Induction|CNS|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Re-induction,4,Dead,216,Dead-Disease,0,>90,,0,0,28.3,17.7,3.5,0,19,14,3,0.97,M5,31.1,10.7,"46,XY,t(6;11)(q27;q23)[20]",,98.4,MLL: 80% of cells had a split signal pattern consistent with the disruption of MLL due to the t(6;11).,31,"dim CD4, partial CD11b, CD13, CD33, CD34, partial      CD38, partial CD64, CD117, CD123, HLA-DR and dim MPO positive.",6.2,21.12,negative,0,negative,,,,MLL (PTD)
14-00774,training,Dead,67,BA2843D,BA2843R,2178,1843,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,4,,,84,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,84,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"Decitabine, Midostaurin",1,Induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,"Decitabine, Midostaurin",Induction,-1,Dead,67,Dead-Disease,,85,88,,,,,,,,,,,M0,,,"46,XY[20]",,,,,"CD34, CD38, CD117, CD13, CD4, HLA-DR, AND TDT",,30,positive,0.851851851851852,negative,,,,FLT3-ITD
14-00780,training,Dead,2661,BA2592D,BA2592R,2070,1098,Waves1+2,Waves1+2,no,no,no,no,Female,Female,,,White,2,,,31,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,38,1496,Post-Chemotherapy|Post-Transplant|Residual Disease,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,4,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),9,"Fludarabine, Melphalan|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Rituximab|Busulfan, Cyclophosphamide",7,Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Experimental|Re-induction,Complete Response,Standard Chemotherapy,-1,Targeted Therapy - Kinase Inhibitor(s),Dasatinib,Experimental,24,Dead,2661,Dead-Unknown,,7,1,,,,,,,15,21,4.2,,,31.9,11,"46,XX[20]",,,nuc ish(DXZ1x2)[200],45,,6.2,2.2,negative,0,negative,,,,BCOR (S259fs*10; MAF 15%)|CCND2 (P281R; MAF 19%)|FLT3-D835 (D835E; MAF 13%)|GATA2 (N297S; MAF 18%)|IKZF1 (Q44*; MAF 14%)|MLL2 (Y2907*; MAF 7%)|PTPN11 (E76V; MAF 17%)|PTPN11 (V45L; MAF 13%)|SETBP1 (H1100R; MAF 51%)|SF3B1 (K700E; MAF 18%)
14-00781,training,Dead,162,BA2497D,BA2497R,2517,1847,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,KMT2A_re,71,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,71,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,5,Standard Chemotherapy,MiDAC,Consolidation,5,Dead,162,Dead-Disease,0,80,80,0,2,21,4,1,0.8,29,282,3.2,1.61,M5,31.8,10,"47,XY,t(1;11)(p32;q23),+8[cp20]",7759,102.3,"CEP 8:  56% had three signals, consistent with the trisomy 8 in the metaphase karyotype|RUNX1T1: 70% had three signals, consistent with the trisomy 8 in the metaphase karyotype|MLL: 72% reflected MLL rearrangement and its involvement in the 1;11 translocation.",59,"CD11b, CD13, partial CD14, CD15, CD33,CD38, CD45, CD56, CD58, CD64, HLA-DR and MPO-positive",6.1,71.19,negative,0,negative,,,,CREBBP (p.Q1765*; MAF 4% )|KRAS (p.G13D; MAF 27%)
14-00787,leaderboard,Alive,442,BA2718D,BA2718R,2119,1848,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,bi,,61,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,61,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC",3,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Sibling,-1,Alive,2423,Alive,0,90,90.5,0,0,8.2,2.2,0.9,0.8,22,43,3.1,1.21,M1,17.3,5.2,"46,XY[20]",1873,96.1,Normal,34,"CD7, CD13, CD33, CD34, CD117, HLA-DR, cMPO (+)",6.9,427.46,negative,0,negative,,,,CEBPA (p.A30fs*130; MAF 40%)|CEBPA (p.N307_V308ins; MAF 50%)
14-00798,leaderboard,Dead,15,BA2575D,BA2575R,2043,1852,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,CBFB-MYH11,36,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,36,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Unknown,Standard Chemotherapy,6,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,6,Dead,15,Dead-Treatment,0,74,82,1.7,1.7,6.7,82.3,3.4,0,45,36,2.7,0.68,M4,20.4,7.1,"46,XX,inv(16)(p13.1q22)[20]",,87.6,"CBFB; 76/100 cells (76%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement. ",12,"Immunophenotyping done on the peripheral blood on 12/1/2014      identified a myeloid blast population with the following immunophenotype:      CD13, partial CD15, CD33, CD34, CD38, CD58, variable CD64, CD117, HLA-DR      and cMPO. And, it identified a promonocyte/monoblast population expressing:",5.8,117.53,negative,0,negative,,,,KRAS (p.G12D; MAF 9% )|NRAS (p.G12D; MAF 10%)
14-00800,training,Dead,114,BA3008D,BA3008R,2404,1854,Waves1+2,Waves1+2,yes,yes,no,yes,Male,Male,White,NON-HISPANIC,White,1,,,68,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,69,0,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,n,y,y,1,Standard Chemotherapy,2,"CPX-351 (Liposomal Cytarabine + Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",3,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,4,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Salvage,4,Dead,114,Dead-Disease,,,,,,,,,3.6,26,65,3.1,1.07,,20.9,7.2,"46,XY[20]",1004,90.1,,17,,5.4,53.76,negative,0,negative,,,,CBL (p.C404Y; MAF 28%)|SF3B1 (p.K666N; MAF 36% )|TET2 (p.L1047fs*11; MAF 34% )
14-00832,leaderboard,Alive,450,BA2620D,BA2620R,2150,1868,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,65,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,65,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC",3,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Mismatched Unrelated Donor,0,Alive,2426,Alive,0.8,,30,0,12.5,24.2,28.3,18.4,0,23,29,3,0.78,,22.4,7.4,,561,107.2,,60,"CD7, minor subset CD11b, CD13, minor subset CD14,      dim CD33, CD34, CD38, CD58, minor subset CD64, CD117, CD123, HLA-DR, subset      myeloperoxidase positive",6.6,31.66,positive,,negative,,ASXL1 (p.R549Pfs*2; 42.0%),,FLT3-ITD (MAF 45%)
14-00901,training,Dead,104,BA2629D,BA2629R,2486,1870,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,61,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,61,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC",3,Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,MiDAC,Consolidation,44,Dead,104,Dead-Treatment,0,80,,0,0,45.5,0.8,0,0.3,14,18,2.4,0.73,M0,21.3,6.9,"46,XY,t(1;4)(q21;p14)[20]",178,103.4,Normal,57,"partial CD7, partial CD13, CD34, partial CD38,      partial CD117, dim CD123, HLA-DR and TDT positive",7,13.68,negative,0,negative,RUNX1 (p.R250Lfs*13; 50.0%),,,BCOR (p.S571*; MAF 90% )|MLL (PTD)|ZRSR2 (p.C181F; MAF 88%)
15-00043,training,Alive,420,BA2348D,BA2348R,2032,1924,Waves1+2,Waves1+2,no,no,no,no,Female,Female,,,White,5,,,43,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,44,0,Post-Chemotherapy,Remission,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|Busulfan, Cyclophosphamide",3,Allogeneic - Sibling|Induction|Re-induction,Refractory,Standard Chemotherapy,12,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1,Alive,1105,Alive,,,,,,,,,,,,,,,,,"46,XX,add(3)(q21)[12]/52,sl,+6,+8,+10,+13,+20,+21[8]",,,"Positive for an EVI1 rearrangement: < 0.9% |ABNORMAL - Low level gain of chromosome 8 and 20q12 sequences, trisomy:  < 0.3%)",,,,,negative,0,negative,,,,
15-00045,training,Alive,854,BA2709D,BA2709R,2346,1925,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,Unknown,,White,2,,CBFB-MYH11,30,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,30,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)",3,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,40,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Re-induction,-1,Alive,1024,Alive,0,36,22,0,,12,44,5,,61,44,4.2,0.59,,31.8,11,"46,XX,inv(16)(p13q22)[20]",441,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2 [199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(RUNX1T1,RUNX1)x2[200],(PML,RARA)x2[200], (5'CBFBx2,3'CBFBx1)(5’CBFB sep 3'CBFBx1)[195/200],(ABL1,BCR)x2[200]",33,"CD34, CD13, partialCD15, CD38, CD45, CD117, CD123, HLA-DR, dimMPO (15% population of variably-sized blasts)",7,55,negative,0,negative,,,,
15-00051,leaderboard,Alive,534,BA2789D,BA2789R,2141,1929,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,66,FALSE,FALSE,FALSE,FALSE,FALSE,y,Breast Cancer,y,y,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,66,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",Allogeneic - Matched Unrelated Donor,2,Dead,1715,Dead-Other,0,95,90.2,0,2.5,4.9,0.8,1.6,0.6,19,23,3,0.5,M1,18.9,6.1,,501,100.5,Normal,10,"CD13, CD33, dim CD71, CD117, CD123, and MPO",6.4,66.67,negative,0,positive,,,,IDH2 (p.R140Q; MAF 46%)|NPM1 (p.W288fs*9; MAF 42%)
15-00057,leaderboard,Dead,680,BA2694D,BA2694R,2552,1933,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,5,,,76,FALSE,FALSE,TRUE,FALSE,FALSE,y,Basal Cell Carcinoma,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,76,0,Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,2,AG-221|Decitabine,2,Hypomethylating/Low Dose Cytarabine|Experimental,,,,Targeted Therapy - Other,AG-221,Experimental,-1,Dead,680,Dead-Disease,,70,55,,,,,,,,,,,,,,"46,XY[20]",,,Normal,46,"positive for CD13, CD34, CD38, CD117, and HLA-DR; negative for MPO, and B-cell and T-cell markers",,4.5,negative,0,negative,RUNX1 (p.E422Afs*173; 58.1%),ASXL1 (p.E657*; 50.0%),,
15-00075,training,Dead,34,BA2583D,BA2583R,2175,1964,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,5,,,80,FALSE,FALSE,TRUE,FALSE,FALSE,n,,n,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,80,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Targeted Therapy - Other,1,AG-221,1,Experimental,,,,Targeted Therapy - Other,AG-221,Experimental,-1,Dead,34,Dead-Disease,,90,48,,,,,,,,,,,,,,"46,XY,del(20)(q11.2q13.1)[12]/45,sl,-7[3]/45,XY,-7[5]/46,XY[2]",,,Tetrasomy 5p/q; Monosomy 7; Loss 20q12 (15.5%); Tetrasomy 8cen and 20q12 (7,65,"positive for CD13, dim CD33, CD34, CD38, dim CD45, CD117, HLA-DR and TdT",,6.6,negative,0,negative,RUNX1 (p.R162G; 80.6%),,,IDH1 (C.G395A; p.R132H; MAF unknown)
15-00084,leaderboard,Dead,35,BA2722D,BA2722R,2244,1953,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,82,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,82,0,Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,122,Dead,35,Dead-Disease,7.6,,,4.2,8.5,28,6.8,12.7,0.1,24,22,3.1,0.96,,31.5,11,"43~46,XX,add(2)(q11.2),-4,del(5)(q23),add(7)(q32),+8,add(11)(q23),-16,del(17)(p12),-18,+22[cp19]/46,XX[1]",1304,86.8,,21,,7.3,17.63,negative,0,negative,,,TP53 (p.P151S; 96.9%),
15-00123,training,Alive,832,BA2806D,BA2806R,2285,1969,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,Unknown,,White,2,,,42,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,42,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,5,Bone Marrow Transplant,Bu/Cy/ATG,Allogeneic - Matched Unrelated Donor,-1,Alive,1016,Alive,,81,85,,,4,7,4,,89,50,3,0.94,,27.8,9.5,,945,95.5,,39,"partialCD4, partial/dimCD7, partialCDllb, CD13, partialCD15, partialCD22, partialCD25, brightCD33, partialCD34, CD38, CD45, CD117, partialCD123, HLA-DR, partialMPO, partialTdT",5.7,48.03,positive,0.96078431372549,positive,,ASXL1 (p.G645Vfs*58; 8.0%),,FLT3-ITD|NPM1
15-00147,leaderboard,Dead,843,BA3025D,BA3025R,2262,1981,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,HISPANIC,HispNative,1,bi,,28,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,30,2,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,6,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Fludarabine, Cyclophosphamide, TBI ",6,Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, TBI ",Double Umbilical Cord Blood Transplant (DUCBT),-1,Dead,843,Dead-Disease,0,,,0,0,4.1,0,2.1,32.3,54,37,3.7,0.3,NOS,27.3,9.2,"46,XX,t(2;9)(q31;p21)[17]/46,X,t(X;9)(q22;p21)[3]",,91.3,,8,"CD7, CD13, CD33, CD34, CD38, CD58, dim CD71, CD117, HLA-DR, MPO and partial TDT positive.",6.3,20.18,negative,0,negative,,,,
15-00171,leaderboard,Dead,309,BA2520D,BA2520R,2400,2002,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,5,,,80,FALSE,FALSE,FALSE,FALSE,FALSE,y,Mature B-Cell Neoplasm,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,80,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s),3,"Cytarabine|Decitabine|PF-04449913 (Hedgehog Inhibitor), LDAC",3,Consolidation|Salvage|Experimental,,,,Targeted Therapy - Kinase Inhibitor(s),Decitabine,Salvage,-1,Dead,309,Dead-Disease,,80,86,,,,,,,,,,,M0,,,"46,XY,del(20)(q11.2q13.1)[15]/46,XY[5]",,,Positive for deletion of 20q12 in 11.5% of 200 cells,4,"positive for dim CD7, dim CD10, CD34, CD38, dim CD45, cCD79a, CD99, HLA-DR, TdT, dim PAX5",,,negative,0,negative,RUNX1 (p.R204*; 45.5%)|RUNX1 (p.S141*; 45.1%),ASXL1 (p.D720Rfs*18; 14.1%),,ASXL1 (p.718_724del; MAF 50.3%)|RUNX1 (p.R177X; MAF 47%)|RUNX1 (p.S114X; MAF 44.8%)|SRSF2 (p.P95H; MAF 45.1%)
15-00175,training,Dead,99,BA2441D,BA2441R,2250,1999,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,HISPANIC,HispNative,1,,,50,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,50,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)",2,Salvage|Induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Salvage,4,Dead,99,Dead-Disease,0,76,93,0,0,6.1,1.7,1.8,0,7,10,2.2,0.44,M0,18.8,6.3,"43~47,XY,del(1)(q42),r(2)(p2?3q37),t(3;5)(q27;q31),del(4)(q31),+del(5)(q31),add(5)(q11.2),-7,del(11)(q23),add(12)(p13),-22,+mar[cp11]/43~46,idem,add(14)(q24)[cp8]",,85.8,deleted 5q and three short arm signals; monosomy 7 and the metaphase karyotype; no evidence for MLL deletion or rearrangement,14,"CD7, CD11b, CD13, dim CD33, CD34, CD38, CD58,   CD117 and HLA-DR+",5.9,50.74,negative,0,negative,,,TP53 (p.R273H; 53.6%)|TP53 (p.G105D; 52.9%),"NRAS ( p.Q61K; MAF 37%)|TP53 (p.G105D, MAF 60%)|TP53 (p.R273H; MAF 44%)"
15-00237,training,Alive,476,BA2932D,BA2932R,2069,2028,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,29,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,IntermediateOrAdverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,29,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,24,Standard Chemotherapy,"Busulfan, Cyclophosphamide",Allogeneic - Matched Unrelated Donor,-1,Alive,2383,Alive,0,95,78,0.9,0,11.7,0,13.5,1.8,20,25,3,0.54,M1,23,7.9,"46,XX[20]",1119,95.8,Normal,12,"dim CD2, dim CD7, CD13, dim CD19, dim CD20,      CD33, partial CD34, variable CD38, dim CD64, CD117, CD123, and HLA-DR      positive.",6.1,68.79,positive,,negative,,,,FLT3-ITD (MAF 50%)|MLL (PTD)
15-00261,training,Dead,245,BA2660D,BA2660R,2170,2052,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,43,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,43,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,3,"7+3 (Cytarabine, Idarubicin)|Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)",3,Induction|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,6,Supportive/Palliative Care,Cytarabine,Supportive/Palliative Care,125,Dead,245,Dead-Disease,0,,,0,0,31.9,12.4,2.6,0.1,26,16,3,0.77,M4,22.1,7.5,"46,XX[20]",297,95.7,Normal,59,"Myeloid blast (52%) immunophenotype: CD13, variable CD33, CD34, variable CD38, variable CD117, HLA-DR, and TdT positive | Monocytic blast/promonocyte (28%) immunophenotype: dim CD2, CD11b, CD13, variable CD14, bright CD33, dim CD34, CD38, CD58, CD64, and HLA-DR positive",6.5,22.95,positive,,negative,RUNX1 (p.R250Lfs*13; 46.7%),,,FLT3-ITD (MAF 47%)|RUNX1 (p.K110Q; MAF 38%)|SUZ12 (p.E261fs*2; MAF 52%)
15-00269,training,Dead,430,BA2836D,BA2836R,2242,2053,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,2,,,59,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,59,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,HiDAC,Consolidation,107,Dead,430,Dead-Unknown,0,35,27.4,0,,36.8,6.6,29.2,,13,25,2.9,1.4,,23.6,7.6,"46,XY[20]",383,,"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",35,"CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(- to partial dim +), CD16(-), CD25(-), CD33(+ to slightly bright +), CD34(partial +), CD36(equivocal), CD38(slightly dim and variable), CD45(dim +), CD56(-), CD64(-), CD117(+), CD123(+), HLA-DR(+), MPO(+), TdT(-).",6,3.6,negative,0,positive,,,,CEBPA (H224fs*97; MAF 7%)|CEBPA (Y181*; MAF 15%)|IDH2 (R140Q; MAF 35%)|NPM1 (W288fs*10+; MAF 26%)|POT1 (splice site 1164-1G>A; MAF 48%)|SRSF2 (P95R; MAF 37%)
15-00275,training,Dead,72,BA3027D,BA3027R,2324,1992,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,5,,,53,FALSE,FALSE,FALSE,FALSE,FALSE,y,Ovarian cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,53,33,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)",2,Induction|Re-induction,Complete Response,Standard Chemotherapy,29,Standard Chemotherapy,"GCLAC (GCSF, Clofarabine & Cytarabine)",Re-induction,17,Dead,72,Dead-Disease,,,,,,,,,,,,,,,,,"53~55,XX,+1,+2,der(5)t(5;13)(q13;q12),+6,add(7)(q32),+8,+11,-13,+14,i(17)(q10),+19,+19,+21,+mar[cp7]/46,XX[7]",,,Gain of 8 (4/301 cells); Gain of 8q22/21q22 (7.7/301 cells); Gain 11q23 (5/200 cells),,,,,negative,0,negative,,,TP53 (p.S215R; 15.2%),
15-00276,leaderboard,Dead,870,BA2714D,BA2714R,2366,2059,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,60,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,60,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)",3,Salvage|Induction|Re-induction,Complete Response,Standard Chemotherapy,167,Standard Chemotherapy,Azacitidine,Salvage,6,Dead,870,Dead-Disease,0,90,61,1,4,47,10,1,0.1,30,26,2.4,1.17,M4,14,4.6,"46,XY[20]",612,104.5,Normal,80,"dim CD4, dim CD7, dim CD11b, CD13, CD33, variable CD34, CD38, CD58, variable CD64, CD117, CD123, dim HLA-DR, MPO, and dim TdT",5.8,70.84,negative,0,positive,,,,FLT3-V491L (p.V491L; MAF 51%)|NPM1 (p.W288fs*12; MAF 50%)|SF3B1 (p.K666Q; MAF 47%)|WT1 (p.Y395fs*51; MAF 49%)
15-00279,training,Alive,435,BA2139D,BA2139R,2342,2087,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,3,,,48,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,48,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|TBI, VP-16",4,Consolidation|Induction|CNS|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"TBI, VP-16",Allogeneic - Matched Unrelated Donor,-1,Alive,939,Alive,,86,77,,,,,,,,,,,M5b,,,"46,XX ",,,,,"Large population of atypical monocytic cells (weaker than  normal CD33, partial loss of CD13) including  promonocytes/monoblasts representing approximately 50% of  the leukocytes suggestive of acute monoblastic or monocytic  leukemia. | Large population of atypical monocytic cells (weaker than normal CD33, partial loss of CD13) including promonocytes/monoblasts representing approximately 50% of the leukocytes",,81,positive,0.785714285714286,positive,,,,DNMT3A (p.Arg882Cys; MAF 47.1%)|FLT3-ITD|NPM1 (p.Trp288fs (NM_002520.6); MAF 27.9%)
15-00287,training,Dead,167,BA2251D,BA2251R,2334,2073,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,bi,,85,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,85,0,Residual Disease|Post-Chemotherapy,Residual,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,105,Dead,167,Dead-Disease,0,,,2.5,0,14.6,2.4,0,0.5,14,15,3.5,0.98,,33.2,10.7,"46,XY[20]",289,89.5,Normal,8,,7.4,25.63,negative,0,negative,,,,CEBPA (p.F77*83; MAF 50%)|CEBPA (p.K313_V314insK; MAF 50%)|TET2 (p.I1025L; MAF 50%)
15-00296,training,Alive,318,BA2952D,BA2952R,2114,2079,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,MLLT3-KMT2A,16,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,16,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine, Mitoxantrone|Etoposide, Cytarabine",2,Induction|Intensification,Complete Response,Standard Chemotherapy,10,Standard Chemotherapy,"Cytarabine, Mitoxantrone",Intensification,-1,Alive,2272,Alive,0,93,,0,0,33,67,0,0,,,,0.72,M5,18.2,6.1,"46,XX,t(9;11)(p22;q23)[3]/50,sl,+6,+8,+der(9)t(9;11),+19[14]/51,sdl1,+5[3]",934,100,"MLL:   14% of cells had a pattern consistent with the t(9;11) seen on metaphase analysis.  An addition 65% of cells had a signal pattern, consistent with the clone with the +der(9). | BCR/ABL+ASS:   62% of cells had three signals for both ABL and ASS (9q34), consistent with the clone with +9. | RUNX1T1 (8q22):   69% of cells had three signals for RUNX1T1, consistent with the clone with +8. | EGR1:   7% of cells had three signals for EGR1 (5q31), consistent with the clone with +5.",39,"CD11b, dim CD13, dim CD15, CD33, CD38, dim CD45, CD56,      CD58, bright CD64, dim CD117, CD123, HLA-DR, and variable MPO positive",,24.72,negative,0,negative,,,,KRAS (p.G13D; MAF 6%)|NRAS (p.Q61H; MAF 19%)
15-00302,training,Dead,21,BA2036D,BA2036R,2445,2068,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,3,,,65,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,UNKNOWN,Standard Chemotherapy,-1,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,-1,Dead,21,Dead-Treatment,,,,,,,,,,,,,,,,,,,,,,"Large population of atypical myeloblasts (CD56 positive,  weak CD117 positive, CD34 negative, HLA-DR negative),  representing approximately 87% of the leukocytes,  consistent with acute myeloid leukemia",,,negative,0,positive,,,,KMT2A (p.Ile3572Ser (NM_001197104.1); MAF 44.1%)|NPM1 (p.Trp288fs (NM_002520.6); MAF 27.4%)|TET2 (p.His724fs; MAF 43.5%)
15-00338,training,Alive,155,BA2532D,BA2532R,2323,2094,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,Unknown,,White,2,,PML-RARA,42,FALSE,FALSE,FALSE,FALSE,FALSE,y,Cervical Cancer|Pituitary Tumor,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,42,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Targeted Therapy - Other|Intrathecal,3,"ATRA, Arsenic Trioxide|ATRA, 6-MP, Methotrexate|Methotrexate",3,Induction|Experimental|Maintenance,Complete Response,Standard Chemotherapy,22,Standard Chemotherapy,"ATRA, 6-MP, Methotrexate",Maintenance,-1,Alive,952,Alive,0,92,83,0,,11,4,0,,35,35,3.9,0.66,M3,22.2,7.6,"46,XX,t(15;17)(q24;q21.1)[1]",475,88.4,"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML, RARA)x3(PML con RARAx2)[154/200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",35,"CD2(-), CD4(partial +), CD11b(few dim +), CD13(+), CD14(-), CD15(-), CD16 (-), CD25(-), CD33(bright +), CD34(-), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(+), CD117(variably +), CD123(+), HLA-DR(-), myeloperoxidase(+), and TdT(-).",5.8,,negative,0,negative,,,,
15-00371,leaderboard,Dead,324,BA2515D,BA2515R,2533,2113,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,Unknown,,White,2,mono,,74,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",75,0,Residual Disease|Post-Chemotherapy,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine",3,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,HiDAC,Consolidation,48,Dead,324,Dead-Unknown,0,32,5,0,,69,8,18,,23,22,4.3,1.21,,32.9,11.1,"46,XY[18]",199,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[198],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",178,"CD2(-), CD4(partial dim +), CD7(partial +), CD11b(partial dim +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD22 (-), CD25(-), CD33(variably +), CD34(bright +), CD36(-), CD38(bright +), CD45(moderate/dim +), CD56(-), CD64(-), CD79a (-), CD117(+), CD123(-), HLA-DR(+), MPO(+), TdT(partial +) (34% population of variably-sized cells)",7.1,2.3,negative,0,negative,,,,
15-00377,training,Alive,569,BA2748D,BA2748R,2566,2116,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,bi,,10,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,10,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|ADE (Cytarabine, Daunorubicin & Etoposide)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide",3,Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,33,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Matched Unrelated Donor,-1,Alive,2143,Alive,0,80,75,1.7,6.1,17.4,7.8,11.3,0.7,24,22,3.7,0.51,M2,30.3,9.1,"46,XX[20]",688,83.7,Normal,74,"variable CD7, variable CD13, CD33, partial CD34, bright CD38, partial CD56, CD58, variable CD71, CD117, CD123, HLA-DR, and MPO positive",7.3,39.69,negative,0,negative,,,,"CEBPA (p.G96fs*12; MAF ~50% )|CEBPA (p.G96fs*12; MAF ~50%)|CEBPA (p.R306_N307insPPT; MAF ~50%)|MLL (PTD (low level mutation))|NRAS (p.G12A, MAF 6%)|NRAS (p.G12A; MAF 6% )|NRAS (p.G12D; MAF 5% )|NRAS (p.G12D; MAF 5%)|NRAS (p.G13D; MAF 8%)|NRAS (p.G13R; MAF 5%)|NRAS (p.Q61H; MAF 10%)"
15-00383,training,Dead,8,BA2970D,BA2970R,2327,2127,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,Black,NON-HISPANIC,Black,2,,,63,FALSE,FALSE,TRUE,FALSE,FALSE,n,,n,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,63,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Supportive/Palliative Care,2,Ruxolitinib|Hydroxyurea,1,Supportive/Palliative Care,,,,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,103,Dead,8,Dead-Disease,1,9,15.4,2.9,,20.2,16.3,42.3,,,,,0.6,,22.7,7,"46,XY[20]",1086,,"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",126,"CD34(+), CD7(partial +), CD13(+), CD33(+), CD38(partial +), CD45(moderately +), CD56 (+), CD117(+), HLA-DR(variably +), other myeloid and lymphoid antigens(-).",,73.4,positive,9,positive,,ASXL1 (p.W898*; 42.1%),,ASXL1 (Foundation; W898*; MAF 47%)|KRAS (Foundation; A59T mutation; MAF 47%)|KRAS (Foundation; G13C; MAF 3%)|SUZ12 (Foundation; W617*; MAF 49%)
15-00464,training,Dead,288,BA2052D,BA2052R,2412,2147,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,Unknown,,White,2,,,71,FALSE,TRUE,FALSE,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",71,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Supportive/Palliative Care,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Supportive/Palliative Care,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1,Dead,288,Dead-Unknown,0.9,34,,2.8,,,,,,28,27,4.2,1.18,,29.3,9.8,"46,XY,inv(4)(p14p16.1)[3]/46,XY[16]",194,,"nuc ish(D5S2064,D5S630,EGR1)x4[32/200],(D7Z1,D7S522)x4[17/200],(D8Z2, D20S108)x4[27/200],(RUNX1T1,RUNX1)x4[32/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[21/200],(PML,RARA)x4 [34/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[35/200]",73,"CD2 (-), CD7(few +), CD11b(-), CD13(partial dim +), CD14(-), CD15(partial dim +), CD16(-), CD22(partial dim +), CD33(-), CD34(bright +), CD36(-), CD38(moderately bright +), CD45(partial +), CD56(-), CD64(-), CD117(partial +), HLADR(+) (32% population of medium to large cells)",7.1,,negative,0,negative,,,,"BCOR (Foundation; Q1337*; MAF 56%)|CTCF (Foundation; R49H; MAF 19%)|RUNX1 (Foundation; loss, splice site 477_508+22>GGG; MAF 50%)|SRSF2 (Foundation; R94_S101del;MAF 39%)|TET2 (Foundation; splice site 3409+2T>G; MAF 51%)"
15-00470,training,Alive,292,BA3011D,BA3011R,2236,2144,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,Multiracial,HISPANIC,HispNative,1,,PML-RARA,32,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,32,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,1,"ATRA, Arsenic Trioxide",2,Consolidation|Experimental,,,,Standard Chemotherapy,"ATRA, Arsenic Trioxide",Consolidation,232,Alive,2104,Alive,0,80,,0,19.6,56.3,0.9,3.6,0.1,31,20,3,0.84,M3,19.1,6.3,"46,XY,t(15;17)(q22;q21)[20]",,96.5,70% PML/RARA,49,"CD13, CD33, CD64, CD117, CD123 and  MPO-positive",6.9,7.19,positive,,negative,,,,"FLT3-ITD (MAF 7%)|MPL (p.E484G, MAF 3%)|WT1 (p.F451C; MAF 51% )"
15-00471,leaderboard,Dead,250,BA2868D,BA2868R,2442,2142,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,3,bi,,69,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,69,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,Azacitidine,Induction,-1,Dead,250,Dead-Disease,,60,,,,,,,,,,,,,,,,,,,,"weak  CD7, CD13, partial CD15, weak CD33, CD34, weak CD64, CD117,  myeloperoxidase, and HLA-DR, but do not express CD14(MO2),  CD42b, or CD61.",,33,negative,0,negative,,,,CEBPA (c.117delC; MAF 27.2%)|CEBPA (c.938_939insATC; MAF 18.1%)|TET2 (c.3454G>T; MAF 40.9%)|WT1 (c.1137_1138insA; MAF 43.7%)|WT1 (c.872+1G>A; MAF 40%)
15-00482,leaderboard,Alive,788,BA2065D,BA2065R,2029,1532,Waves1+2,Waves1+2,no,no,no,no,Female,Female,White,NON-HISPANIC,White,1,,,46,TRUE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,47,424,Relapse,Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,5,"7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC",3,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Re-induction,4,Dead,1373,Dead-Disease,0,70,59,3.5,0.9,17.7,0,13.3,0,184,77,2.8,0.72,M4,37,12.6,"46,XX[20]",,94.4,Normal,138,"CD13, CD33, partial CD34, partial CD38, dim partial  CD64, CD117 and CD123 positive",5.7,16.95,negative,0,positive,,,,DNMT3A (p.R882C; MAF 39%)|NPM1 (p.W288fs*>9 ; MAF 39%)|PTPN11 (p.E76Q; MAF 41%)
15-00534,training,Dead,249,BA2804D,BA2804R,2101,2195,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,5,mono,,87,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,87,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,2,AG-120|Decitabine,2,Hypomethylating/Low Dose Cytarabine|Experimental,,,,Targeted Therapy - Other,AG-120,Experimental,-1,Dead,249,Dead-Disease,,60,39,,,,2,,,,,,,M5,,,"47,XY,+21[3]/46,XY[9]",,,9.5% gain 21q22,43,"A distinct blastic population, expressing CD7, CD13, CD15, CD33, CD34, CD38, dim CD45, CD64, MPO, and HLA-DR | A large monocytic population, positive for CD11b, CD13, CD14, CD15, CD33, CD38, CD45, CD64, HLA-DR and MPO",,139.9,negative,0,negative,,,,ASXL1 (p.G642fs; MAF 31.6%)|CEBPA (p.A66fs; MAF 37.3%)|CEBPA (p.Q162fs; MAF 50.3%)|IDH1 (p.R132C; MAF 48.7%)|TP53 (p.N107D; MAF 97.6%)
15-00539,training,Dead,465,BA2670D,BA2670R,2456,2196,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,,White,2,,,72,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,73,0,Residual Disease|Post-Chemotherapy,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Other,4,"Lenalidomide|Azacitidine|Decitabine|Clofarabine, Cytarabine",2,Hypomethylating/Low Dose Cytarabine|Maintenance,,,,Other,"Clofarabine, Cytarabine",Hypomethylating/Low Dose Cytarabine,-1,Dead,465,Dead-Disease,0,,25,0,,2,54,18,,41,34,3.6,0.58,,27.5,8.8,"46,XX,+1,der(1;21)(q10;q10)[6]/46,XX[14]",,,"nuc ish(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200]",,,6.2,58.2,negative,0,negative,,,,RUNX1 (PB)|SF3B1 (PB)
15-00556,training,Alive,75,BA2675D,BA2675R,2133,2202,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,mono,,10,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,IntermediateOrAdverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,10,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,4,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Other,4,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|Unknown|MiDAC",3,Unknown|Induction|Re-induction,Refractory,Standard Chemotherapy,10,Bone Marrow Transplant,Unknown,Unknown,-1,Alive,2095,Alive,0,75,86,0,0,7.5,1.8,4.7,0.1,13,23,3.6,0.47,M2,21.6,6.9,"46,XY[20] ",970,96,,42,"variable CD7, dim CD11b, CD13, CD33, partial CD34, dim CD64, CD117, CD123, HLA-DR, and dim MPO positive",7.8,133.63,positive,,negative,,,,CEBPA (p.R142fs*19; MAF 52%)|FLT3-ITD (MAF 48%)
15-00559,training,Dead,448,BA2589D,BA2589R,2064,2205,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,HispNative,5,,,42,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,42,0,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,3,"7+3 (Cytarabine, Idarubicin)|AG-221|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",3,Salvage|Induction|Experimental,Refractory,Standard Chemotherapy,-1,Targeted Therapy - Other,AG-221,Experimental,-1,Dead,448,Dead-Disease,,50,51,,,,,,,,,,,,,,"46,XX[20]",,,Normal,256,"positive for CD13, CD34, CD38, dim CD45, CD117, HLA-DR, and MPO",,10.7,negative,0,negative,,,,ASXL1 (p.G652S; MAF 41.3%)|ASXL1 (p.S1231F; MAF 50.4%)|DNMT3A (p.S307fs; MAF 45.6%)|IDH1 (c.C315T; p.G105G; MAF 46.6%)|IDH2 (p.R140Q; MAF 43.8%)|SRSF2 (p.P95H; MAF 42.2%)
15-00563,training,Alive,428,BA2031D,BA2031R,2387,2204,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,KMT2A_re,2,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,2,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,4,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide",3,Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,136,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Matched Unrelated Donor,-1,Alive,1937,Alive,0,80,70,0,1.8,46,0,0,0.2,22,53,,0.24,M5,22,6.9,"46,XX,t(6;11)(q27;q23)[19]/46,XX[1]",,92.8,,40,"CD4, CD11b, variable CD13, CD15, CD33, variable CD56, CD58, CD64, lysozyme, and dim HLA-DR positive",,57.08,negative,0,negative,,,,
15-00578,training,Alive,27,BA2066D,BA2066R,2066,2214,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,KMT2A_re,62,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,62,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Other,4,"3+7 (Cytarabine, Daunorubicin)|MiDAC|Hydroxyurea|Fludarabine, Melphalan, TBI, ATG",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Child,Complete Response,Standard Chemotherapy,7,Bone Marrow Transplant,"Fludarabine, Melphalan, TBI, ATG",Allogeneic - Child,-1,Dead,317,Dead-Other,0,95,70,0,0,9.5,23.3,0,0.1,54,57,3.3,0.78,M5,27.4,9.1,"46,XX,t(1;11)(p36.1;q23),add(9)(p22)[13]/46,sl,del(2)(p21p23),del(20)(q11.2-13.1)[4]/46,sl,add(12)(p11.2)[2]",861,93.2,"MLL: 85%  The t(1;11) with these breakpoints in not common, but has been associated with monoblastic leukemia",26,"CD4, partial CD11b, CD15, CD33, CD38, moderate CD45, partial CD56, CD64, CD123, partial CD117, and HLA-DR",6.8,87.72,negative,0,negative,,ASXL1 (p.R693*; 19.8%),,ASXL1 (p.R693*; MAF 19%)|BCOR (p.S209L (possibly a benign germline polymorphism); MAF 48%)|FLT3 (p.A680V; MAF 17%)|FLT3 (p.I836delI (in-frame deletion of one amino acid in TK domain); MAF 11%)|NRAS (p.G12S; MAF 19%)
15-00593,training,Dead,280,BA2344D,BA2344R,2077,2225,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,3,,,71,FALSE,FALSE,FALSE,FALSE,FALSE,y,Follicular lymphoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,71,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,5,"7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Hydroxyurea|Mitoxantrone",4,Hypomethylating/Low Dose Cytarabine|Induction|Re-induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,-1,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,-1,Dead,280,Dead-Disease,,82,66,,,,,,,,,,,,,,"46,XX,del(7)(q22q36)[20]",,,"ABNORMAL FISH RESULT 7cen (D7Z1), 7q31 (D7S486): deletion present",,"CD7, CD13, weak CD33, CD34, CD117, and HLA-DR",,133.7,negative,0,negative,,,,FLT3-ITD (MAF 4%)|WT1 (c.1138delinsAA; MAF 31.2%)
15-00608,leaderboard,Alive,464,BA2229D,BA2229R,2240,2232,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,5,,,61,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,61,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"Cyclophosphamide, Fludarabine, TBI|7+3 (Cytarabine, Idarubicin) plus Sorafenib",2,Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Cyclophosphamide, Fludarabine, TBI",Double Umbilical Cord Blood Transplant (DUCBT),-1,Alive,884,Alive,,40,28,,,,,,,,,,,,,,"46,XX,del(5)(q31q33),der(21)(qter->q22::p11.2->qter),del(21)(q22)[19] ",,,"65% Loss 5q31; 14.5% Gain of 8 centromere, trisomy; Trisomy for 21q22  (40.5%), and trisomy for 8q22 and 21q22 (7.0%)",26,"positive CD13, CD34, dim CD45, CD117 and HLA-DR",,4.8,negative,0,negative,,,,BCOR (p.1189_1192del; MAF 33.1%)|NRAS (p.G12D; MAF 10%)|SRSF2 (p.P95H; MAF 34.4%)
15-00610,training,Alive,505,BA2559D,BA2559R,2329,2233,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,5,,,42,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,42,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Fludarabine, Cyclophosphamide, TBI ",3,Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT),Refractory,Standard Chemotherapy,-1,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, TBI ",Double Umbilical Cord Blood Transplant (DUCBT),-1,Alive,878,Alive,,35,2,,,,,,,,,,,M5,,,"46,XX[20]",,,Normal,35,"The immature cells were positive for CD13, CD33, and many showed aberrant expression of CD7. The myeloblast portion was positive for CD34, CD117, and HLA-DR.  The immature monocyte portion was negative for CD34 and CD117, and expressed variable CD64 (including some cells with bright CD64), CD11b, an",,49.7,positive,,negative,,,,FLT3-ITD (MAF 34.8%)|RUNX1 (p.L29S; MAF 52.7%)
15-00614,training,Alive,296,BA2093D,BA2093R,2343,2234,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,51,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,51,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)|Bu/Cy/TBI",5,Consolidation|Salvage|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,Azacitidine,Salvage,62,Dead,628,Dead-Disease,0,90,,0,0,85.8,1.9,8.5,0,25,25,3,0.93,M0,25.1,8.2,"60~61<3n>,XYY,-1,-2,-3,-4,-5,del(5)(q13q33),-6,-7,+8,-9,+11,-12,+13,-15,-16,-17,-18,+21,+22[cp15]/70~73,idem,+Y,+1,+2,+5,+del(5)(q13q33),+6,+9,+11,+12,+20,+20[cp4]/46,XY[1]",634,81.8,"EGR-1/ D5S23, D5S721: 60/100 cells (60%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the first clone, above; 38 cells (38%) had a 2 red/ 4 green signal pattern, consistent with two copies of the deleted 5q in the second clone.",77,"partial CD7, CD13, dim partial CD22, CD33, CD3,  partial CD56, dim CD71, CD117, dim CD123, and dim HLA-DR ",6.5,0.5,negative,0,negative,,,TP53 (p.X187_splice; 40.1%)|TP53 (p.X125_splice; 28.4%),"NRAS (p.G13D; MAF ~40%)|TP53 (Splice site (3' splice site mutation, intron 5); MAF 42%)|TP53 (Splice site (5' splice site mutation in intron 4); MAF 44%)"
15-00615,leaderboard,Dead,633,BA2000D,BA2000R,2304,2235,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,Asian,3,mono,,24,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",24,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Leukapheresis,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,6,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)",5,Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Sibling,-1,Dead,633,Dead-Disease,,85,,,,,,,,,,,,,,,"46,XX[20]",,,Normal,,"weak CD4, partial  CD7, partial CD11b, CD13, CD33, partial CD34, weak CD64,  CD117, MPO, and HLA-DR",,,positive,0.666666666666667,negative,,,,CEBPA (p.Gln41fs; MAF 4%)|FLT3-ITD (p.Glu611_Phe612ins27; MAF 8%)|JAK3 (p.Gln865Glu; MAF 48.9%)
15-00616,training,Dead,314,BA2425D,BA2425R,2532,2236,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,68,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,68,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC",3,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Mismatched Unrelated Donor,-1,Dead,314,Dead-Disease,2.6,,49,5.1,6.8,36.8,0.9,14.5,0.2,18,16,2.8,0.67,,21.9,7.5,"43-45,XX,del(5)(q16q33),der(7)t(7;12)(q11.1;q12)ins(7;?)(q11.1;?),-12,der(21;22)(q10;q10),+mar[cp20]/46,XX[1] ",821,88.7,,8,"CD13, CD33, CD34, CD71, CD117, dimCD123, HLA-DR, and dim CD 64 positive (Peripheral Blood)",7.2,11.01,negative,0,negative,,,TP53 (p.L130Pfs*19; 33.3%),TP53 (p.I254N; MAF 40%)
15-00633,training,Alive,544,BA2304D,BA2304R,2010,2241,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,3,,MLLT3-KMT2A,52,FALSE,FALSE,FALSE,FALSE,FALSE,y,Breast Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,52,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Melphalan, ATG, Methotrexate",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Fludarabine, Melphalan, ATG, Methotrexate",Allogeneic - Matched Unrelated Donor,-1,Alive,804,Alive,,51,,,,,,,,,,,,M5,,,"46,XX,t(9;11)(p22;q23)[5]",,,11q23 (MLL): rearrangement present (89.5%),,"The monocytic cells (percentages shown) are  atypical in that they express partial CD56 (about 50%  positive), but otherwise demonstrate phenotypically normal  expression of CD13, bright CD33, bright CD64, CD15, HLA-DR,  and partial myeloperoxidase (Flow cytometric analysis of the bone marrow aspirate  specimen indicates that 4% of the CD45 positive leukocytes  are lymphocytes, 89% are monocytic cells, and 7% are  myeloid cells.) | CD10, CD11b, CD13,  CD16, CD33, and CD64 (Myeloid (phenotypically normal))",,,negative,0,negative,,,,KRAS (p.Gly13Asp; MAF 38.9%)
15-00650,training,Dead,80,BA2976D,BA2976R,2494,2251,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,85,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,85,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Maintenance,,,,Standard Chemotherapy,Azacitidine,Maintenance,232,Dead,80,Dead-Disease,0,36,,0,8.7,20.2,27.2,20.2,1.6,24,23,3.4,0.88,M4,31.5,9.6,"46,XY,del(12)(p11.2p13)[20]",200,95.7,"ETV6: 84% of cells were missing a signal for ETV6 (12p13), consistent with the deletion seen on metaphase analysis. ",46,"CD34, CD117, dim CD123, CD33, dim HLA-DR, CD13, and CD58. (Blasts) | CD64, CD11b, CD33, CD15, dim HLA-DR, CD13, dim CD71, and CD58. (Monoblasts/promonocytes.)",7,40.53,negative,0,negative,,,,NRAS (p.Q61R; MAF 30%)|U2AF1 (p.S34F ; MAF 50%)
15-00653,training,Dead,633,BA2386D,BA2386R,2292,2254,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,Unknown,,White,2,,,52,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,52,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)",3,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Salvage,-1,Dead,633,Dead-Disease,0,83,48.6,0,,9.4,0.9,40.2,,21,47,3.3,0.55,M1,25.3,8.3,"46,XX[20]",,,"nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",48,"CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(+ and dim +), CD14(-), CD15(+), CD16(-), CD25(-), CD33(slightly bright +), CD34(-), CD36(-), CD38(variably +), CD45(+), CD56(small subset +), CD64(-), CD117(dim and variably +), CD123(variably +), HLA-DR(+), TdT(-), MPO(+).",6.6,22.1,negative,0,positive,,,,FLT3 (Foundation; A680V; MAF 6%)|FLT3 (Foundation; Y842C; MAF 2%)|KDM6A (Foundation; P738fs*2;MAF 31%)|NPM1 (Foundation; W288fs*10+; MAF 25%)|TET2 (Foundation; Q742*; MAF 45%)|TET2 (Foundation; R1712fs*6;MAF 44%)
15-00670,training,Alive,276,BA2035D,BA2035R,2424,2265,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,61,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,61,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),5,"Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC|Midostaurin|Hydroxyurea",5,Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Maintenance,Complete Response,Standard Chemotherapy,6,Targeted Therapy - Kinase Inhibitor(s),Midostaurin,Maintenance,284,Alive,2182,Alive,0,92,98,0,0.8,2.6,0,0,0.1,35,23,3.2,0.86,M1,19.9,6.8,,330,106.4,Normal,49,"dim CD33, CD34, CD38, dim CD45, CD117, and MPO",8,84.96,positive,,negative,,,,DNMT3A (p.R882H; MAF ~50%)|FLT3-ITD (MAF 40%)|IDH1 (p.R132S; MAF ~50%)|SRSF2 (p.P95L; MAF ~40% )
15-00680,training,Alive,447,BA2201D,BA2201R,2291,2272,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,68,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,68,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"HiDAC|3+7 (Cytarabine, Daunorubicin)|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,23,Bone Marrow Transplant,"Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)",Allogeneic - Matched Unrelated Donor,-1,Dead,861,Dead-Other,0.9,86,,0,0,2.6,20.8,0.9,0.2,20,28,2.9,1.49,M5,33,10.8,"46,XY[20]",1211,95.9,Normal,83,"Variable CD13, variable CD14, CD33, variable CD64, CD117, CD123, and partial HLA-DR positive",7.2,134.36,positive,,positive,,,,FLT3-ITD (MAF 91%)|IKZF1 (p.Q156H; MAF 45%)|NPM1 (p.W288fs*; MAF 49%)|SF3B1 (p.K666Q; MAF 50%)
15-00688,training,Dead,25,BA2113D,BA2113R,2088,2276,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,63,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Induction,Unknown,Standard Chemotherapy,9,Standard Chemotherapy,Decitabine,Induction,9,Dead,25,Dead-Disease,1.8,41,,0.9,0,79.6,0.9,14.2,0,21,19,2.7,0.98,M2,27.7,9.4,"45~46,XX,add(1)(q42),del(5)(q31q35),del(6)(q13),del(9)(q13q34),del(17)(p13),i(21)(q10)[cp12]/46~47,idem,+mar[cp6]/46,XX[2]",404,88.5,"EGR1 (5q31): 73% of cells were missing a signal for EGR1 (5q31), consistent with the deletion seen on metaphase analysis.  TP53 (17p13.1): 71% of cells were missing a signal for TP53 (17p13.1), consistent with the deletion seen on metaphase analysis.  RUNX1 (21q22): 77% of cells had three signals fo",6,"CD13, dimCD33, CD34, CD38, CD58, partial CD64, CD117, CD123, and HLA-DR positive.",7.6,1.61,negative,0,negative,,,TP53 (p.R248Q; 53.3%),TP53 (p.R248Q; MAF 56%)|U2AF1 (p.Q157P; MAF 41%)
15-00692,leaderboard,Dead,565,BA2155D,BA2155R,2402,2277,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,Unknown,,White,2,bi,,72,TRUE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,73,0,Relapse|Post-Chemotherapy,Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,-1,Supportive/Palliative Care,Azacitidine,Hypomethylating/Low Dose Cytarabine,112,Dead,565,Dead-Disease,0,81,94,0,,51,3,2,,11,16,4.5,0.99,M0,28.2,9.6,"46,XX,der(3)t(3;17)(q29;q21)[19]/46,XX,t(3;21)(q26.2;q22)[2]",,,"nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1, D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200], (PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",10,"CD2(-), CD4(-), CD7(partial +), CD11b(-), CD13(variably +), CD14(-), CD15(partial +), CD16(-), CD19 (-/few dim +), CD25(-), CD33(partial +), CD34(partial +), CD36(-), CD38(bright and variably +), CD45(+), CD56(variably +), CD64(-), CD117(variably +), CD123(-/few +), MPO(+), TdT(-/few dim +) (87% pop of med to large size cells) | HLA-DR(partial +)",6.9,35,negative,0,negative,,,TP53 (p.X187_splice; 30.4%),CEBPA (Foundation; M1fs*60; MAF 34%)|CEBPA (Foundation; N307_V308insVETQQK; MAF 36%)|TP53 (Foundation; splice site 560-2insA; MAF 44%)
15-00693,training,Alive,838,BA2955D,BA2955R,2039,2279,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,66,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,66,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),4,"3+7 (Cytarabine, Daunorubicin), Bortezomib|MiDAC|Fludarabine, Cytarabine|Ibrutinib",4,Allogeneic - Sibling|Consolidation|Induction|Maintenance,Refractory,Standard Chemotherapy,6,Targeted Therapy - Kinase Inhibitor(s),Ibrutinib,Maintenance,382,Alive,2175,Alive,0,60,52,0,0.9,29.8,54.4,1.8,0.5,23,19,2.5,0.84,M5,24.2,7.7,"47,XX,+6[6]/46,XX[19]",453,104.8,"IGH/MAF: 74/100 cells (74%) had variant abnormal 0-1 red/ 1-4 green/ 2-7 yellow signal patterns reflecting IGH/MAF fusion. The majority of cells (56%) were 0 red/ 1 green/ 3 yellow. IGH: 68/100 (68%) cells scored had signal patterns consistent with IGH rearrangement and the 14;16 translocation,above | CDKN2C/CKS1B: 61/100 cells (61%) had 3-6 CKS1B (1q21) signals and 2 CDKN2C signals, reflecting gain of 1q. | The IGH/CCND1 and IGH/FGFR3 probe sets had extra IGH signals reflecting IGH involvement in the 14;16 ",92,"dimCD4, CD11b, CD13, dimCD14, CD33, CD56, CD58, CD64, dimCD123 and HLA-DR positive; Minor subset of blasts with immunophenotype: CD13, CD33, CD34, CD58, CD117, dimCD123, HLA-DR and MPO positive.",7.4,14.94,positive,,negative,RUNX1 (p.P240Qfs*22; 40.0%),,,"BCOR (p.G1659E MAF ~10%,)|FLT3-ITD (MAF 38%)|NRAS (p.Q61R MAF ~5%)|RUNX1 (p.P240fs*22; MAF 37%)|RUNX1 (splice site [at invariant AG (G>A) splice acceptor site at end of Intron 6];  MAF 36% ))"
15-00701,training,Dead,302,BA2502D,BA2502R,2328,2280,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,50,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,50,0,Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Other,6,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Hydroxyurea",5,Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6,Other,Hydroxyurea,Hypomethylating/Low Dose Cytarabine,365,Dead,302,Dead-Disease,0,,,0,2.6,8.8,17.6,2.6,0,,,,,M0,19.8,6.4,"48,XX,+11,+13[19]",,93.4,,31,,,206.64,negative,0,negative,,,,
15-00702,training,Alive,188,BA2322D,BA2322R,2060,2281,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,CBFB-MYH11,35,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,35,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,10,Standard Chemotherapy,HiDAC,Consolidation,112,Alive,1937,Alive,1.7,42,,0.9,0,40,18.3,7.8,0.2,54,23,3.5,0.6,M2,20.3,6.8,"46,XX,inv(16)(p13.3q22)[21]",319,102.5,"CBFB:  83/100 cells (83%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting CBFB rearrangement and consistent with the inverted  chromosome 16 in the metaphase karyotype.",63,"Partial CD2, CD33, CD34, CD38, CD117, CD123, partial HLA-DR, dim MPO and partial TdT positive.",6.7,12.78,negative,0,negative,,,,NRAS (p.Q61P; MAF 15% )
15-00717,training,Alive,123,BA2376D,BA2376R,2513,2295,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,61,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,6,Alive,1891,Alive,0.4,68,,0.1,3,17,62.6,16.9,0.1,29,17,3.7,1.51,M5,27.7,8.9,"46,XY[20]",296,104.9,Normal,74,"dim CD4, CD11b, partial CD14, CD15, dim CD33, CD38, CD56, CD58, CD64 and HLA-DR positive",8,16.84,negative,0,positive,,,,DNMT3A (p.S714C; MAF 35%)|NPM1 (p.W288fs*12; MAF 40%)|NRAS (p.G13V; MAF 6%)|PTPN11 (p.A72V; MAF 10%)|TET2 (p.Q876*; MAF 6%)
15-00734,leaderboard,Alive,202,BA2226D,BA2226R,2014,2293,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,53,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,53,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,SWOG S1203 (7+3 +/- Vorinostat),1,Induction,Complete Response,Standard Chemotherapy,153,Standard Chemotherapy,SWOG S1203 (7+3 +/- Vorinostat),Induction,153,Alive,1833,Alive,0,93,80,0,1.7,19.3,20.2,13.2,0.6,47,37,3.1,0.79,M5,26.8,8.8,"46,XX[20]",977,92.1,Normal,36,"Blast immunophenotype: partial CD11b, CD13, CD33, CD38, CD58, partial CD64, partial CD117 and a subset with MPO - Blast/promonocyte immunophenotype: CD11b, CD13, partial CD14, CD15, CD33, CD38, CD58 and CD64",6,42.34,negative,0,positive,,,,FLT3-D835 (p.D835Y; MAF: 40%)|NPM1 (p.W288fs*12; MAF 40%)
15-00742,leaderboard,Alive,0,BA2889D,BA2889R,2360,2300,Waves1+2,Waves1+2,yes,yes,no,yes,Female,Female,White,NON-HISPANIC,White,1,,PML-RARA,34,FALSE,FALSE,FALSE,FALSE,FALSE,y,Pituitary macroadenoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,34,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,n,y,y,1,Standard Chemotherapy,1,"ATRA, Arsenic Trioxide",1,Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"ATRA, Arsenic Trioxide",Induction,-1,Alive,1881,Alive,0,96,,0,4,60,14,22,0,21,15,4,0.58,M3,30.1,10.7,"46,XX,t(15;17)(q22;q21)[8]/46,idem,add(6)(p23),der(6)add(6)(p21)add(6)(q13),add(9)(p22),add(11)(q21),add(14)(q24)[12]",191,95.9,21/200 (10.5%) interphase cells  scored had the 1 red/ 1 green/ 2 yellow fusion signal pattern consistent  with PML/RARA fusion.,32,"CD13, CD33, CD38, CD58, CD64, CD117, CD123, and  MPO-positive",7,0.5,negative,0,negative,,,,
15-00755,training,Dead,256,BA2200D,BA2200R,2371,2304,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,3,,,59,TRUE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,59,0,Relapse|Post-Chemotherapy,Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"Azacitidine, Sorafenib|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)",3,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"Azacitidine, Sorafenib",Re-induction,-1,Dead,256,Dead-Disease,,93.2,47.5,,,,,,,,,,,,,,"46,XY,t(3;4)(p21;q25)[3]/46,XY[17]",,,,,"CD4, CD7, CD11b, CD13,  CD33, partial CD34, CD117, HLA-DR, partial weak TdT and  partial CD64",,42.91,positive,,positive,,,,DNMT3A (c.2251T>C; MAF 36.9% (33.1% on 3/13/15))|FLT3-ITD (c.1759_1800dup; MAF 24% (39% on 3/13/15))|NPM1 (c.860_863dup; MAF 9.9% (24% on 3/13/15))
15-00756,leaderboard,Alive,213,BA2121D,BA2121R,2356,2305,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,RUNX1-RUNX1T1,36,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,36,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"HiDAC|3+7 (Cytarabine, Daunorubicin)|Hydroxyurea",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,HiDAC,Consolidation,103,Alive,552,Alive,0,25,38,0,3.4,29.1,2.6,23.9,0,32,39,2.3,0.7,M2,21,7.5,"45,X,-Y,t(8;2;21)(q22;p21;q22)[20]",,104.5,RUNX1T1/RUNX1: (92%),29,"CD13, CD33, partial CD34, CD64, CD19 dim, CD71, CD117 partial, HLA-DR, dim CD123, CD58 and MPO",6.7,24.98,negative,0,negative,,,,CBL (p.E369_Y371delinsH; MAF 31%)
15-00763,training,Alive,466,BA2944D,BA2944R,2577,2307,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,3,,RUNX1-RUNX1T1,23,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,23,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"7+3 (Cytarabine, Idarubicin)|Busulfan, Fludarabine, Cyclophosphamide, Thymoglobulin (Bu/Flu/Cy/ATG)",2,Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine, Cyclophosphamide, Thymoglobulin (Bu/Flu/Cy/ATG)",Allogeneic - Matched Unrelated Donor,-1,Alive,747,Alive,,88,,,,,,,,,,,,M1,,,"46,XY,add(6)(q23),del(7)(q33),t(8;21)(q22;q22)[2]/46,sl,add(17)(p11.1)[5]/46,sdl1,add(16)(p11.2)[2]/46,sdl2,add(3)(q21)[8]/46,sdl3,add(20)(q11.2)[3]",,,62% t(8;21) (RUNX1T1;RUNX1) translocation present,,"CD13, CD33, CD34, CD38, CD117, HLA-DR, cMPO, CD19 and partial CD56",,,negative,0,negative,,,,BRCA2 (c.6275_6276delTT; MAF unlisted)|BRCA2 (c.6859A>T; MAF unlisted)|FLT3-ITD (MAF unlisted)
15-00766,training,Dead,11,BA2033D,BA2033R,2432,2310,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,5,,,71,FALSE,FALSE,TRUE,FALSE,FALSE,y,Non-Hodgkins Lymphoma,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,71,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,Lenalidomide|Decitabine,2,Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care,,,,Standard Chemotherapy,Decitabine,Hypomethylating/Low Dose Cytarabine,-1,Dead,11,Dead-Disease,,60,14,,,,7,,,,,,,,,,"45,XY,add(3)(p10),add(5)(q11.2),psu dic(9;?;6)(6qter- > 6p22::?::9p22- > 9qter)[1]/44,sl,-add(3)(p10), +der(3;13)(q10;q10)[2]/48,sdl1,+8,+14,+21,+22[8]/42-44,sl,-add(3)(p10),add(4)(p15),-7,-8, add(12)(p11.2),+mar,+1-2r[cp7]/80-82 < 4n > ,slx2,-2,add(4)(q22)x2,-6,+8,+8,add(8)(p23)x2, (dic(8;11)(p12;p11.2)x2,-psu dic(9;?;6)(6qter- > 6p22::?::9p22- > 9qter),-10,der(10;17)(q10;q10), der(12;13)(p10;q10),der(14;17)(q10;q10),-16,-17,-18,add(20)(p11.2)[cp4])",,,"FISH assays were positive for loss of 5q31 sequences in 85.5% of cells, positive for findings consistent with trisomy 8 in 49% of cells, and positive for findings consistent with monosomy 7 in around 8% of cells.",17,"Flow cytometry was negative for increased myeloblasts. The flow showed a mild increase in   immature monocytic cells, but not to the degree seen in the marrow smears. This is likely   attributable to hemodilution of the sample received for flow cytometry. (Aberrant CD56, unusually dim CD38 - but only 3-4% assayed cells are myeloblasts)",,21.6,negative,0,negative,,,TP53 (p.P151H; 97.9%),TET2 (p.G355D; MAF 33.8%)|TP53 (p.P19H; MAF 8.9%)
15-00767,training,Dead,347,BA2867D,BA2867R,2116,2311,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,NON-HISPANIC,White,2,mono,,78,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,78,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Decitabine,Hypomethylating/Low Dose Cytarabine,-1,Dead,347,Dead-Disease,0.2,25,4,1,,25,10,60,,22,21,4.5,0.82,,47.3,15.3,"46,XY[20]",,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",15,"CD2(-), CD7 (-), CD10(-), CD11b(-), CD13(dim +), CD14(-), CD15(+), CD16(-), CD19(-), CD22(partial +), CD33(-), CD34(bright +), CD36 (-), CD38(variably +), CD45(partial dim +), CD56(-), CD64(-), CD117(partial +), HLA-DR(partial +), MPO(-) and TdT(+) (Population #1 - 5.3%) | CD2(-), CD7(-), CD10 (-), CD11b(-), CD13(bright and variably +), CD14(-), CD15(-), CD16(-), CD22(-), CD33(partial +), CD34 (variably +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR(partial +), MPO(partial +), and TdT (-). (Population #2 - 25%)",7.5,5.79,negative,0,negative,RUNX1 (p.P383Afs*217; 46.0%),,,
15-00777,training,Dead,122,BA2089D,BA2089R,2080,2314,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,68,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,68,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Initial Diagnosis,Leukapheresis,y,y,y,y,y,y,1,Standard Chemotherapy,2,"3+7 (Cytarabine, Daunorubicin)|Azacitidine",2,Induction|Maintenance,Refractory,Standard Chemotherapy,7,Standard Chemotherapy,"3+7 (Cytarabine, Daunorubicin)",Induction,7,Dead,122,Dead-Unknown,0,,83,0,0.8,8.1,9.8,1.6,0.7,29,137,3.3,2.67,M5,35.5,11.4,"46,XY[20]",3615,92.4,normal,104,,6.4,140.18,negative,0,negative,,ASXL1 (p.G645Wfs*12; 60.0%),,ASXL1 (p.G645fs*12; MAF 52%)|IDH1 (p.R132L; MAF 47%)|KRAS (p.G12A; MAF 36%)|MLL (Partial tandem duplication )|SRSF2 (p.P95H; MAF 49%)
15-00786,leaderboard,Alive,164,BA2972D,BA2972R,2111,2322,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,bi,,40,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,40,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"HiDAC|3+7 (Cytarabine, Daunorubicin)|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)",Allogeneic - Matched Unrelated Donor,-1,Alive,2163,Alive,0,80,27.8,0,0,62.6,4.4,5.2,0,26,22,3.9,0.78,M1,37.6,13.2,"46,XY[20]",,91.7,normal,66,"dim CD7, CD13, CD33, CD34, CD38, partial CD56 (25%), CD58, dim CD64, CD117, dim CD123, HLA-DR, and MPO+.",7.4,2.68,negative,0,negative,,,,CEBPA (p.K313_V314insK; MAF 39%)|CEBPA (p.S28fs*81; MAF 28%)|ZRSR2 (p.R378W; VAF 100%)
15-00807,training,Alive,252,BA2978D,BA2978R,2411,2333,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,Declined,HISPANIC,HispNative,1,,RUNX1-RUNX1T1,14,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,14,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,DLI|Standard Chemotherapy|Bone Marrow Transplant,8,"Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Donor Lymphocyte Infusion|HiDAC|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide|Clofarabine, Cytarabine",4,Allogeneic - Sibling|Salvage|Induction|Re-induction,Complete Response,Standard Chemotherapy,189,Bone Marrow Transplant,Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501),Allogeneic - Sibling,-1,Alive,2083,Alive,,18,,,,,,,,,,,,M2,,,"46,XX,t(8;21)(q21.3;q22)[17]/49,sl,+4,+15,+der(21)t(8;21)[2]/53,sdl,-4,+13,+18,+19,+20,+21[4]",,,"All twenty-three metaphase cells examined were abnormal, with t(8;21), leading to RUNX1/RUNX1T1 fusion.   Two subclones, comprising 6 cells total, had an additional copy of the der(21).",,"CD13, CD33, CD34, CD38, CD56, CD58, dim/partial CD64, CD117, CD123, HLA-DR and MPO",,,negative,0,negative,,,,FBXW7 (p.G79S; MAF 50%)|KIT (p.D816Y; MAF 45%)|NRAS (p.G12D; MAF 45%)
15-00811,leaderboard,Dead,168,BA2829D,BA2829R,2238,2337,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,53,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,54,7,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4,"HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea",4,Induction|Experimental|Re-induction|Maintenance,Refractory,Standard Chemotherapy,6,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,49,Dead,168,Dead-Disease,0,9,,1.7,0.9,6.1,8.8,43,0.4,38,29,3.4,0.71,,27,9.1,"46,XY,add(3)(p24)[cp4]/46,XY[14]",321,95.1,normal,170,"CD117 (Initial diagnosis on 7/27/2015 BMBX: CD7, dim CD11b, CD13, CD33, partial CD34, CD58, CD117, CD123, dim MPO, and HLA-DR positive)",6.7,16.65,positive,,positive,,,,CBL (p.I423N; MAF <0.5%)|DNMT3A (p.R882C; MAF 0.9%)|FLT3-ITD (MAF 2.9)|NPM1 (p.W288fs*12; MAF 0.7%)|TET2 (p.Q548*; MAF 0.7%)
15-00813,leaderboard,Alive,119,BA2851D,BA2851R,2437,2339,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,53,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,53,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)",2,Induction|Re-induction,Refractory,Standard Chemotherapy,4,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Re-induction,7,Dead,128,Dead-Disease,0,45,50,0,19.4,6.4,1.6,11.3,0,73,83,3.3,0.88,M2,29.4,9.6,"46,XX[20]",2008,109.3,Normal,33,"partial CD7, CD13, CD33, CD34, variable CD38, CD117, CD123, partial HLA-DR and dim MPO",6.8,137.54,negative,0,negative,,,,DNMT3A (p.R882H; MAF 45%)|FLT3-D835 (p.D835Y; MAF 3%)|MLL (Partial Tandem Duplication)|NRAS (p.G13D; MAF 35%)|NRAS (p.Q61R; MAF 3%)
15-00837,training,Dead,188,BA2623D,BA2623R,2049,2350,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,3,,CBFB-MYH11,72,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,72,0,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),2,Azacitidine|Momelotinib,2,Hypomethylating/Low Dose Cytarabine|Experimental,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,-1,Dead,188,Dead-Disease,,,58,,,,,,,,,,,,,,"46,XY,inv(16)(p13.1q22)[20]",,,,,,,8.21,negative,0,negative,,,,
15-00855,leaderboard,Alive,172,BA2271D,BA2271R,2386,2360,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,HISPANIC,HispNative,1,,,8,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid leukaemia associated with Down syndrome,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid leukaemia associated with Down syndrome,8,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Intrathecal,2,"ADE (Cytarabine, Daunorubicin & Etoposide)|Cytarabine",2,Induction|CNS,Complete Response,Standard Chemotherapy,151,Intrathecal,Cytarabine,CNS,151,Alive,1957,Alive,10.8,70,,0,1.8,8.1,13.5,8.1,0,13,25,3.2,0.72,M1,26.8,9.3,"47,XY,+21c[20]",,90.5,RUNX1 (21q22): 89% of cells had three signals for RUNX1 (21q22) consistent with the three copies of chromosome 21 seen on metaphase analysis.,40,"dim CD11b, variable CD13, dim variable CD14, CD15, CD38, CD58, dim CD64, and MPO",8.2,67.53,negative,0,positive,,,,NPM1 (p.W288fs*12; MAF 50%)
15-00858,training,Dead,26,BA3004D,BA3004R,2420,2362,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,76,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,76,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"5+2 (Cytarabine, Idarubicin)|Decitabine",2,Induction|Re-induction,Refractory,Standard Chemotherapy,8,Standard Chemotherapy,"5+2 (Cytarabine, Idarubicin)",Re-induction,4,Dead,26,Dead-Disease,0,95,54,0,0.9,16.8,3.5,24.8,1.1,23,22,3.5,1.33,M1,31.5,10.3,"46,XX[22]",244,92.6,Normal,29,"dimCD13, CD33, CD45, CD56, dimCD117 and MPO positive",7,27.17,positive,,positive,,,,ASXL1 (p.G966delG; MAF 50%)|DNMT3A (p.R736H; MAF 45%)|FLT3-ITD (MAF 20%)|NPM1 (p.W288fs*12; MAF 35%)
15-00870,leaderboard,Dead,51,BA3010D,BA3010R,2478,2364,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,6,,,71,FALSE,FALSE,TRUE,FALSE,FALSE,y,Non-Hodgkins Lymphoma,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,71,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,Vidaza|Rituximab|Decitabine,2,Consolidation|Maintenance,,,,Standard Chemotherapy,Decitabine,Maintenance,86,Dead,51,Dead-Disease,,20,10,1,,22,48,16,,6,33,3.7,1.57,,26,8.1,"46,XY[20]",,91.9,,13,"Positive for CD34, CD117, HLADR, CD33, CD13 but negative for CD14, CD64, CD11b, CD19, and CD3 (Peripheral Immunophenotyping) | The blasts are positive for CD34 and CD117 (Bone marrow Immunophenotyping)",7,44.8,negative,0,negative,RUNX1 (p.R320*; 40.9%),ASXL1 (p.G646Wfs*12; 39.4%),,BCOR (p.A603pfs*66; MAF55%)|KRAS (p.G12V; MAF 49%)|RUNX1 (pR320*; MAF 47%)|SRSF2 (p.P95H; MAF 49%)|STAG2 (p.Y636*; MAF 96%)
15-00872,training,Alive,181,BA2662D,BA2662R,2393,2367,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,65,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,FavorableOrIntermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Other,4,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea",4,Consolidation|Unknown|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1,Alive,1962,Alive,0,74,60,1.9,15.1,21.7,50,11.3,0,23,32,2.6,0.78,M5,21.6,7.2,"46,XX[20]",905,100.5,Normal,150,,6.7,84.69,positive,,positive,,,,CEBPA (p.K298Q; MAF 25%)|DNMT3A (p.R882C; MAF 44%)|FLT3-ITD (MAF 25%)|IDH2 (p.R140Q; MAF 18%)|NPM1 (p.W288fs*12; MAF 46%)
15-00874,training,Alive,523,BA2674D,BA2674R,2301,1973,Waves1+2,Waves1+2,no,no,no,no,Male,Male,White,NON-HISPANIC,White,1,,,70,TRUE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,71,281,Post-Chemotherapy|Relapse,Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,4,"7+3 (Cytarabine, Idarubicin)|Azacitidine, Itacitinib|Azacitidine|Decitabine",2,Salvage|Induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,"Azacitidine, Itacitinib",Salvage,449,Dead,1389,Dead-Disease,0,90,,0,0,27.8,2.9,8.6,0.4,81,43,3.3,,M0,31.9,10.2,"47,XY,+4[2]/46,XY[18]",235,94.7,"Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously.",91,"partial CD7 (~35%), CD13, partial dim CD33, CD34, CD38, variable CD56, and CD117",6.6,73.42,negative,0,negative,,ASXL1 (p.Q588*; MAF 49%),,ASXL1 (p.Q588*; MAF 49%)
15-00883,leaderboard,Dead,118,BA2280D,BA2280R,2044,2416,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,72,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,72,0,Residual Disease|Post-Chemotherapy,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),3,"7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib",2,Induction|Experimental,Refractory,Standard Chemotherapy,10,Targeted Therapy - Kinase Inhibitor(s),Ponatinib,Experimental,15,Dead,118,Dead-Disease,0.9,90,78,0,0,2.7,3.6,17.3,1.4,28,23,2.8,0.56,M1,31.7,9.9,"46,XX[20]",261,98.1,Normal,211,"CD13, CD33, CD38, partial CD56, partialCD64, CD117, dimCD123, and MPO",6.5,24.01,positive,,positive,,,,CEBPA (p.E163*; MAF 39%)|FLT3-ITD (MAF 40%)|NPM1 (p.W288fs*12; MAF 40%)
15-00892,leaderboard,Dead,179,BA2512D,BA2512R,2257,2421,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,3,,,72,FALSE,TRUE,FALSE,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,72,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Targeted Therapy - Other,1,SGN-CD33A,1,Experimental,,,,Targeted Therapy - Other,SGN-CD33A,Experimental,-1,Dead,179,Dead-Disease,,41,,,,,,,,,,,,M5,,,,,,Normal,,"partial CD56, bright CD33,  CD13, bright CD64, HLA-DR (Monocytic cells)",,,negative,0,positive,,,,DNMT3A (c.2645G>A; MAF 45.4%)|FLT3-D835 (c.2503G>T (D835Y); MAF 15.5%)|NPM1 (c.860_863dup; MAF 11%)|PTPN11 (c.178G>C; MAF 8.4%)|PTPN11 (c.211T>C; MAF 10%)|TET2 (c.3955-2A>G; MAF 45.4%)
15-00900,leaderboard,Alive,187,BA2658D,BA2658R,2218,2420,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,24,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,24,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,7,"7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Decitabine|Fludarabine, Cyclophosphamide, TBI |Busulfan, Cyclophosphamide",7,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction|Maintenance|Double Umbilical Cord Blood Transplant (DUCBT),Refractory,Standard Chemotherapy,7,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, TBI ",Double Umbilical Cord Blood Transplant (DUCBT),-1,Alive,2133,Alive,0,,,1.8,0.9,23.9,23,7.9,0,37,28,3.7,0.95,M4,32.3,11.3,"46,XY[20]",243,92.8,Normal,102,"dimCD13, CD33, CD34, CD56, CD117, and  CD123",7.1,21.84,negative,0,negative,,,,NRAS (p.G12C; MAF 40%)
15-00903,training,Dead,36,BA2394D,BA2394R,2381,2423,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Female;Male,,,White,3,,,73,FALSE,FALSE,FALSE,FALSE,FALSE,y,Lung Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,73,0,Residual Disease|Post-Chemotherapy,Residual,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Hypomethylating/Low Dose Cytarabine,,,,Standard Chemotherapy,Azacitidine,Hypomethylating/Low Dose Cytarabine,7,Dead,36,Dead-Disease,,,79,,,,,,,,,,,,,,"45,X,-Y[20]",,,Normal,,,,19.64,negative,0,negative,RUNX1 (c.319C>G; MAF 73.9%),ASXL1 (c.1940dup; MAF 37.9%),,ASXL1 (c.1940dup; MAF 37.9%)|BCORL1 (c.3496dup: MAF 7.5%)|RUNX1 (c.319C>G; MAF 73.9%)|TET2 (c.3803+1G>A; MAF 39.3%)
15-00912,training,Dead,151,BA2981D,BA2981R,2156,2426,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,6,,,76,FALSE,FALSE,FALSE,FALSE,FALSE,y,Breast Cancer,y,y,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,77,0,Residual Disease|Post-Chemotherapy,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,1,Unknown,1,Azacitidine,1,Unknown,,,,Unknown,Azacitidine,Unknown,424,Dead,151,Dead-Unknown,,86,50,1,,14,5,20,,32,20,2.9,0.62,,24.3,7.8,"48-51,XX,del(4)(q25),del(5)(q11.2),-17,-18,+22,+3-5mar[20]",,84.1,,27,"POSITIVE FOR DIM CD45, HLADR, CD34, CD117, CD13, CD33, CD43, CD81, CD58. (Bone Marrow Immunophenotyping)",5.4,14.3,negative,0,negative,,,TP53 (p.R175H; 91.7%),
15-00936,training,Dead,168,BA2249D,BA2249R,2238,2337,Waves1+2,Waves1+2,no,no,no,no,Male,Male,White,NON-HISPANIC,White,1,,,53,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,54,63,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),4,"HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea",4,Induction|Experimental|Re-induction|Maintenance,Refractory,Standard Chemotherapy,6,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,49,Dead,168,Dead-Disease,1.8,48,,3.6,6.2,23.2,18.7,17,1.3,29,41,3.6,1,,20.9,6.9,"46,XY,t(7;17)(q22;q21)[3]/46,XY,t(2;4)(q33;q25),del(9)(q2?1;q3?2),add(17)(q21)[cp3]/46,XY,t(1;2)(q31;p25),inv(9)(q3?1q34)[2]/46,XY,t(13;14)(q14;q32)[cp2]/46,XY,add(3)(p24)[1]/46,XY[3]",,96.3,normal,21,"dimCD7, CD13, dimCD11b, CD33, variable CD34, CD58,  CD117, CD123, and HLA-DR positive",6.8,20.77,positive,9,positive,,,,DNMT3A (p.R882C; MAF 45%)|FLT3-D835 (p.D835H; MAF 15%)|FLT3-ITD (MAF 78%)|NPM1 (p.W288fs*12; MAF 40%)|TET2 (p.Q548*; MAF 45%)
15-00939,training,Dead,122,BA2034D,BA2034R,2080,2314,Waves1+2,Waves1+2,no,no,no,no,Male,Male,White,NON-HISPANIC,White,1,,,68,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,68,72,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"3+7 (Cytarabine, Daunorubicin)|Azacitidine",2,Induction|Maintenance,Refractory,Standard Chemotherapy,7,Standard Chemotherapy,"3+7 (Cytarabine, Daunorubicin)",Induction,7,Dead,122,Dead-Unknown,0.8,,,0.9,0,9.3,0,0,0.5,12,14,2.5,0.9,M5,20.6,6.4,"46,XY[19]",,90.4,normal,60,,6.3,6.21,negative,0,negative,,,,
15-00961,training,Alive,181,BA2109D,BA2109R,2251,2444,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,52,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,MissingKaryo,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,52,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,8,Standard Chemotherapy,HiDAC,Consolidation,81,Dead,585,Dead-Disease,0,,,30,13,9,21,19,0.1,54,50,2.2,0.84,M4,18.8,6.5,,,98.9,,21,,6.5,65.58,negative,0,negative,,,,NOTCH1 (p.K2181R ; MAF 50%)|SRSF2 (p.P95H ; MAF 50%)
15-00965,training,Alive,187,BA2242D,BA2242R,2507,2447,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,61,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),6,"Fludarabine, Melphalan|Ruxolitinib|7+3 (Cytarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC|Ibrutinib",5,Consolidation|Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6,Targeted Therapy - Kinase Inhibitor(s),Ruxolitinib,Maintenance,-1,Alive,2027,Alive,0,>95,,0,0,89.9,9.3,0.8,0,43,31,2.4,0.5,M1,19.5,6.5,,313,92.4,normal,32,"partial CD13, CD33, CD38, moderate CD45, CD56, CD58,  CD64, dim CD117, CD123 and MPO+",5.8,67.36,negative,0,positive,,,,CREBBP (p.R2353Q; MAF 51%)|NPM1 (p.W288fs*12; MAF 46%)|TET2 (p.Q270*; MAF 90%)
15-00967,training,Dead,118,BA2277D,BA2277R,2044,2416,Waves1+2,Waves1+2,no,no,no,no,Female,Female,White,NON-HISPANIC,White,1,,,72,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,72,40,Residual Disease|Post-Chemotherapy,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),3,"7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib",2,Induction|Experimental,Refractory,Standard Chemotherapy,10,Targeted Therapy - Kinase Inhibitor(s),Ponatinib,Experimental,15,Dead,118,Dead-Disease,0,,70,0,1.8,34.8,3.6,0.9,23.2,13,40,3.2,0.55,M1,22.7,7.5,"46,XX[5]",339,89.7,Normal,32,,6.4,6.04,positive,0.639344262295082,positive,,,,CEBPA (p.E163*; MAF 40%)|FLT3-ITD (MAF 45%)|NPM1 (p.W288fs*12; MAF 32%)
15-00976,training,Dead,434,BA2618D,BA2618R,2498,2453,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,83,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,83,0,Residual Disease|Post-Chemotherapy,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,2,"AG-221|Azacitidine, SGN-CD33A",2,Induction|Experimental,Refractory,Standard Chemotherapy,-1,Targeted Therapy - Other,AG-221,Experimental,-1,Dead,434,Dead-Disease,0.3,12,3,0,9.4,26.9,24.5,38.9,0,42,47,3.2,1.3,,21.1,6.8,"46,XY[20]",,87.9,Normal,213,,6,3.72,negative,0,negative,,ASXL1 (p.Y425*; 46.8%),,CREBBP (p.M2408V; MAF 48%)|IDH2 (p.R140Q; MAF 47%)|NRAS (p.G12D; MAF 49%)
15-00990,training,Dead,14,BA2885D,BA2885R,2139,2459,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,81,FALSE,FALSE,FALSE,FALSE,FALSE,y,Skin cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,81,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Induction,Unknown,Standard Chemotherapy,6,Standard Chemotherapy,Azacitidine,Induction,6,Dead,14,Dead-Disease,0,90,70,0,0.8,6.1,72.2,12.2,0.4,62,50,2.9,4.22,M5,22.8,7.3,"46,XX[20]",262,90.8,Normal,29,"CD11b, variable CD13, variable CD14, CD33, CD56, CD64, dim CD123 and dim HLA-DR positive",5.8,97.26,negative,0,positive,,ASXL1 (p.G645Vfs*58; 16.7%),,ASXL1 (p.W796fs*22; MAF 48%)|NPM1 (p.W288fs*12; MAF 40%)|TET2 (p.S825fs*1; MAF 49%)
16-00001,training,Alive,209,BA2639D,BA2639R,2368,2460,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,CBFB-MYH11,36,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,36,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),6,"Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Hydroxyurea|Busulfan, Cyclophosphamide",5,Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,1,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Matched Unrelated Donor,-1,Alive,2075,Alive,0,40,60,1.7,0,33.4,5.1,18.8,0.1,38,28,3.2,0.53,M2,22.9,7.6,"46,XX,t(16;16)(p13.2;q22)[20]",508,99.6,"CBFB: 191/200 cells (95.5%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting CBFB rearrangement, consistent with the 16;16 translocation observed in the metaphase karyotype.",24,"Immunophenotype: CD13, partial CD15, dim CD33, CD34, CD38, dim CD45, CD58, variable CD64, variable CD117, CD123, and dim HLA-DR positive.",7.3,20.44,negative,0,negative,,,,KIT (p.T417_D419delinsY; MAF 33%)
16-00003,training,Alive,603,BA2775D,BA2775R,2138,2461,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,,White,3,,,26,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,27,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,16,Standard Chemotherapy,HiDAC,Consolidation,-1,Alive,647,Alive,,35,,,,,,,,,,,,,,,"46,XY[15]",,,Normal,,"weak  CD13, CD33, partial CD117, and myeloperoxidase",,,negative,0,positive,,,,IDH2 (p.Arg140Gln; MAF 45.9%)|NPM1 (p.Trp288fs; MAF 19.5%)
16-00004,leaderboard,Dead,268,BA2402D,BA2402R,2410,2462,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,82,FALSE,FALSE,FALSE,FALSE,FALSE,y,Breast Cancer,y,y,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,82,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,268,Dead-Disease,0,50,,0,1.8,42.8,0,5.4,3.7,13,18,2.8,1.03,,27.7,9.2,"46,XX ",279,91.1,trisomy 8 in 5 of 20 metaphase cells ,44,,7,1.36,negative,0,negative,,,,DNMT3A (p.R882H; MAF 39%)|GATA1 (p.R191C; MAF 51%)|IDH2 (p.R172K; MAF 36%)
16-00007,training,Alive,217,BA2097D,BA2097R,2201,2464,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,,White,4,,,77,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,77,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"Azacitidine, Sorafenib|Decitabine, Midostaurin",2,Induction|Re-induction,Refractory,Standard Chemotherapy,165,Standard Chemotherapy,"Azacitidine, Sorafenib",Re-induction,-1,Alive,288,Alive,,41,18,,,,,,,,,,,,,,"46,XY[20]",,,"CD15, AND PARTIAL CD56 -7/DEL(7q) TRISOMY #8MLL GENE REARRANGEMENTDEL(20q)",,"ABNORMAL CD34+ BLAST POPULATION EXPRESSING ABERRANT CD7,CD4, AND CD2, AND CD38, CD10, CD22, CD11C, HLA-DR, CD117,CD13, CD33,CD15, AND PARTIAL CD56",,2.2,positive,0.612903225806452,negative,,,,FLT3-ITD
16-00027,leaderboard,Alive,393,BA2399D,BA2399R,2196,2473,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,Asian,,AdmixedWhite,2,,,55,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",55,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI |7+3 (Cytarabine, Idarubicin) plus Crenolanib",4,Consolidation|Induction|Allogeneic - Child|Maintenance,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,Cyclophosphamide,Maintenance,1,Alive,668,Alive,0,91,99.2,0,,0.8,0,0,,33,27,3,0.85,,18.8,6.2,"46,XY[29]",808,,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",28,"CD2(-), CD4(partial dim +), CD7(-), CD11b(-), CD13(dim +), CD14(-), CD15(-/few dim +), CD16(-), CD33(+), CD34 (partial +), CD36(equivocal/small subset appears +), CD38(partial +), CD45(+), CD56(-), CD64(-/few dim +), CD117(+), HLA-DR(+ and variable), TDT(-), MPO(+)",6.1,181.08,positive,1,negative,,,,FLT3-ITD (S584_S585INSSDNEYFYVDFRE; MAF 29.0%)|IDH1 (R132H; MAF 47.0%)|MLL (Foundation; MLL-PTD Exons 2-8; not GeneTrails)|TET2 (SPLICE SITE 3500+1G>A; MAF 48.0%)
16-00031,leaderboard,Alive,576,BA2850D,BA2850R,2210,2477,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,Multiracial,,White,6,,,50,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",50,0,Residual Disease|Post-Chemotherapy,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Allogeneic - Sibling|Induction|Re-induction,Refractory,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Sibling,-1,Alive,576,Alive,,75,73,,,6,6,8,,44,20,3.5,1,,24.8,8,"46,XY[20]",,91.5,,26,"These are postive for CD34, CD117, HLADR, CD13 and CD33. These are negative for CD3, CD20, CD4, CD11b. (Bone Marrow Immunophenotyping)",5.8,17.1,positive,1.5,negative,RUNX1 (p.E454Gfs*149; 21.4%),,,
16-00048,training,Dead,637,BA2174D,BA2174R,2341,2483,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,Asian,1,,,46,FALSE,FALSE,FALSE,FALSE,FALSE,y,Anaplastic Astrocytoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,46,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,7,"7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|Hydroxyurea|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG",4,Consolidation|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT),Refractory,Standard Chemotherapy,1,Bone Marrow Transplant,"Fludarabine, Melphalan, ATG",Double Umbilical Cord Blood Transplant (DUCBT),-1,Dead,637,Dead-Disease,0.9,25,16,1.7,4.3,6.1,32.2,48.7,0.2,14,15,3.1,0.64,,32,9.5,"46,XX,del(3)(p25),add(6)(p22),t(10;12)(p15;q13)[5]/46,XX[18]",440,80.6,Normal,92,"Immunophenotype: CD13, CD34, CD38, CD58, CD117, CD123, HLA-DR and TdT-positive; small subset of blasts also express CD19, CD22, and CD79a",6.8,42.57,negative,0,negative,,,,DNMT3A (p.I824V; VAF 50%)|GATA1 (p.S412R; MAF 60%)|NRAS (p.G13R; MAF 50%)|RUNX1 (p.T196I ; MAF 50%)|U2AF1 (p.I24T; MAF 5%)
16-00056,training,Alive,201,BA3001D,BA3001R,2344,2490,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,51,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,51,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"HiDAC|Hydroxyurea|7+3 (Cytarabine, Idarubicin) plus Sorafenib",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,2,Standard Chemotherapy,HiDAC,Consolidation,-1,Alive,1910,Alive,0,95,95,0,0,7.8,0,3.1,0.1,22,12,2.9,0.93,M1,20.6,6.6,"46,XX[20]",189,112.6,Normal,57,"Immunophenotype: CD7, CD13, CD33, CD38, CD117, CD123 and MPO positive",6.5,25.02,negative,0,positive,,,,CBL (p.R420Q; MAF ~20%)|FLT3 (p.N841K; MAF ~30%)|IDH2 (p.R140Q; MAF ~30%)|NPM1 (p.W288fs*12; MAF ~25%)
16-00067,leaderboard,Alive,517,BA2311D,BA2311R,2222,2496,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,HISPANIC,HispNative,2,,,53,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,53,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI ",4,Consolidation|Induction|Allogeneic - Child|Maintenance,Complete Response,Standard Chemotherapy,-1,Supportive/Palliative Care,Cyclophosphamide,Maintenance,1,Alive,653,Alive,0,20,8,0,,37,20,30,,18,23,3.3,0.86,M4,20,6.2,"46,XX[20]",426,105.3,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",38,"CD34(+), CD13(dim +), CD15(partial +), CD33(dim to partial +), CD34(+), CD38(variably +), CD45(dim +), CD56(-), CD64 (small subset +), CD117(+), HLA-DR(partial +), other myeloid and lymphoid antigens(-).",7,6.63,negative,0,negative,,,,IDH2 (R140Q; MAF 51.0%)|KMT2A (Foundation; MLL-PTD exons 2-10)|PAX5 (V26G; MAF 1.0%)|SRSF2 (R94_S101DEL; MAF 40.0%)
16-00073,leaderboard,Dead,348,BA2483D,BA2483R,2172,2443,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,KMT2A_re,63,FALSE,FALSE,FALSE,FALSE,FALSE,y,Cervical Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,64,44,Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other,6,"7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea",5,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,-1,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,29,Dead,348,Dead-Disease,1.5,85,38.5,0,0,55,3.5,1.5,0,25,22,3.8,1.3,,21.1,7.1,"48,XX,+8,+21[16]/46,XX[4]",,91.3,"RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21, as seen on metaphase analysis.  MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) rearrangement. Disruption of MLL was not apparent on banded chromosomes and the partner remains unkn",18,"CD4, partial CD11b, partial CD13, CD33, CD34, CD38,  partial CD56, CD64, partial CD117, CD123, and dim HLA-DR positive | CD4, partial CD11b, partial CD13, CD33, CD34, CD38, partial CD56, CD64, partial CD117, CD123, and dim HLA-DR positive",7.7,19.76,negative,0,negative,,,,
16-00075,training,Alive,13,BA3040D,BA3040R,2183,2498,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,,White,4,,,69,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,69,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Refractory,Standard Chemotherapy,7,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,7,Dead,238,Dead-Disease,,39,11,,,,,,,,,,,,,,"45,XY,add(1)(p13),del(5)(q13q33),add(6)(q13),-7,del(7)(q11.2),der(9)t(1;9)(p13;q22),add(12)(p13),-15,-16,-17,+3mar[19]/43~45,idem,der(3)t(3;17)(p21;q11.2),-17[cp3]",,,"COMPLEX DEL(5q)/DEL(7q)/-7 CLONE OBSERVED, CONSISTENT WITH AML",,"Positive (ABNORMAL CD34+ BLAST POPULATION, 29%, EXPRESSINGMYELOPEROXIDASE (VARIABLE), CD34, CD38, CD117, CD33, CD4, HLA-DR,CD13 (PARTIAL), CD56 (dim minor subset), AND CD61 (dim subset))",,1.6,negative,0,negative,,,TP53 (p.Y220C; 48.0%)|TP53 (p.F113V; 39.4%),
16-00077,leaderboard,Dead,605,BA2837D,BA2837R,2322,2500,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,,White,2,,,78,FALSE,FALSE,FALSE,FALSE,FALSE,y,Esophageal Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,80,0,Residual Disease|Post-Chemotherapy,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,5,"AG-120|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine",4,Consolidation|Induction|Experimental|Maintenance,Complete Response,Standard Chemotherapy,7,Targeted Therapy - Other,AG-120,Experimental,-1,Dead,605,Dead-Disease,0,,70,0,,7,3,9,,11,57,2.6,1.28,,25.6,8.1,"45,XY,-7[2]/45,XY,t(6;8)(q21;q21.2),-7,del(10)(q24q26),t(12;15)(p13;q15)[19]",1897,,"nuc ish(D5S2064,D5S630,EGR1)x2 [200],(D7Z1x2,D7S522x1)[1/200]/(D7Z1,D7S522)x1[185/200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",23,"CD2(subset +), CD4(dim +), CD7(partial +), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial +), CD38(variably +), CD45(+), CD56(partial +), CD64(-), CD117(+), HLA-DR(partial +). (63% population)",4.3,240.43,negative,0,negative,,,,
16-00088,training,Dead,324,BA2256D,BA2256R,2074,2442,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,AdmixedBlack,6,,,25,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",26,49,Post-Chemotherapy|Residual Disease,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Cladribine, Cytarabine, Idarubicin",3,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"Azacitidine, Sorafenib",Re-induction,67,Dead,324,Dead-Unknown,,98,95,,,2,3,,,46,30,4.1,0.54,,27.2,8.9,"46,XX,t(7;12)(q22;p13)[12]/46,XX,t(7;17)(p10;q10),-9,+mar[7]/46,XX[1]",,90.4,This test has detected a translocation between 7 and 12 in 12 cells; a translocation between 7 and 17 with loss of a chromosome 9 and a marker in 7 cells.,81,"These are positive for CD34, CD117, HLADR, CD33 but negative for CD13 and CD11b. TdT and CD79a are partially expressed. (Bone Marrow Immunophenotyping)",6.9,67.7,positive,1,negative,,,,
16-00094,training,Alive,17,BA2821D,BA2821R,2145,2501,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,37,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",37,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"HiDAC|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Hydroxyurea",4,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Re-induction,Refractory,Standard Chemotherapy,8,Standard Chemotherapy,Azacitidine,Consolidation,-1,Dead,542,Dead-Disease,1.7,95,74,2.5,0.8,13.6,14.4,10.2,0.4,23,14,3.1,0.46,M0/M1,27.9,9.2,"46,XX[20]",,89.4,Normal,49,"variable CD11b, CD13, dim CD19, dim CD33, CD34, variable CD64, CD117, CD123, and HLA-DR",7,26.57,negative,0,negative,,,,ASXL1 (p.A1312V; MAF 50%)|KRAS (p.K117N; MAF 48%)|WT1 (p.L378P; MAF 48%)|WT1 (p.R380fs*69 (1 bp deletion with frameshift); MAF 48%)
16-00102,training,Alive,95,BA2233D,BA2233R,2316,2508,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,,White,4,,,72,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,72,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,CPX-351 (Liposomal Cytarabine + Daunorubicin)|Hydroxyurea,1,Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,CPX-351 (Liposomal Cytarabine + Daunorubicin),Induction,-1,Alive,95,Alive,,97,96,,,,,,,,,,,M1,,,"46,XY[5]",,,"D5S721, EGR1  del(5q)/monosomy 5, D7Z1, D7S522  del(7q)/monosomy 7, D8Z2 trisomy #8, D20S108, 20qter del(20q)   ",,"CD117, MPO,CD38(PARTIAL), CD33(DIM) AND NOT EXPRESSING CD34 AND HLA-DR",,125.9,negative,0,positive,,,,"FLT3 (p.D839G; MAF~45%)|IDH2 (p.R140L; MAF ~50%)|MLL2 (p.V2338I; MAF ~50%)|NPM1 (p.W288fs*12;MAF ~35%)|SRSF2 (p.P95H, MAF~55%)"
16-00109,leaderboard,Dead,8,BA2744D,BA2744R,2232,2511,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,76,FALSE,FALSE,TRUE,FALSE,FALSE,n,,n,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,76,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Leukapheresis,y,y,y,y,y,y,1,Supportive/Palliative Care,1,Hydroxyurea,1,Supportive/Palliative Care,,,,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,7,Dead,8,Dead-Unknown,0,,96,0,0.7,4.7,0,1.3,0.6,23,43,2.3,0.46,M1,31,10.4,"46,XY[20]",839,93.9,Normal,17,"CD13, CD33, CD38, variable CD56, CD58, CD117 and MPO positive",5.1,230.05,positive,0.176470588235294,positive,,,,FLT3-ITD (MAF 45%)|NPM1 (p.W288fs*12; MAF 50%)|TET2 (p.W564*; MAF 50%)
16-00115,training,Dead,14,BA2621D,BA2621R,2347,2522,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,,White,6,,,74,FALSE,TRUE,FALSE,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",74,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,14,Dead-Disease,,19,7,4,,12,2,51,,29,38,3.7,0.86,,24.2,7.8,"45,XY,-7,del(12)(p11.2p13)[20]",,90.6,Monosomy 7 is detected in 87% of cells.,35,,6.6,47.5,negative,0,negative,,,,
16-00118,training,Dead,348,BA3002D,BA3002R,2172,2443,Waves1+2,Waves1+2,no,no,no,no,Female,Female,White,NON-HISPANIC,White,1,,KMT2A_re,63,FALSE,FALSE,FALSE,FALSE,FALSE,y,Cervical Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,64,58,Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other,6,"7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea",5,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,-1,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,29,Dead,348,Dead-Disease,0,85,,0,0,12.6,0,0,0.2,16,36,3.1,1.57,,20.9,7,"48,XX,+8,+21[16]/46,XX[4]",887,89.7,"RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21 MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) ",21,"CD4, partial CD11b, partial CD13, CD33, CD34, CD38, partial CD56, CD64, partial CD117, CD123, and dim HLA-DR positive",7.3,49.93,negative,0,negative,,,,
16-00120,leaderboard,Alive,514,BA2501D,BA2501R,2031,2515,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,3,,PML-RARA,36,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,36,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,"Methotrexate, Mercaptopurine, Tretinoin|ATRA, Idarubicin|ATRA, Cytarabine, Idarubicin",3,Consolidation|Induction|Maintenance,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"Methotrexate, Mercaptopurine, Tretinoin",Maintenance,-1,Alive,604,Alive,,91.8,95,,,,,,,,,,,M3,,,"46,XY,t(15;17)(q24;q21)[18]/46,XY[2]",,,Normal,,"weak partial CD2, CD13, CD33, CD64, CD117, and  myeloperoxidase",,55.42,positive,0.25,negative,,,,"CEBPA (c.935A>G; MAF 45%, except VUS)|FLT3-ITD (c.1780_1800dup; MAF 17%)"
16-00139,training,Dead,560,BA2133D,BA2133R,2383,2530,Waves1+2,Waves1+2,no,no,no,no,Female,Female,White,,White,6,,,73,FALSE,FALSE,TRUE,FALSE,FALSE,y,Breast Cancer,y,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,73,0,Post-Chemotherapy,Remission,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,4,Ruxolitinib|AG-221|Cytarabine|Azacitidine,4,Induction|Experimental|Maintenance|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,90,Standard Chemotherapy,Cytarabine,Supportive/Palliative Care,8,Dead,560,Dead-Unknown,,,,0.5,,39.2,7.5,52.5,,10,21,4.5,0.87,,34.1,10.9,,,92.4,,6,,7.6,3.8,negative,0,positive,,,,IDH2 (p.R140Q; MAF 32%)|JAK2 (p.V617F; MAF 30%)|NPM1 (p.W288Cfs*12; MAF 35%)|SRSF2 (p.R94dup; MAF 31%)|WT1 (p.R440Tfs*14; MAF 29%)
16-00145,training,Dead,159,BA2212D,BA2212R,2035,2533,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,Asian,,Asian,2,,,75,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,75,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"Vidaza|Decitabine|Fludarabine, Cytarabine",2,Salvage|Supportive/Palliative Care,,,,Standard Chemotherapy,"Fludarabine, Cytarabine",Salvage,-1,Dead,159,Dead-Disease,0,27,2,0,,60.2,8.4,29.4,,12,15,4.8,0.98,,30.7,9.3,"46,XY,t(1;12)(p32;p13)[3]/46,XY[17]",215,,"nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[194],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]",121,"CD2(-), CD4(-),CD7(-), CD10(partial +), CD11b(-), CD13(dim +), CD14(-), CD38(variably +/small subset -), CD45(dim to moderately +), CD56(-), CD64(-), CD117(variably +), HLA-DR(variably +). | Population #2 (0.48% of total events) comprises small cells with the following immunophenotype: CD5(- to partial dim +),CD10(-), CD19(slighty bright +), CD20(bright +), CD38(-), CD45(+), kappa(-), lambda(dim +).",7.5,3.09,negative,0,negative,,ASXL1 (p.G646Wfs*12; 39.3%),,ASXL1 (G646fs*12; MAF 37.0%)|BCOR (S1608*; MAF 3.0%)|KRAS (G12R; MAF 5.0%)|STAG2 (Q932fs*6; MAF 91.0%)|SUZ12 (E601fs*10; MAF 38.0%)|TET2 (C127fs*92; MAF 6.0%)|TET2 (S1870*; MAF 45.0%)
16-00157,training,Alive,528,BA2477D,BA2477R,2219,2538,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,67,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,67,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,5,"AG-120|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC",5,Consolidation|Salvage|Induction|Experimental|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Mismatched Unrelated Donor,-1,Dead,864,Dead-Other,0,93,94,0,0,1,2.8,1.9,0.1,20,30,2.4,1.23,M4,31.2,10.1,"46,XY[20]",,96.3,Normal,30,"partial CD7, CD13, dim CD15, CD33, CD38, CD58, CD117, dim CD123, HLA-DR and partial MPO+. (BM) | dim CD4, CD11b, variable CD13, partial CD14, dim CD15, variable CD16, CD33, CD38, CD58, CD64, CD123 and HLA-DR. (Promonocyte/blast equivalents)",,125.16,negative,0,positive,,,,DNMT3A (p.R882H; MAF 46% )|FLT3 (p.V592D; MAF 43% )|IDH1 (p.R132H; MAF 46%  )|NPM1 (p.W288fs*12 MAF 47% )|SETBP1 (p.K459E; MAF 50% )
16-00217,training,Dead,596,BA2659D,BA2659R,2057,2569,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,mono,,86,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,86,0,Residual Disease,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,3,AG-221|Azacitidine|Hydroxyurea,3,Hypomethylating/Low Dose Cytarabine|Consolidation|Experimental,,,,Standard Chemotherapy,Hydroxyurea,Consolidation,55,Dead,596,Dead-Disease,0,23,,0,0.8,8.6,19,59.5,0,16,15,3.4,1.52,,27.8,9,"47,XY,+8[20]",398,97.5,"(FISH) was performed with a chromosome 8 probe, listed below. 95/100 (95%) interphase cells scored had three signals, consistent with trisomy 8 and the metaphase karyotype. ",299,"dimCD7, CD13, dimCD14, dimCD20, CD33, CD34, CD117, CD123, dim HLA-DR and MPO positive",7.6,10,negative,0,negative,,,,BCOR (p.S1139*; MAF 80%)|CEBPA (p.R343fs*79; MAF 40%)|DNMT3A (p.E285*; MAF 45%)|DNMT3A (p.G707fs*72; MAF 45%)|IDH2 (p.R140Q; MAF 40%)|SRSF2 (p.P95H; MAF 40%)
16-00220,training,Alive,31,BA2124D,BA2124R,2310,2571,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,3,,,67,FALSE,FALSE,FALSE,FALSE,FALSE,y,Skin cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,67,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|IDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,IDAC,Consolidation,-1,Alive,579,Alive,,71.5,56,,,,,,,,,,,,,,"46,XY[20]",,,Normal,,"CD33, CD38, CD56, CD117, and myeloperoxidase",,16.24,negative,0,positive,,,,NPM1 (p.Trp288fs; MAF 16.4%)|TET2 (p.Leu1081fs; MAF 42.3%)|TET2 (p.Leu1780fs; MAF 46.3%)|ZRSR2 (p.Arg126*; MAF 97.7%)
16-00226,training,Alive,53,BA2363D,BA2363R,2337,2503,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,79,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,79,35,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other,4,Azacitidine|Decitabine|Hydroxyurea|V212,2,Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care,,,,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,-1,Dead,152,Dead-Disease,1.7,,35,0,0,0.9,64.4,8.7,0.2,9,22,3.1,2.11,,25.5,7.8,"46,XY[22]",722,95.5,Normal,438,"CD13, dim CD33, bright CD34, CD38, CD117, dim HLA-DR positive",5.8,116.52,negative,0,negative,RUNX1 (p.R320*; 44.9%),,,
16-00249,training,Alive,302,BA2369D,BA2369R,2276,2581,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,6,,,75,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,75,0,Residual Disease|Post-Chemotherapy,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Vidaza,1,Supportive/Palliative Care,,,,Standard Chemotherapy,Vidaza,Supportive/Palliative Care,-1,Alive,302,Alive,,60,50,,,,2,,,,,,,,,,"46,XY[20]",,,,,"These are positive for HLA-DR, CD34,CD117, CD33, CD11B, CD64 but Negative for CD13, CD14, CD16, MPO, TDT and all B and T cell markers (Bone Marrow Immunophenotyping)",,25,negative,0,negative,,,,
16-00269,leaderboard,Alive,170,BA2400D,BA2400R,2426,2593,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,44,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,44,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"HiDAC|3+7 (Cytarabine, Daunorubicin)",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,8,Standard Chemotherapy,HiDAC,Consolidation,99,Alive,1856,Alive,0,65,11.2,3.5,0,76.7,0,8.6,0,19,11,2.8,0.53,M2,23.7,7.8,,197,100.4,Normal,222,"CD13, CD33, CD117, CD123, dim HLA-DR and MPO | CD11b, CD13, CD33, CD117, CD64, CD123, and dim HLA-DR. (Blasts with monocytic differentiation (about 10% of blasts).)",6.1,2.41,negative,0,positive,,,,FLT3-ITD (MAF 2%)|IDH1 (p.R132H; MAF 44%)|NPM1 (p.W288fs*12; MAF 44%)|PTPN11 (p.R265Q; MAF 3%)
16-00271,leaderboard,Alive,464,BA2762D,BA2762R,2061,2594,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,,White,2,,,22,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,22,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),3,"Fludarabine, Melphalan|Crenolanib|7+3 (Cytarabine, Idarubicin) plus Crenolanib",3,Allogeneic - Sibling|Induction|Experimental,Complete Response,Standard Chemotherapy,39,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Sibling,-1,Alive,603,Alive,0,63,42,0,,32.7,4.4,26.6,,27,39,3.1,0.68,,19.3,6,"46,XX[20]",,,"nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con3'CBFBx2)[200]",176,"CD2(-), CD4(partial dim +), CD7(variably +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial+), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(+), HLA-DR(partial +).",6.3,22.01,positive,0.666666666666667,positive,,,,FLT3-ITD (K602_W603INSCEYDLK; MAF 33.0%)|NPM1 (K292FS*6+; MFA 35.0%)|TCL1A (E54FS*28; MAF 44.0%)|WT1 (A382FS*4; MAF 40.0%)
16-00273,training,Dead,169,BA2312D,BA2312R,2537,2595,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,3,mono,,62,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",62,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Refractory,Standard Chemotherapy,7,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,7,Dead,169,Dead-Disease,,20.399999999999999,,,,,,,,,,,,,,,"46,XX[20]",,,Normal,,"partial weak  CD7, CD13, CD33, CD34, CD117, myeloperoxidase, and partial  HLA-DR",,,negative,0,negative,,,,CEBPA (c.68dup; MAF 21%)|DNMT3A (c.2645G>A; MAF 43.9%)|NRAS (c.35G>A; MAF 30.2%)|WT1 (c.1140dup; MAF 4%)|WT1 (c.1142C>A; MAF 36.4%)
16-00278,training,Alive,440,BA2813D,BA2813R,2206,2597,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,,White,5,,,64,FALSE,FALSE,FALSE,FALSE,FALSE,y,Prostate Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,64,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, Thiotepa, TBI",2,Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,41,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, Thiotepa, TBI",Double Umbilical Cord Blood Transplant (DUCBT),-1,Alive,636,Alive,0,83,74,0,,13,0,13,,15,45,4,1.27,,25.2,8.7,"46,XY[20]",,,Normal,39,"Positive (""The large majority of cells (around 90%) are an abnormal population of myeloblasts. The myeloblasts are positive for CD33, CD13, HLA-DR, and CD117, and show uniform aberrant expression of CD7. A subset of the blasts are positive for myeloperoxidase, and a smaller subset shows dim aberrant expression of CD19. The blasts are almost entirely negative for CD34."")",6,53.3,positive,0.428571428571429,positive,,,,DNMT3A (c.2645G>A; p.R882H)|FLT3-ITD (FLT3-ITD 63bp insertion)|NPM1 (c.859_860insTCTG; p.W288fs)
16-00289,training,Dead,142,BA2211D,BA2211R,2471,2606,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,65,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib",2,Consolidation|Induction,Complete Response i,Standard Chemotherapy,17,Standard Chemotherapy,Azacitidine,Consolidation,34,Dead,142,Dead-Disease,0,95,92.9,0,0.7,3.6,1.4,1.4,0.1,101,55,3.2,0.83,M1,37,12.4,"46,XX[20]",697,95.1,normal,42,"CD13, CD33, CD38, CD56, CD58, partial CD64, CD117, CD123, and MPO positive",6.3,166.91,positive,1,positive,,,,FLT3-ITD (MAF 50%)|NPM1 (p.W288fs*12; MAF 45%)
16-00292,leaderboard,Dead,4,BA2171D,BA2171R,2321,2607,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,Unknown,UNKNOWN,White,1,,,73,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,73,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Unknown,Standard Chemotherapy,3,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,3,Dead,4,Dead-Disease,0,90,98.4,0,0,0.8,0,0.8,0.1,18,36,2.9,1.44,M1,25.9,8.2,"46,XX[20]",,90.6,Normal,19,"CD13, CD33, CD38, CD58, dim CD64, CD117, CD123, and MPO",7.7,122.89,positive,0.428571428571429,positive,,,,DNMT3A (p.R326P; MAF 50%)|FLT3-ITD (MAF 46%)|IDH2 (p.R140Q; MAF 40%)|NPM1 (p.W288fs*12; MAF 40%)
16-00303,leaderboard,Dead,323,BA2746D,BA2746R,2522,2611,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,HISPANIC,HispNative,5,,,56,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,56,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI",4,Consolidation|Salvage|Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,27,Standard Chemotherapy,"GCLAC (GCSF, Clofarabine & Cytarabine)",Salvage,-1,Dead,323,Dead-Disease,0,1.5,2,0,,23,57,13,,67,33,3,1.87,,29,9.5,"46,XX[19]",,,Normal,28,"Positive (""Approximately 55% of assayed cells are an abnormal population of immature monocytic cells (consistent with monoblasts and promonocytes). Approximately 30% of assayed cells are mature monocytes. Both the immature and mature monocytic cells show uniform aberrant expression of CD56. A small population of myeloblasts (CD117+/CD34neg) is present, accounting for less than 5% of assayed cells.)",7.5,58.7,positive,0.111111111111111,positive,,,,ASXL1 (c.1954G>A; p.G652S)|DNMT3A (c.2644C>T; p.R882C)|FLT3 (c.2503G>T; p.D835Y)|FLT3-ITD (FLT3-ITD 21 bp insertion)|NPM1 (c.859_860insTCTG; p.W288fs)
16-00315,training,Alive,523,BA2809D,BA2809R,2301,1973,Waves1+2,Waves1+2,no,no,no,no,Male,Male,White,NON-HISPANIC,White,1,,,70,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,72,423,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,4,"7+3 (Cytarabine, Idarubicin)|Azacitidine, Itacitinib|Azacitidine|Decitabine",2,Salvage|Induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,"Azacitidine, Itacitinib",Salvage,449,Dead,1389,Dead-Disease,0,,,0,0,15.5,6.9,5.2,0,79,38,3.1,0.8,M0,27.9,9.1,"47,XY,+4[2]/46,XY[18]",,87.7,"Two of twenty metaphase cells examined were abnormal, with trisomy 4, as seen previously.",44,,6.3,50.58,negative,0,negative,,,,
16-00332,training,Dead,292,BA2801D,BA2801R,2146,2621,Waves1+2,Waves1+2,no,no,no,no,Male,Male,,NON-HISPANIC,White,6,,,72,FALSE,FALSE,FALSE,TRUE,FALSE,y,Lung Cancer,y,n,y,n,n,n,n,n,MYELODYSPLASTIC SYNDROMES,"Myelodysplastic syndrome, unclassifiable",NonAML,MYELODYSPLASTIC SYNDROMES,"Myelodysplastic syndrome, unclassifiable",73,0,Residual Disease,,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Vidaza,1,Supportive/Palliative Care,,,,Standard Chemotherapy,Vidaza,Supportive/Palliative Care,268,Dead,292,Dead-Unknown,,,4,1,,13,5,23,,13,57,2.5,1.83,,25,8.2,,,105.9,,32,,5.8,66.7,negative,,negative,RUNX1 (p.S322Nfs*277; 44.4%),ASXL1 (p.R693*; 38.7%),,"ASXL1 (p.R693* MAF 48%)|EZH2 (p.1131T, MAF 71%)|EZH2 (p.C565R MAF 27%)|JAK2 (p.V617F, MAF 26%)|KRAS (p.Q61P, MAF 13%)|RUNX1 (p.S322Nfs*277, MAF 42%)|TET2 (p.Q1813*, MAF 51%)|TET2 (p.Q866Rfs*14, MAF 39%)|ZRSR2 (p.R295*, MAF 97%)"
16-00339,training,Alive,1,BA3030D,BA3030R,2046,2626,Waves1+2,Waves1+2,no,no,no,no,Female,Female,Unknown,UNKNOWN,White,1,,,70,FALSE,FALSE,FALSE,TRUE,FALSE,n,,n,n,n,n,y,n,n,n,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,"Atypical chronic myeloid leukaemia, BCR-ABL1 negative",NonAML,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,"Atypical chronic myeloid leukaemia, BCR-ABL1 negative",70,0,Unknown,,Bone Marrow Aspirate,y,y,y,y,y,y,1,Targeted Therapy - Kinase Inhibitor(s),1,Hydroxyurea,1,Induction,Unknown,Targeted Therapy - Kinase Inhibitor(s),-1,Targeted Therapy - Kinase Inhibitor(s),Hydroxyurea,Induction,-1,Dead,33,Dead-Disease,1.6,13,6.8,0.8,0,5.7,2.5,72.1,5.7,24,36,2.9,0.95,,29.1,8.9,"46,XX[20]",953,105.1,Normal,208,"CD13, CD33, CD34, partial CD117, CD123, HLA-DR",6.7,109.77,positive,0.428571428571429,negative,,,,FLT3-ITD (MAF 45%)|IKZF1 (p.N159S ; MAF 45%)|SF3B1 (p.K666N ; MAF 45%)
16-00344,training,Alive,188,BA2588D,BA2588R,2441,2628,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,59,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,59,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,5,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC",3,Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",Re-induction,4,Dead,597,Dead-Disease,0,30,10.5,0,0,19.7,0.9,71.4,0,77,27,3.4,1.01,M2,26.4,8.9,"46,XY[20]",479,96.4,Normal,101,"CD13, CD33, CD117, CD123, and HLA-DR",6.4,4.4,negative,0,positive,,,,DNMT3A (p.R882C; MAF 40%)|NPM1 (p.W288fs*12 ; MAF 40%)|PTPN11 (p.K70R; MAF 40%)|SOCS1 (p.Q210H ; MAF 55%)
16-00351,leaderboard,Alive,192,BA2296D,BA2296R,2497,2630,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,HISPANIC,HispNative,1,bi,,46,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,46,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,5,Standard Chemotherapy,HiDAC,Consolidation,120,Alive,1950,Alive,,40,,,,,,,,,,,,M2,,,"46,XX[19] ",,,Normal,,"CD13, CD33, CD34, partial CD64, CD71, CD117, CD123, and HLA-DR ",,,negative,0,negative,,,,CEBPA (p.R297P ; MAF 50%)|CEBPA (p.T98fs*10 ; MAF 40%)|TET2 (p.Q758*; MAF 45%)
16-00356,training,Dead,207,BA2903D,BA2903R,2161,2633,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,HISPANIC,HispNative,6,,,59,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,59,0,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,6,"HiDAC|Lenalidomide|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Etoposide, Mitoxantrone|Cytarabine, OXi4503",5,Salvage|Induction|Experimental|Frontline|Re-induction,Refractory,Standard Chemotherapy,8,Targeted Therapy - Other,"Cytarabine, OXi4503",Experimental,4,Dead,207,Dead-Unknown,,,1,9,,1,6,58,,135,44,3.2,0.79,,21.6,7.3,,,85,,22,,5.9,9.1,negative,0,negative,,ASXL1 (p.G646Wfs*12; 50.0%),,"NRAS (p.Q61H, MAF 21%)|RAD21 (p.G273V ,MAF 64%)"
16-00392,training,Dead,24,BA2840D,BA2840R,2468,2664,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,78,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,78,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),3,"Ruxolitinib|Hydroxyurea|Decitabine, Ruxolitinib",3,Induction|Experimental|Maintenance,Refractory,Standard Chemotherapy,7,Standard Chemotherapy,"Decitabine, Ruxolitinib",Induction,7,Dead,24,Dead-Unknown,0,60,,0,1.6,43.7,9.4,29.7,5.5,27,39,2,0.41,M7,26.2,8.2,"46,XX,t(7;13)(q22;q12),del(20)(q11.2)[1]/46,sl,dup(1)(p25),del(2)(q21q23),add(8)(q13q22)[3]/46,sdl,add(5)(p15)[8]/46,sdl,add(12)(p13)[3]/46,sdl,add(12)(p13),add(13)(p12)[4]/46,XX[1]",1024,89.4,"RUNX1T1 (8q21.3): 35% of cells had three signals for RUNX1T1 on 8q. No evidence for t(8;21). | FISH was also performed with a probe for chromosome 20, so that the stemline clone and all subclones could be followed by interphase FISH. 88/100 cells were missing a signal for D20S108 (20q12), consistent with the deletion of 20q seen in all abnormal cells above.",17,"CD33, CD34 (subset), CD41, CD58, CD61 and Factor-8 positive",5.5,6.28,negative,0,negative,,,,GATA1 (p.M1V; MAF 32%)|MPL (p.S505N; MAF 70%)|TET2 (p.V636fs*3; MAF 46%)
16-00410,training,Alive,320,BA2646D,BA2646R,2535,2678,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,PML-RARA,62,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,62,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"ATRA, Arsenic Trioxide",1,Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"ATRA, Arsenic Trioxide",Induction,-1,Alive,1719,Alive,0,90,,0.9,3.5,35.7,1.7,5.2,0.7,28,24,2.8,1.12,M3,19.8,7,"46,XY,t(3;16)(p13;q22),t(13;14)(q32;q24),t(15;17)(q22;q21)[20]",519,85.7,"PML/RARA: 98/100 cells (98%) had a 1 red/ 1 green/ 2 yellow signal pattern, reflecting PML/RARA fusion and consistent with the 15;17 translocation observed in the metaphase karyotype.",38,"CD13, CD33, CD38, CD58, CD64, dim CD71, CD123, CD117, MPO positive -FISH for t(15;17)",5.4,9.87,negative,0,negative,,,,
16-00459,training,Dead,263,BA2240D,BA2240R,2181,2687,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,HISPANIC,HispNative,1,,,61,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61,0,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),5,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Sorafenib|Hydroxyurea",4,Consolidation|Induction|Experimental|Re-induction,Complete Response,Standard Chemotherapy,7,Targeted Therapy - Kinase Inhibitor(s),Sorafenib,Experimental,61,Dead,263,Dead-Disease,0,,,0,0,30.8,10.3,0,0.3,195,75,3.6,0.68,,25.4,8.2,,1033,95.5,,49,,6.7,73.28,positive,9,positive,,,,
16-00465,leaderboard,Alive,233,BA2272D,BA2272R,2052,2690,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,HISPANIC,HispNative,1,,,12,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,12,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Leukapheresis,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal,4,"Cytarabine|Sorafenib|Cytarabine, Daunorubicin, and Etoposide|Busulfan, Cyclophosphamide",3,Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction,Refractory,Standard Chemotherapy,0,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Mismatched Unrelated Donor,-1,Alive,1905,Alive,0,70,85,0,1.8,14.7,51.4,8.3,50,28,150,3.7,0.64,M4,14.3,4.6,"47,XY,+8[19]/46,XY[1]",,132.4,RUNX1T1 signal consistent with the trisomy 8 clone ,49,"dimCD11b, dimCD13, CD14, dimCD33, CD64, variable CD123, HLA-DR CD13,dimCD33, dim variable CD34, CD117, CD123, HLA-DR",7.1,214.49,positive,0.538461538461538,negative,,,,FLT3-ITD (~16 amino acid insertion; MAF 11%)|FLT3-ITD (~8 amino acid insertion; MAF 20%)
16-00481,leaderboard,Dead,336,BA2904D,BA2904R,2450,2699,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,3,,CBFB-MYH11,60,FALSE,FALSE,FALSE,FALSE,FALSE,y,Adenocarcinoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,61,0,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|IDAC",2,Consolidation|Induction,UNKNOWN,Standard Chemotherapy,-1,Standard Chemotherapy,IDAC,Consolidation,-1,Dead,336,Dead-Disease,,,,,,,,,,,,,,,,,"46,XX,inv(16)(p13q22)[20]",,,,,Increased atypical CD34+myeloblasts representing 80%of leukocytes suggestive of recurrent AML.,,,negative,0,negative,,,,
16-00483,training,Alive,402,BA2883D,BA2883R,2395,2612,Waves1+2,Waves1+2,no,no,no,no,Male,Male,White,,White,6,N/A,,71,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",71,57,Post-Chemotherapy|Residual Disease,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,5,"AG-120|KB004|Lenalidomide|Venetoclax (ABT-199), Azacitidine|Decitabine",4,Salvage|Induction|Experimental|Maintenance,Refractory,Standard Chemotherapy,32,Standard Chemotherapy,"Venetoclax (ABT-199), Azacitidine",Salvage,77,Dead,548,Dead-Unknown,,33,,,,,8,,,,,,,,,,"46,XY,del(7)(q32),add(13)(p11.2)[20]",,,"This test has detected 7q deletion and an abnormal chromosome 13 in all 15 metaphase cells analyzed. 7q deletion is the most cp,,om abnormality in MDS and other types of myeloid malignancies.",22,"They are positive for CD34, HLADR, CD117, CD13 and MPO and negative for TDT. (Bone Marrow Immunophenotyping)",,,negative,0,negative,RUNX1 (p.G408Vfs*193; 20.4%),ASXL1 (p.Q428*; 43.4%),,
16-00494,training,Dead,148,BA2234D,BA2234R,2247,2705,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,KMT2A_re,72,FALSE,FALSE,FALSE,FALSE,FALSE,y,Non-Hodgkins Lymphoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,72,1,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,4,"3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea",3,Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)",Salvage,5,Dead,148,Dead-Disease,0,90,90,1.9,0,4.6,89.8,3.7,0.2,,,2.8,0.93,M5,37.1,11.9,"46,XX,t(1;11)(p32;q23)[20]",,96.6,MLL: 94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal,33,"dim CD4, CD11b, partial CD13, partial CD14, CD15, CD33, partial CD56, CD58, bright CD64, partial CD123 and HLA-DR-positive",,104.44,negative,0,negative,,,,DNMT3A (p.E283*; MAF 30%)
16-00498,training,Alive,468,BA2022D,BA2022R,2318,2706,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,3,,PML-RARA,33,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,33,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"ATRA, Arsenic Trioxide",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"ATRA, Arsenic Trioxide",Consolidation,-1,Alive,559,Alive,,,,,,,,,,,,,,M3,,,,,,This analysis showed evidence of a PML-RARA rearrangement in 177/200 (88.5 percent) interphase cells scored.,26,"Large population of CD117pos, CD34neg, HLA-DR neg myeloblasts, representing 78% of leukocytes consistent w/AML.",,12.75,positive,0.923076923076923,negative,,,,FLT3-ITD (p.Leu601_Lys602ins9; MAF 15%)
16-00504,training,Dead,259,BA2228D,BA2228R,2572,2708,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,,White,2,,,60,FALSE,FALSE,FALSE,FALSE,FALSE,y,Breast Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,60,0,Post-Chemotherapy|Residual Disease,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,5,"HiDAC|AG-221|3+7 (Cytarabine, Daunorubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)",4,Consolidation|Salvage|Induction|Experimental,Complete Response,Standard Chemotherapy,-1,Targeted Therapy - Other,AG-221,Experimental,-1,Dead,259,Dead-Disease,2,2,0,1,,12,12,71,,27,,4.4,0.99,,33.5,11.4,"46,XX[20]",,95.4,"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",219,The study reveals a minute subset of myeloblasts with mild immunophenotypic variation; the significance of this finding is unclear and it is not diagnostic for recurrent or persistent myeloid neoplasia. (No evidence of disease by flow),7.1,5.54,negative,0,positive,,,,FLT3 (R311Q; MAF 48%)
16-00510,leaderboard,Dead,291,BA2037D,BA2037R,2182,2712,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,HISPANIC,HispNative,1,,GATA2-MECOM,34,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,34,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s),5,"7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|anti-CD33|Azacitidine",3,Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,6,Targeted Therapy - Kinase Inhibitor(s),anti-CD33,Experimental,-1,Dead,291,Dead-Disease,0,60,40,0,2.1,44.3,8.2,16.5,5.5,117,61,3.9,1,M1,35.6,11.7,"46,XY,t(3;3)(q21;q26),der(7)del(7)(p11.1)del(7)(q11.1)[13]/45,idem,-der(7)[6]/46,XY[1]",424,96,D7S522/CEP 7: 65/100 cells (65%) had a signal pattern consistent with the deleted chromosome 7 long arm from the small marker observed in the metaphase karyotype; 9 cells (9%) had a signal pattern consistent with the monosomy 7 sideline observed in the metaphase karyotype.,916,"CD2, CD11b, CD13, CD33, CD34, CD38, CD56, CD58, CD117,  CD123, and HLA-DR positive",7.7,6.13,negative,0,negative,,,,NRAS (p.Q61H; MAF 45%)
16-00519,training,Alive,381,BA2184D,BA2184R,2320,2713,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,bi,,47,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,47,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"HiDAC|Cyclophosphamide, Fludarabine, TBI|3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)",4,Allogeneic - Sibling|Consolidation|Induction|Re-induction,Complete Response,Standard Chemotherapy,5,Bone Marrow Transplant,"Cyclophosphamide, Fludarabine, TBI",Allogeneic - Sibling,-1,Dead,582,Dead-Disease,0,75,,0,0,20.3,3.4,3.4,6.9,49,21,3.5,1.08,M1,42.6,15,"46,XY[20]",353,86.8,Normal,34,"CD7, CD13, CD33, CD34, CD38, CD58, CD117, dim CD123 HLA-DR and MPO+ ,",7.4,8.98,negative,0,negative,,,,CEBPA (p.D320_N321ins22; MAF 50%)|CEBPA (p.R35fs*125; MAF 50%)|CREBBP (p.P505L; VAF 45%)
16-00525,training,Alive,352,BA3009D,BA3009R,2213,2715,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,Asian,NON-HISPANIC,Asian,1,,,26,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,26,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"HiDAC|Cyclophosphamide, Fludarabine, TBI|3+7 (Cytarabine, Daunorubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",4,Consolidation|Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT),Refractory,Standard Chemotherapy,6,Bone Marrow Transplant,"Cyclophosphamide, Fludarabine, TBI",Double Umbilical Cord Blood Transplant (DUCBT),-1,Alive,1610,Alive,0,75,,0,0,45.5,9.8,4.5,0.2,32,58,3.1,0.69,M0,22.3,7.4,"46,XX,r(2)(p23q31),der(4)t(4;16)(q21;q12-13)del(16)(q22q22),der(16)t(4;16)(q21;q12-13),add(18)(p11.2),del(20)(q13.2)[16]/46,XX[4]",,97.8,"CBFB: 88% of cells were missing a signal for CBFB, consistent withdeletion associated with the unbalanced t(4;16) seen on chromosome analysis. No evidence for disruption. This probe will be useful in following this abnormal clone.",154,"CD13, partial CD15, CD34, CD38, partial CD56, CD58, partial CD117 and CD123+",5.8,9.27,negative,0,negative,,,,PTPN11 (p.D61G; MAF 15%)|TET2 (p.S1039L; MAF 50%)
16-00538,leaderboard,Alive,424,BA2842D,BA2842R,2085,2694,Waves1+2,Waves1+2,no,no,no,no,Male,Male,Black,,Black,6,,RUNX1-RUNX1T1,50,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,50,21,Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"HiDAC|3+7 (Cytarabine, Daunorubicin)",2,Consolidation|Induction,Refractory,Standard Chemotherapy,20,Standard Chemotherapy,HiDAC,Consolidation,182,Alive,424,Alive,,8,0,0,,12,29,54,,19,9,2.3,0.51,,22.8,7.5,"46,XY,t(8;21)(q22;q22)[20]",,88.7,RUNX1/RUNX1T1 fusion positive in 6.5% of cells,224,,5.1,6.8,negative,0,negative,,,,"ASXL1 (p.P581R, MAF 46%)|PDGFRB (p.D111N, MAF 52%)|SMC1A (p.R586Q, MAF 96%)"
16-00547,training,Dead,65,BA2882D,BA2882R,2463,2723,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,HispNative,1,,MLLT3-KMT2A,29,FALSE,FALSE,FALSE,FALSE,FALSE,y,Non-Hodgkins Lymphoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,29,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)",2,Induction|Re-induction,Complete Response,Standard Chemotherapy,19,Standard Chemotherapy,HiDAC,Re-induction,4,Dead,65,Dead-Unknown,0.9,82,20,0,2.6,26.3,33.4,7.9,3.6,40,19,3.1,0.84,M5,27.3,9.1,"46,XY,t(9;11)(p22;q23)[20]",324,89.5,"94/100 cells (94%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, consistent with MLL rearrangement and the 9;11 translocation observed in the metaphase karyotype.",52,"CD11b, varibleCD13, CD14, brightCD33, CD64, and HLA-DR positive",6.7,3.88,negative,0,negative,,,,
16-00548,training,Dead,520,BA2758D,BA2758R,2453,2119,Waves1+2,Waves1+2,no,no,no,no,Male,Male,White,NON-HISPANIC,White,1,,,76,TRUE,FALSE,FALSE,FALSE,FALSE,y,Basal Cell Carcinoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,77,417,Post-Chemotherapy|Relapse,Relapse,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor),2,Consolidation|Induction,Complete Response,Standard Chemotherapy,35,Standard Chemotherapy,Incyte trial (azacitidine and JAK 1 inhibitor),Induction,77,Dead,520,Dead-Unknown,0,50,10,0.9,,60.3,38.5,0.3,,19,19,3.2,1,M0,24.2,8.6,"47,XY,+8[cp14]/47,sl,der(21)t(1;21)(q11;p11.1)[2]/46~47,sl,der(22)t(1;22)(q11;p11.2)[cp2]/46,XY[1]",261,102.5,50/100 (50%) interphase cells scored had a signal pattern reflecting trisomy 8.,7,"dim CD4, CD13, bright CD34, dim CD45, CD117, HLA-DR, and dim TdT positive",7.2,3.4,negative,0,negative,RUNX1 (p.A338Rfs*256; 71.0%),ASXL1 (p.G646Wfs*12; 21.1%),,
16-00564,training,Alive,0,BA2385D,BA2385R,2277,2740,Waves1+2,Waves1+2,no,no,no,no,Female,Female,White,,White,6,,,81,FALSE,FALSE,FALSE,TRUE,FALSE,y,Rectal Cancer,y,y,n,n,y,n,n,n,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,NonAML,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,81,0,Unknown,,Bone Marrow Aspirate,y,y,y,n,y,y,,,,,,,,,,,,,,Unknown,0,,,5,0,,,,2,,,,,,,,,,"45,X,-X,del(9)(q13)[12]/46,sl,i(X)(q10)[8]",,,,30,Not detected for the FLT3 Internal Tandem Duplication (ITD). Not detected for the FLT3 TKD Mutation. MLL partial tandem duplication (MLL-PTD) is not detected. Pathogenic alteration is detected in the TET2 gene. Genomic alterations of uncertain significance are detected in the EZH2 and NF1 genes. (Bone Marrow Immunophenotyping) | MLL partial tandem duplication is not detected. Not detected for the FLT3 ITD and TKD mutations. (Bone Marrow Immunophenotyping (Continued)),,35.1,negative,,negative,,,,"EZH2 (p.L128S ,MAF 49%)|NF1 (p.F2388I, MAF 45%)|TET2 (p.R1452*, MAF 98%)"
16-00699,training,Dead,9,BA2570D,BA2570R,2367,3975,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,HISPANIC,HispNative,2,,,46,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",46,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Unknown,Standard Chemotherapy,6,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,6,Dead,9,Dead-Disease,,92,75,,,5,19,1,,,,2.8,1.13,,18.4,6.2,"46,XY[20]",,113.6,"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",31,"CD2(+), surface CD3(-),  cytoplasmic CD3(dim +), CD4(-), CD7(partial +), CD11b(partial +),  CD13(variably +), CD14(few +), CD15(-), CD16(-),  CD33(-), CD34(partial +), CD36(-), CD38(bright +), CD45(dim  +), CD56(small subset +), CD64(-), CD117(+), HLA-DR(partial +), MPO(partial +), TdT(partial dim+)",,151.6,negative,0,negative,,,,
16-00701,training,Alive,256,BA2347D,BA2347R,2440,2747,Waves1+2,Waves1+2,yes,yes,no,yes,Male,Male,White,,White,6,,,62,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,n,n,y,n,n,n,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,62,34,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,n,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"Azacitidine|Fludarabine, Melphalan, ATG",2,Unknown|Allogeneic - Matched Unrelated Donor,,,,Bone Marrow Transplant,"Fludarabine, Melphalan, ATG",Allogeneic - Matched Unrelated Donor,-1,Alive,281,Alive,,,1,0,,22,28,42,,37,29,4.7,1.03,M4,38.2,12.4,"46, XY [20]",,91,The abnormalities normally seen in MDS are not detected.,237,,7.8,16.4,negative,0,negative,,,,
16-00705,leaderboard,Dead,1824,BA2209D,BA2209R,2363,3978,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,,White,5,,,59,TRUE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,64,0,Relapse,Relapse,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, TBI ",2,Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, TBI ",Double Umbilical Cord Blood Transplant (DUCBT),-1,Dead,1824,Dead-Disease,0,59.5,12,0,,55,3,29,,37,22,4.1,,,25.2,8.3,"47,XY,+13[2]/94,slx2[2]/46,XY[19]",,,"5p15.2/5q31(EGR1), 7 centromere/7q31, 8 centromere/20q12, 12 centromere/13q14 D13S319/13q34 (13qter)",46,"Negative (CD10, CD19, CD20, CD22, Cyt CD79a, Cyt CD3, CD7, CD16, CD56, CD11b, CD14, CD15, CD33, CD64, MPO) | Positive (CD38, CD13, CD34, Dim CD45, Dim CD117, HLA-DR, TdT)",6.4,,negative,0,negative,,,,
16-00710,leaderboard,Alive,424,BA2855D,BA2855R,2085,2694,Waves1+2,Waves1+2,no,no,no,no,Male,Male,Black,,Black,6,,,50,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,50,73,Post-Chemotherapy,Remission,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"HiDAC|3+7 (Cytarabine, Daunorubicin)",2,Consolidation|Induction,Refractory,Standard Chemotherapy,20,Standard Chemotherapy,HiDAC,Consolidation,182,Alive,424,Alive,,0,,,,,0,,,,,,,,,,"46,XY[20]",,,RUNX1/RUNX1T1 fusion negative,126,No morphological evidence of acute leukemia (Bone Marrow Immunophenotyping),,7.7,negative,0,negative,,,,
16-00724,training,Dead,198,BA2261D,BA2261R,2528,3986,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,,White,2,,,62,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,62,0,Residual Disease|Post-Chemotherapy,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,4,"Vidaza|7+3 (Cytarabine, Idarubicin)|Lenalidomide|Hydroxyurea",3,Hypomethylating/Low Dose Cytarabine|Induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,7,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,-1,Dead,198,Dead-Disease,0.8,34,3.3,1.6,,14.9,5,68.6,,13,11,2.6,0.5,,32.4,10.7,"46~47,XX,del(5)(q15q35),i(8)(q10),add(11)(q23),add(17)(p11.2),add(21)(q22),+2~3mar[cp3]/47~49,idem,add(7)(q11.2),-add(11),+11,+14,-20[cp4]/45~49,idem,del(7)(q22q36),-add(11),+11,+14,-20[cp2]/45~48,idem,der(7)del(7)(q22q31)dic(7;20)(q36;q11.2),-add(11),+11,+14[",304,,"nuc ish(D5S2064x2,D5S630x2,EGR1x1)[184/200],(D7Z1x2,D7S522x1)[115/200],(D8Z2x2,D20S108x1)[142/200],(RUNX1T1x3,RUNX1x2)[180/200],(5'MLL amp,3'MLL amp)(5'MLL con 3'MLL amp)[66/200],(PML,RARA)x2[197],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",36,"CD2(-), CD4(-), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(+),CD56(+), CD64(-), CD117(partial +), HLA-DR(partial +). | In addition, there is a 0.01% population of small cells with the following immunophenotype: CD5(+), CD10(-), CD19(+), CD20(dim+), CD38(-), CD45(+), lambda(dim +), and kappa(-).",5.3,8.35,negative,0,negative,,,TP53 (p.R213Dfs*34; 85.5%),TP53 (R213fs; MAF 34%)
16-00731,training,Alive,442,BA2721D,BA2721R,2556,3990,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,69,FALSE,FALSE,FALSE,FALSE,FALSE,y,Breast Cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with maturation,69,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other,8,"7+3 (Cytarabine, Idarubicin)|Sorafenib|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC|IMGN779 (Immunogen Trial)|Fludarabine, Cyclophosphamide, Thiotepa, TBI|ALRN-6924|Azacitidine, Midostaurin, Ponatinib",4,Salvage|Induction|Experimental|Re-induction,Refractory,Standard Chemotherapy,6,Targeted Therapy - Other,IMGN779 (Immunogen Trial),Salvage,-1,Dead,565,Dead-Disease,1.8,,40,0.9,8.8,10.5,9.6,26.3,2.8,27,22,3.4,0.64,M2,23.5,7.1,"46,XX[20]",399,103.5,normal,12,"CD13, CD34, CD58, CD117, partial MPO and HLA-DR +",6.5,61.22,positive,1,negative,RUNX1 (p.A187T; MAF 42%),,,CREBBP (p.S893L; MAF 41%)|FLT3-ITD (MAF 47%)|RUNX1 (p.A187T; MAF 42%)|SF3B1 (p.K700E; MAF 51%)|TET2 (p.K751fs*61; MAF 44%)
16-00733,training,Dead,520,BA2930D,BA2930R,2453,2119,Waves1+2,Waves1+2,no,no,no,no,Male,Male,White,NON-HISPANIC,White,1,,,76,FALSE,FALSE,FALSE,FALSE,FALSE,y,Basal Cell Carcinoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,77,472,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor),2,Consolidation|Induction,Complete Response,Standard Chemotherapy,35,Standard Chemotherapy,Incyte trial (azacitidine and JAK 1 inhibitor),Induction,77,Dead,520,Dead-Unknown,0,54,occasional,6.9,,51.6,39.6,1.9,,20,23,3.2,1,M0,25.4,8.6,"47,XY,+8[cp15]/47,sl,der(22)t(1;22)(q11;p11.2)[2]/46,XY,dup(1)(q21q42)[cp2]",,92,60/100 (60%) interphase cells scored had a signal pattern reflecting trisomy 8. ,22,"Positive (The myeloid blasts are CD13, CD34, CD38, CD117, and HLA-DR;Atypical monocytic cells comprise approximately 41% of analyzed events and are CD11b, CD13, CD14, CD64, and dim HLA-DR positive. T cells show a CD4:CD8 ratio of 6.9:1 without aberrant antigen expression. B cells are polytypic by surface light chain expression)",7.2,4.5,negative,0,negative,RUNX1 (p.A338Rfs*256; 76.9%),,,
16-00766,training,Dead,97,BA2715D,BA2715R,2192,4006,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,,White,2,,,81,FALSE,FALSE,TRUE,FALSE,FALSE,n,,n,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,81,0,Residual Disease|Post-Chemotherapy,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,1,Supportive/Palliative Care,2,Vidaza|Decitabine,2,Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care,,,,Supportive/Palliative Care,Decitabine,Supportive/Palliative Care,3,Dead,97,Dead-Disease,,33,8,4,,28,24,44,,22,20,4.1,1.07,,27.5,9.5,"45,XY,add(5)(q11.2),der(6)t(5;6)(p13;p23),der(8)t(8;8)(p23;q11.2),-13,-16,der(22)t(16;22)(q22;q11.2),+r[cp11]/44,idem,-18[cp4]/46,XY[5]",333,,"nuc ish(D5S2064x3,D5S630x3,EGR1x1)[97/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1x3,RUNX1x2)[110/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5’CBFB con 3’CBFB dimx1,5’CBFB con 3’CBFBx1)[200]",28,"CD4(+), CD5(partial +), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(predominantly -), CD16(-), CD33(+), CD34(+), CD36(-),CD38(variably +), CD45(variably +), CD56(predominantly -), CD64(partial +), CD117(+), HLA-DR(predominantly + and variable),MPO(-), TdT(-).",6.6,2.2,negative,0,negative,,,TP53 (p.R273H; 39.7%)|TP53 (p.L206Wfs*41; 32.4%),EP300 (Foundation; EP300-ZNF205 fusion)|TP53 (Foundation; L206fs*41; MAFs: 31%)|TP53 (Foundation; R273H; MAFs: 38%)
16-00770,training,Alive,555,BA2469D,BA2469R,2530,4007,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,HISPANIC,White,6,,,50,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,51,0,Residual Disease|Post-Chemotherapy,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Busulfan, Fludarabine|5+2 (Cytarabine, Idarubicin)|HiDAC|7+3 (Cytarabine, Idarubicin, Bortezomib",3,Unknown|Induction|Re-induction,Unknown,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Unknown,-1,Alive,716,Alive,,12,,,,,17,,,,,,,,,,"46,XX[20]",,,,16,"FLT3 (ITD) Not detected. Not detected for the FLT3 TKD Mutation. Pathogenic alterations are detected in the BCOR, IDH2 and WT1 genes. Positive for CD34, HLADR, CD117, CD13, CD33 and CD43 and negative for CD11B, CD14, CD64, TDT and MPO. (Bone Marrow Immunophenotyping)",,1.5,negative,0,negative,,,,"BCOR (p.E1348Ifs, MAF 32%)|IDH2 (p.R172K, MAF 41%)|WT1 (p.T171Cfs*116, MAF 39%)"
16-00771,leaderboard,Dead,157,BA2269D,BA2269R,2033,4008,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,HISPANIC,HispNative,6,,,34,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,34,0,Residual Disease|Post-Chemotherapy,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Intrathecal,3,"7+3 (Cytarabine, Idarubicin)|Cytarabine|Etoposide, Mitoxantrone",3,Unknown|Induction|Re-induction,Refractory,Standard Chemotherapy,35,Intrathecal,Cytarabine,Unknown,6,Dead,157,Dead-Unknown,,15,,,,,12,,,,,,,,,,"46,XX[20]",,,,426,,,26.4,negative,0,negative,,,TP53 (p.R282Q; 46.6%),"CSF3R (p.A470V, MAF 51%)|DNMT3A (p.R882C, MAF 51%)|NRAS (p.G13R, MAF 48%)|TP53 (p.R282Q, MAF 51%)"
16-00810,training,Alive,189,BA2098D,BA2098R,2414,4028,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,UNKNOWN,White,1,,,61,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1,Alive,1830,Alive,0,83,,1.8,1.8,13.3,63.7,7.9,0.1,69,35,3,0.87,M5,34.7,11.6,"46,XX[20]",337,95.6,Normal,146,"Positive (dim CD4, CD11b, variable CD13, partial CD14, CD33, variable CD56, bright CD64, dim CD123 and HLA-DR-positive, comprising ~75% of WBCs. There is also about 5% of blasts are positive for CD117, CD13, CD33, HLA-DR, CD123, amd CD11b. Lymphocytes account for 13% of WBCs and include 74% T cells, 19% B cells and 7% NK cells. T cells show a CD4:CD8 ratio of 5:1 without aberrant antigen expression.) | Positive (B cells are polytypic by surface light chain expression with a kappa to lambda ratio of 1.2:1.)",6.1,44.83,negative,0,positive,,,,IDH1 (p.R132H; MAF 37%)|NPM1 (p.W288fs*12; MAF 40%)|NRAS (p.G13D; MAF 38%)
16-00815,leaderboard,Alive,197,BA2778D,BA2778R,2083,4030,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,60,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,60,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),6,"Fludarabine, Melphalan|Ruxolitinib|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC|Hydroxyurea",5,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction|Maintenance,Refractory,Standard Chemotherapy,18,Targeted Therapy - Kinase Inhibitor(s),Ruxolitinib,Maintenance,496,Alive,1801,Alive,0,75,44,0,0.9,28.7,46.1,24.3,0,18,13,2.9,1.19,M5,26.4,8.8,"46,XX[20]",222,96.4,Normal,175,"Positive (CD11b, variable CD13, CD14, CD33, dim CD56, bright CD64, and HLA-DR+)",6.9,34.6,negative,0,positive,,,,FBXW7 (p.T15_G16insP; MAF 48%)|NPM1 (p.W288fs*12; MAF 40%)|NRAS (p.G12S; MAF 40%)|TET2 (p.H437fs*7; MAF 42%)
16-00822,training,Alive,256,BA2379D,BA2379R,2440,2747,Waves1+2,Waves1+2,no,no,no,no,Male,Male,White,,White,6,,,62,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,n,n,y,n,n,n,MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS,Chronic myelomonocytic leukaemia,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,62,81,Residual Disease,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"Azacitidine|Fludarabine, Melphalan, ATG",2,Unknown|Allogeneic - Matched Unrelated Donor,,,,Bone Marrow Transplant,"Fludarabine, Melphalan, ATG",Allogeneic - Matched Unrelated Donor,-1,Alive,281,Alive,,9,,,,,7,,,,,,,,,,"46,XY[12]",,,The abnormalities normally seen in MDS are not detected.,,A very dim/negative CD45 population was also detected by the flow analysis. This population is negative for all the myeloid and lymphoid markers including CD34. This is mentioned here for documentation purposes but we believe that they do not represent blasts. (Bone Marrow Immunophenotyping),,,negative,0,negative,,,,
16-00831,training,Dead,1490,BA2817D,BA2817R,2557,4038,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,Black,,Black,2,,,73,FALSE,FALSE,FALSE,FALSE,FALSE,y,Prostate Cancer,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",77,0,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,2,Supportive/Palliative Care|Targeted Therapy - Other,6,Vidaza|AG-221|Bortezomib|Cytarabine|Lenalidomide|Decitabine,3,Hypomethylating/Low Dose Cytarabine|Experimental|Supportive/Palliative Care,,,,Targeted Therapy - Other,AG-221,Experimental,267,Dead,1490,Dead-Disease,,95,48,1,,42,6,2,,14,14,3.5,1.1,,27.3,9.4,"88<4n>,XXYY,+del(1)(p22p36),i(2)(p10),-5,-7,-7,-21,-21[12]",453,,"nuc ish(RUNX1T1x4,RUNX1x2)[200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[200],(PML,RARA)x4[200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[174/200]",23,"92% population of variably-sized cells with the following immunophenotype: CD2(-), CD4(-), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(+), CD16(-), CD33(-), CD34(+), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(variably +), HLA-DR(partial +).",6.5,3,negative,0,negative,RUNX1 (loss),,,IDH2 (R140Q)|PTPN11 (E76Q)|RUNX1 (loss)
16-00836,leaderboard,Dead,28,BA2820D,BA2820R,2542,4039,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,73,FALSE,FALSE,TRUE,FALSE,FALSE,y,Prostate Cancer,y,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,73,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"S0919 Trial (Pravastatin, Idarubicin, Cytarabine)|Hydroxyurea",1,Induction,unknown,Standard Chemotherapy,167,Standard Chemotherapy,"S0919 Trial (Pravastatin, Idarubicin, Cytarabine)",Induction,21,Dead,28,Dead-Disease,0,88,38,0,1.7,20.9,60.9,1.7,0.1,27,40,3,1.2,M4,33,11.2,"46,XY[20]",,105.8,normal,55,"Positive (Myeloid blast immunophenotype: CD13, CD33, dim CD64, CD117, CD123 (+) Monocytic/monoblastic immunophenotype: bright CD11b, CD13, bright CD14, CD33, bright CD64, HLA-DR (+))",7.5,58.97,positive,1,positive,,,,DNMT3A (p.R882H; MAF 42%)|EP300 (p.N674D; MAF 50%)|EP300 (p.V2140I; MAF 50%)|FLT3-ITD (MAF ~48%)|MLL2 (p.M3398V; MAF 51%)|NPM1 (p.W288fs*12; MAF 43%)
16-00867,training,Dead,8,BA2704D,BA2704R,2255,4042,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,61,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61,3,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Hydroxyurea,1,Induction,Unknown,Standard Chemotherapy,8,Standard Chemotherapy,Hydroxyurea,Induction,8,Dead,8,Dead-Disease,0,93,85,0.8,0,16.5,0.8,1.6,0.2,19,21,2.7,0.78,M1,21.1,7.1,"46,XX[20]",360,84.4,Normal,43,"partial CD13, CD33, dim/partial CD56, CD58, dim CD117, CD123 and MPO",5.7,30.54,positive,0.851851851851852,positive,,,,FLT3-ITD (MAF ~50%)|IDH2 (p.R140Q; MAF ~50%)|NPM1 (p.W288fs*12; MAF ~50%)
16-00882,training,Dead,97,BA2116D,BA2116R,2192,4006,Waves1+2,Waves1+2,no,no,no,no,Male,Male,White,,White,2,,,81,FALSE,FALSE,TRUE,FALSE,FALSE,n,,n,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,81,41,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,1,Supportive/Palliative Care,2,Vidaza|Decitabine,2,Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care,,,,Supportive/Palliative Care,Decitabine,Supportive/Palliative Care,3,Dead,97,Dead-Disease,0,N/A,70,0,,3,1,36,,25,33,4.1,1.26,,24.1,8.1,"45,XY,add(5)(q11.2),der(6)t(5;6)(p13;p23),der(8)t(8;8)(p23;q11.2),-13,-16,der(22)t(16;22)(q22;q11.2),+r[cp11]/44,idem,-18[cp4]/46,XY[5] ",853,98,"nuc ish(D5S2064x3,D5S630x3,EGR1x1)[97/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1x3,RUNX1x2)[110/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5’CBFB con 3’CBFB dimx1,5’CBFB con 3’CBFBx1)[200]",74,,,39.12,negative,0,negative,,,TP53 (p.R273H; 56.3%)|TP53 (p.L206Wfs*41; 40.7%),
16-00951,training,Alive,223,BA2584D,BA2584R,2422,4075,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,,,White,3,,KMT2A_re,42,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,42,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)",4,Allogeneic - Sibling|Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Sibling,-1,Alive,427,Alive,,80,,,,,,,,,,,,,,,"45,XY,t(3;17)([21;q11.2),add(4)(q21),add(5)(p15),ins(10;11)(p12;q23q13),der(12;18)(q10;q10)[19]/46,XY[1]",,,11q23 rearrangement involving the  KMT2A (MLL) locus in 184/200 (92.0 percent) cells scored | One cell line showed the following clonal abnormalities in 19/20 (95%) cells: an apparent insertion of material form the long arm of chromosome 11 into the short arm of chromosome 10;  a translocation between chromosomes 3 and 17; added material on the long arm of chromosome 4 and on the short arm of chromosome 5; an unbalanced whole arm rearrangement between the long arms of chromosomes 12,,,,,negative,0,negative,,,,
16-01004,training,Alive,95,BA2417D,BA2417R,2333,4195,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,,White,2,,,70,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,70,0,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,"Vidaza|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Hypomethylating/Low Dose Cytarabine|Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,Vidaza,Hypomethylating/Low Dose Cytarabine,4,Alive,486,Alive,0,85,77.8,0,,7.4,0,11.1,,12,32,2.8,0.62,,21.8,7,,1195,,,103,"CD11b(partial +), CD13(equivocal), CD15(bright +), CD16(-), CD33(bright +), CD34(-), CD36(-), CD38(bright +), CD45(bright +), CD56(+),CD64(bright+), CD117(-), and HLA-DR(+).",5.2,25.85,negative,0,negative,,,,
16-01005,training,Alive,153,BA2361D,BA2361R,2444,4196,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,,White,5,,,55,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,55,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"7+3 (Cytarabine, Idarubicin) plus Enasidenib|Busulfan, Cyclophosphamide",2,Allogeneic - Sibling|Induction,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1,Alive,428,Alive,1,30,0,0,,31,4,6.8,,10,11,4.3,,,32.4,9.9,"46,XX,del(5)(q22q35)[2]/46,XX,+8,-16,der(17)t(16;17)(p11.2;p11.2)[14]/46,XX[3]",,,Probe: 8 centromere/20q12 | Normal (5p15.2/ 5q31 (EGR1); 7 centromere/ 7q31),83,Negative (CD19) | Negative (CD22) | Positive (CD38) | Negative (CD7) | Negative (CD56) | Negative (CD11b) | Positive (CD13) | Negative (CD14) | Negative (CD15) | Negative (CD33) | Positive (CD34) | Negative (CD45) | Negative (CD64) | Negative (CD117) | Negative (MPO) | Positive (HLA-DR),7.2,10.6,negative,0,negative,,,,ASXL1 (c.190 0_1922 delAGAGAGGCGGCCACCACTGCCAT; p.R634Rfs; MAF 33%)|IDH2 (c.419G>A; P.R140Q; MAF 46%)
16-01010,training,Dead,634,BA2450D,BA2450R,2284,4197,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,46,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,46,0,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,5,"7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea",4,Consolidation|Salvage|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,32,Standard Chemotherapy,Sunitinib,Consolidation,2,Dead,269,Dead-Disease,0,,,0,0,20.4,0,66.7,1,58,44,3.3,1.04,,23.8,8.1,,401,88.5,"metaphases positive for 45XX monosomy chromosome 17,20/22 metaphases positive for 46XX diploid",14,,7.3,6.18,positive,0.25,positive,,,,
16-01017,training,Alive,444,BA2492D,BA2492R,2390,4043,Waves1+2,Waves1+2,no,no,no,no,Male,Male,White,HISPANIC,AdmixedHispNative,6,,,25,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",26,28,Residual Disease|Post-Chemotherapy|Post-Transplant,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"Bu/Cy/ATG|HiDAC|3+7 (Cytarabine, Daunorubicin)|Decitabine|Clofarabine, Cytarabine",5,Consolidation|Salvage|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,7,Standard Chemotherapy,Decitabine,Salvage,9,Dead,463,Dead-Disease,,70,8,,,,4,,,,,,,,,,"46,XY,-3,del(5)(q31q35),der(7)t(7;?)(p11.2;?),+der(11)(q23),-12,+mar[20]",,,,10,"MONOBLASTS, 61%. These are dim45positive and also express CD13, CD33, CD11b, CD14, CD64  but lack CD16, CD34, CD117, HLADR  (Bone Marrow Immunophenotyping)",,30.2,negative,0,negative,,,,
16-01049,training,Dead,372,BA2472D,BA2472R,2546,4207,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,Asian,,Asian,2,,,78,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",78,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,5,"7+3 (Cytarabine, Idarubicin)|Decitabine|7+3 (Cytarabine, Idarubicin) plus Azacitidine|IDAC|Etoposide, Cytarabine",4,Induction|Re-induction|Maintenance|Supportive/Palliative Care,Refractory,Supportive/Palliative Care,-1,Standard Chemotherapy,"Etoposide, Cytarabine",Supportive/Palliative Care,-1,Dead,372,Dead-Disease,0,20,3.8,7.8,,40,5.2,40,,9,49,3.1,1.41,,25.7,8.5,"46,XY[20]",675,,"nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",30,"CD2(-), CD3(-), CD4(dim +), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(small subset+), CD16(-), CD19(-), CD20(-), CD33(+), CD34(+),CD36(-), CD38(dim+), CD45(dim +), CD56(-), CD64(variably+), CD117(+), HLA-DR(dim +), MPO(partial +), and TdT(-).",6.9,4.9,negative,0,negative,RUNX1 (p.L89Pfs*49; 15.8%),,,
16-01061,leaderboard,Dead,634,BA2994D,BA2994R,2284,4197,Waves1+2,Waves1+2,no,no,no,no,Female,Female,White,NON-HISPANIC,White,1,,,46,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,47,14,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,5,"7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea",4,Consolidation|Salvage|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,32,Standard Chemotherapy,Sunitinib,Consolidation,2,Dead,269,Dead-Disease,,,,,,,,,,,,,,,,,,,,"metaphases positive for 45XX monosomy chromosome 17,20/22 metaphases positive for 46XX diploid",,,,,negative,0,positive,,,,
16-01094,training,Dead,633,BA2879D,BA2879R,2292,2254,Waves1+2,Waves1+2,no,no,no,no,Female,Female,Unknown,,White,2,,,52,TRUE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,53,462,Relapse,Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)",3,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Salvage,-1,Dead,633,Dead-Disease,,76,1,,,,,,,,,,,M1,,,"46,XX[20]",,,"nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",,,,,negative,0,negative,,,,
16-01097,training,Alive,569,BA2577D,BA2577R,2566,2116,Waves1+2,Waves1+2,no,no,no,no,Female,Female,White,NON-HISPANIC,White,1,bi,,10,TRUE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,12,568,Post-Chemotherapy|Relapse,Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|ADE (Cytarabine, Daunorubicin & Etoposide)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide",3,Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,33,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Matched Unrelated Donor,-1,Alive,2143,Alive,0,46,,0,0,81.3,8.3,10.4,18.1,31,27,3.8,0.53,M2,30.5,10.2,"47,XX,+10[19]/46,XX[1]",,96.8,Normal,11,"variable CD7,  dim CD13, CD33, CD34 bright CD38,CD56, CD58, CD117, HLA-DR positive",7,1.93,negative,0,negative,,,,
16-01100,training,Dead,2,BA2456D,BA2456R,2481,4231,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,,White,2,,,65,FALSE,FALSE,FALSE,FALSE,FALSE,y,Skin cancer,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Cytarabine,1,Supportive/Palliative Care,,,,Standard Chemotherapy,Cytarabine,Supportive/Palliative Care,-1,Dead,2,Dead-Unknown,,,,,,,,,,,,,,,,,,,,"nuc ish (PML,RARA)x2[199]",,,,,negative,0,positive,,,,
16-01102,training,Alive,358,BA2175D,BA2175R,2382,4232,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,,White,2,,,72,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,72,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Supportive/Palliative Care,,,,Standard Chemotherapy,Decitabine,Supportive/Palliative Care,-1,Alive,373,Alive,,30,5,,,,,,,37,93,,,,,,"45,XX,der(5)inv(5)(p13q15)del(5)(q15q33),-16,-17,der(17)t(17;17)(p13;q11.2),der(18;22)(q10;q10),+22,+r[cp20] .ish r(MLL+)[2]",,,"nuc ish(D4Z1,D10Z1)x2[200],(D5S2064x2,D5S630x2,EGR1x1)[196/200],(D7Z1,D7S522)x2[200], (D8Z2,D20S108)x2[197],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3) [142/200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[200]",16,,,44.63,negative,0,negative,,,,
16-01103,training,Dead,634,BA2824D,BA2824R,2284,4197,Waves1+2,Waves1+2,no,no,no,no,Female,Female,White,NON-HISPANIC,White,1,,,46,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,47,23,Residual Disease|Post-Chemotherapy,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Supportive/Palliative Care,5,"7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea",4,Consolidation|Salvage|Induction|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,32,Standard Chemotherapy,Sunitinib,Consolidation,2,Dead,269,Dead-Disease,0,90,90,0,0,5,0,0,0,27,43,1.6,0.93,,22.5,7.9,,,82.1,Positive,43,"variable CD7, CD13, dim CD33, partial CD34, CD38,dim CD58, partial and variable CD117 and CD123 positive",5.1,18.38,positive,0.515151515151515,positive,,,,
16-01109,leaderboard,Alive,116,BA2507D,BA2507R,2377,4235,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,Black,,Black,5,,CBFB-MYH11,33,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,33,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,HiDAC,Consolidation,-1,Alive,402,Alive,0,72,95,0,,3,0,1,,29,24,3.4,,,19.8,6.5,"46,XY,inv(16)(p13.1q22)[20]",,,Positive for CBFB rearrangment for 91% of cells,31,"Positive (CD38, CD13, CD33, CD34, CD45, CD117, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD11b, CD14, CD15, CD64, TdT)",6.6,93.2,negative,0,negative,,,,TET2 (c.652G>A; p.V218M; MAF 50%)
16-01121,training,Alive,184,BA2563D,BA2563R,2493,4239,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,,White,3,,,61,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|IDAC plus Midostaurin|7+3 (Cytarabine, Daunorubicin) plus Sorafenib",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Matched Unrelated Donor,-1,Alive,398,Alive,,86,89,,,,,,,,,,,,,,"46,XY[20]",,,Normal,57,,,115.15,positive,0.0638297872340425,positive,,,,DNMT3A (p.Arg326Cys; MAF 44.5%)|FLT3-ITD (p.Phe594_Asp600dup; MAF 45%)|NPM1 (p.Trp288fs; MAF 20.7%)|TET2 (p.Ala911fs; MAF 40.6%)|TET2 (p.His1036fs; MAF 39.4%)
16-01127,leaderboard,Alive,528,BA2244D,BA2244R,2219,2538,Waves1+2,Waves1+2,no,no,no,no,Male,Male,White,NON-HISPANIC,White,1,,,67,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,68,261,Post-Chemotherapy,Remission,Leukapheresis,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,5,"AG-120|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC",5,Consolidation|Salvage|Induction|Experimental|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Mismatched Unrelated Donor,-1,Dead,864,Dead-Other,,,,,,,,,,,,,,M4,,,"46,XY,t(4;8)(q21;p23)[2]/46,XY[18]",,,Normal,,,,,negative,0,positive,,ASXL1 (p.G645Vfs*58; 10.0%),,
16-01138,training,Dead,424,BA2470D,BA2470R,2202,2315,Waves1+2,Waves1+2,no,no,no,no,Male,Male,White,NON-HISPANIC,White,1,,,62,TRUE,FALSE,TRUE,FALSE,FALSE,n,,y,n,y,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63,412,Relapse,Relapse,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,Decitabine|Hydroxyurea,2,Induction|Re-induction,Complete Response i,Standard Chemotherapy,-1,Standard Chemotherapy,Hydroxyurea,Re-induction,263,Dead,424,Dead-Disease,0.9,,,0,0,7.8,1.7,4.3,0.1,18,21,2.8,1.43,M2,25,8.2,"46,XY,del(5)(q22q35),del(12)(q24.1q24.1),add(17)(p11.2)[19]/46,XY[1]",564,102.5,EGR1 (73.5%) ;  TP53: (85.5%),139,,6.6,46.79,negative,0,negative,,,TP53 (p.G266V; 91.4%),
16-01151,training,Alive,355,BA2984D,BA2984R,2520,4248,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,81,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,81,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"Vidaza, BI836858 (anti-CD33)",1,Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"Vidaza, BI836858 (anti-CD33)",Induction,-1,Dead,581,Dead-Disease,0,80,80,0,7,7.8,0,6.9,0.5,31,42,3.2,1.3,M1,25.1,8.8,"46,XY[19]",665,85.1,Normal,16,"dim CD13, CD33, CD38, CD58, dim CD64, CD71, dim CD117 and CD123-positive",7.2,33.81,negative,0,positive,,,,CSF3R ( p.T640N; MAF: 14%)|EZH2 (p.G709D; MAF: 17%)|EZH2 (p.R684C; MAF: 4%)|IDH2 (p.R140Q; MAF: 46%)|KDM6A (Splice site-Intron 5 3' end mutation; MAF:3%)|NPM1 (p.W288fs*12; MAF: 39%)
16-01185,leaderboard,Dead,201,BA2414D,BA2414R,2307,4252,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,,White,5,,,50,FALSE,FALSE,FALSE,FALSE,FALSE,y,Hodgkin Lymphoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,50,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI",2,Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, Thiotepa, TBI",Double Umbilical Cord Blood Transplant (DUCBT),-1,Dead,201,Dead-Unknown,0,75,82,2,,4,0,8,,39,45,3.7,,,20.1,6.5,"46,XY,add(1)(p11),del(5)(q15q33),del(7)(q22q36),der(11)t(1;11)(p31;p12-14)[20] ",,,Loss of 5q31 sequences for 99% of total cells | Loss of 7q31 sequences for 96% of total cells,12,"Positive: CD38, CD56, CD13, CD34, CD45, CD117, HLA-DR | Partially positive: CD7, CD11b, CD33, CD64 | Negative: CD19, CD22, Cyt CD79a, Cyt CD3, CD14, CD15, MPO, TdT",6.3,119.6,positive,0.818181818181818,negative,,,,BCOR (C.3067T>C; p.F1023L)|FLT3-ITD|NOTCH1 (c.7625G>A; p.S2542N)
16-01191,training,Alive,246,BA2697D,BA2697R,2168,4256,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,White,3,,,65,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,65,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Vidaza|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)",3,Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1,Alive,338,Alive,,20.6,,,,,,,,,,,,,,,"45,XX,-7[20]",,,"7cen (D7Z1), 7q31 (D7S486): monosomy present ",,,,,negative,0,negative,,,,DNMT3A (p.Gln231fs; MAF 33.2%)|IDH2 (p.Arg140Gln; MAF 44.2%)|NRAS (p.Gln61Glu; MAF 47.8%)
16-01192,leaderboard,Alive,414,BA2079D,BA2079R,2224,4201,Waves1+2,Waves1+2,no,no,no,no,Female,Female,White,NON-HISPANIC,White,1,,,52,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,52,34,Post-Chemotherapy,Remission,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,5,"MiDAC|Idarubicin and Cytarabine|FLAG-IDA plus Midostaurin|Azacitidine, Midostaurin, Ponatinib|7+3 (Cytarabine, Idarubicin) plus Dasatinib ",4,Consolidation|Salvage|Induction|Maintenance,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,Idarubicin and Cytarabine,Salvage,3,Dead,559,Dead-Disease,1.4,1.5,,0.2,,9.2,24.3,64.9,,119,151,3.2,0.76,M5,28.4,9.2,"46,XX[20] ",380,93.4,Normal,395,,6.6,6.5,negative,0,negative,,,,DNMT3A (p.R882C; MAF 14%)
16-01201,training,Dead,543,BA2999D,BA2999R,2117,4260,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,,,53,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",54,0,Post-Chemotherapy|Residual Disease,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,7,"AG-120|7+3 (Cytarabine, Idarubicin)|Azacitidine|MGD006 (CD123 x CD3) |MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)",5,Salvage|Induction|Experimental|Re-induction|Maintenance,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,Incyte trial (azacitidine and JAK 1 inhibitor),Salvage,-1,Dead,543,Dead-Disease,0,75,90,0,0,22.1,6.2,1.8,0,19,33,1.8,0.84,,25.5,8.1,"46,XY,t(4;12)(q12;p13)[10]/46,XY[10] ",706,91.4,"42/100 (42%) interphase cells scored were positive for  ETV6 rearrangement.  Metaphase FISH showed part of the ETV6 signal (red) on  the long arm of chromosome 4.  Based on the breakpoint, ETV6/CHIC2 fusion  is predicted, consistent with AML",25,"partial CD7, CD13, CD33, CD38, CD34, CD58, CD117, CD123,  HLA-DR positive ",6.6,118,negative,0,negative,RUNX1 (p.R166*; 41.5%),,,DNMT3A (p.R882H; MAF 49%)|IDH1 (p.R132S; MAF 48%)|RUNX1 (p.R166*; MAF 50%)|SRSF2 (p.P95H; MAF 50%)
16-01216,training,Alive,395,BA2011D,BA2011R,2280,4263,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,,White,3,,,63,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,63,1,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin) plus Crenolanib|IDAC",3,Consolidation|Induction|Allogeneic - Child,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Child,-1,Alive,306,Alive,,26.3,,,,,,,,,,,,,,,"46,XY[11] ",,,Normal,,,,,negative,0,negative,,,,BCOR (p.Tyr354*; MAF 72.2%)|DNMT3A (p.Phe755Ser; MAF 38.6%)|DNMT3A (p.Thr835Met; MAF 47%)|IDH1 (p.Arg132Cys; MAF 2.9%)
16-01219,training,Alive,317,BA2217D,BA2217R,2538,4271,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,White,1,bi,,47,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,47,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,HiDAC,Consolidation,116,Alive,214,Alive,0,83,82,3.4,0,23.1,3.4,0,1.6,23,11,3.5,0.95,M1,31.1,10.2,"46,XY[20]",290,88.9,,24,"CD7, CD13, CD33, CD34, CD38, partial CD56,  CD58, dim CD64, CD117, CD123, HLA-DR, and cMPO ",6.5,18.71,negative,0,negative,,,,"CEBPA (p.I68fs; MAF 50%)|CEBPA (p.K313_V314insK; MAF 50%)|EZH2 (p.S519P; MAF 51%)|NRAS (p.G13D, MAF 3%)|WT1 (p.M392fs*10; MAF 13%)|WT1 (p.R458*; MAF 23%)"
16-01223,training,Dead,31,BA2454D,BA2454R,2234,4273,Waves1+2,Waves1+2,yes,yes,yes,yes,Male,Male,White,,White,2,,,73,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",73,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Supportive/Palliative Care,,,,Standard Chemotherapy,Decitabine,Supportive/Palliative Care,-1,Dead,31,Dead-Unknown,,83,59,,,,,,,21,23,,,,,,"46,XY[20]",,,"nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[195],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",22,,,24.23,negative,0,negative,RUNX1 (p.S322*; 51.4%),ASXL1 (p.R693*; 50.0%),,
16-01225,training,Dead,316,BA2776D,BA2776R,2431,4274,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,61,FALSE,FALSE,TRUE,FALSE,FALSE,n,,n,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,61,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Supportive/Palliative Care,1,Hydroxyurea,1,Supportive/Palliative Care,,,,Supportive/Palliative Care,Hydroxyurea,Supportive/Palliative Care,-1,Dead,316,Dead-Disease,,,,,,,,,,,,,,M1,,,"46,XX[20]",,,Normal,,"CD13, CD33, CD38, CD56, CD58, CD117, CD123 and dim MPO positive",,,positive,9,positive,,,,FLT3-ITD (30 bp insertion; MAF 70%)|NPM1 (p.W288fs*12; MAF 45%)
16-01227,leaderboard,Alive,399,BA2218D,BA2218R,2282,4275,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,HISPANIC,HispNative,6,,,39,TRUE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,40,0,Relapse|Post-Chemotherapy,Relapse,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|ME (Etoposide, Mitoxantrone)|Decitabine",3,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,39,Standard Chemotherapy,Decitabine,Salvage,69,Dead,433,Dead-Unknown,,,91,,,9,,,,21,34,3.8,0.49,,29.3,9.9,,,93.6,,66,,5.8,73,negative,0,positive,,,,
16-01237,training,Alive,122,BA2135D,BA2135R,2547,4291,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,,,HispNative,6,,,73,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,73,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Decitabine,1,Supportive/Palliative Care,,,,Standard Chemotherapy,Decitabine,Supportive/Palliative Care,-1,Alive,122,Alive,,71,3,1,,68,8,11,,11,23,2.9,0.51,,24.9,7.8,"46,XX,del(1)(p22),der(15)t(15;?)(q15;?),-17,+mar[19]/46,XX[1]",,110.7,Loss of RARA gene at 17q21 is detected in 69% of cells Gain of MLL gene at 11q23 is detected in 8% of cells.,95,"blasts 55% of all events; they are positive for cd34, hla-dr, cd117, cd13, cd33, and negative for cd11b, cd14, cd64, tdt and mpo",4.8,63.4,negative,0,negative,,ASXL1 (p.G646Wfs*12; 32.6%),,
16-01254,training,Alive,303,BA2914D,BA2914R,2508,4299,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,,38,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,38,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,HiDAC,Consolidation,106,Alive,1586,Alive,,47,,,,,,,,,,,,M4,,,"46,XX[20]",,,Normal,,"CD117, dimCD4,  heterogeneous CD13, CD33, dimCD64 and  MPO positive  (Myeloid Blast Population) | heterogeneous CD13, bright CD33, dimCD4,  dimCD14, bright CD64 positive  (Monocytes/promonocytes Population)",,46.27,negative,0,positive,,,,DNMT3A (p.R882H; MAF 46%)|IDH1 (p.R132H; MAF 25%)|KRAS (p.Q61L; MAF 10%)|NPM1 (p.W288fs*12; MAF 51%)|NRAS (p.G13D; MAF 24%)
16-01262,training,Alive,28,BA2500D,BA2500R,2120,4303,Waves1+2,Waves1+2,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,White,1,,PML-RARA,59,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA,59,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"ATRA, Arsenic Trioxide, Idarubicin",1,Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"ATRA, Arsenic Trioxide, Idarubicin",Induction,-1,Alive,28,Alive,0.9,90,90,1.7,44,8.6,0,6,1.5,110,255,2.4,0.86,M3,19.8,6.7,"46,XX,t(15;17)(q22;q21)[20]",,88.4,86/100 cells (86%) had the 1r/1g/2f dual fusion signal pattern consistent  with PML/RARA fusion and with t(15;17) as seen on metaphase analysis. ,30,"CD13, CD33, CD58, CD64, CD117, CD123, MPO",5.4,47.35,negative,0,negative,,,,ASXL1 (p.M1050V; MAF 51%)|FLT3-ITD (MAF 46%)
17-00066,validation,Alive,322,BA3195D,BA3195R,2827,4364,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,,,,5,,,77,FALSE,FALSE,TRUE,FALSE,FALSE,n,,n,n,n,n,y,y,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,77,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other,4,"Venetoclax, Idasanutlin|anti-CD123, Decitabine|Enasidenib|cd47mAb",3,Salvage|Induction|Experimental,Refractory,Targeted Therapy - Kinase Inhibitor(s),-1,Targeted Therapy - Kinase Inhibitor(s),Enasidenib,Salvage,-1,Alive,322,Alive,0,90,92,0,,4,1,3,,17,22,3.8,,,24.7,7.4,"46,XY[19]",,,Normal,72,"Positive (CD38, CD15, CD34, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD11b, CD13, CD14, CD33, CD64, TdT) | Dim Positive (CD45, CD117)",6.4,224.2,negative,0,negative,RUNX1 (p.L98Pfs*40; 52.3%)|RUNX1 (p.N434Kfs*166; 32.4%),,,DNMT3A (c.2644C>T; p.R882C; MAF 47%)|IDH2 (c.419G>A; p.R140Q; MAF 48%)|JAK2 (c.1849G>T; p.V617F; MAF 50%)|RUNX1 (c.1289_1290insTGCC; p.P430fs; MAF 17%)|RUNX1 (c.1301 1302insA; p.N434Â£s; MAF 21%)|RUNX1 (c.292_293insC; p.L98fs; MAF 45%)|SRSF2 (c.284C>A; p.P95H; MAF 48%)
17-00111,validation,Alive,279,BA3118D,BA3118R,2709,4389,Waves3+4,Waves3+4,yes,yes,yes,yes,Female,Female,Asian,,,2,,CBFB-MYH11,45,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid sarcoma,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Myeloid sarcoma,45,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,5,Standard Chemotherapy,HiDAC,Consolidation,92,Alive,279,Alive,,,,,,,,,,,,,,,,,"46,XX[20]",,,,,,,,negative,0,negative,,,,MYH11 (CBFB-MYH11 fusion)|NRAS (G12D)
17-00113,validation,Alive,805,BA3206D,BA3206R,2668,4390,Waves3+4,Waves3+4,yes,yes,yes,yes,Female,Female,White,HISPANIC,,1,,RUNX1-RUNX1T1,35,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(8;21)(q22;q22); RUNX1-RUNX1T1,35,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine, Venetoclax",4,Consolidation|Salvage|Induction|Re-induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,"Decitabine, Venetoclax",Salvage,165,Dead,1220,Dead-Disease,0,60,10,0,0.9,88.7,0.9,9.5,0,34,12,3,0.8,M2,22,7.8,"45,X,-X,t(8;21)(q22;q22)[20] ",334,93.2,"RUNX1T1(8q21.3)/RUNX1(21q22):   64% of cells had an atypical 1r/2g/1f  signal pattern, a fusion pattern consistent with t(8;21) as seen on metaphase analysis.  | All twenty metaphase cells examined were abnormal, with monosomy X and  t(8;21).",34,"CD13, dim CD19, dim CD33, CD34, CD38, CD56, CD58, CD117, dim CD123, HLA-DR and MPO+ ",7,4.73,negative,0,negative,,,,FLT3-ITD (MAF 5%)
17-00123,validation,Alive,293,BA3217D,BA3217R,2624,4395,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,White,,,5,,,60,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",60,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)",2,Allogeneic - Sibling|Induction,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Sibling,-1,Alive,293,Alive,,95,70,,,27,1,2,,37,32,3.2,,,29.2,9.9,"46,XY[20]",,,Normal,48,"Positive (CD38, CD33, CD34, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD13, CD14, CD15, CD117, TdT) | Dim (CD11b, CD45, CD64)",6,25.5,positive,0.96078431372549,negative,,,,"FLT3-ITD (ITD, c.1769_1770ins42; p.Y589_F590insl4 (MAF 38%))|IDH2 (c.419G>A; p.R140Q (MAF 48%))|STAG2 (c.3034delC; p.R1012fs (MAF 92%))"
17-00177,validation,Alive,289,BA3306D,BA3306R,2811,4406,Waves3+4,Waves3+4,yes,yes,yes,yes,Female,Female,White,,,5,,,26,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,26,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Cyclophosphamide, Thiotepa, TBI",3,Consolidation|Induction|Double Umbilical Cord Blood Transplant (DUCBT),Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, Thiotepa, TBI",Double Umbilical Cord Blood Transplant (DUCBT),-1,Alive,289,Alive,0,89.5,88,0,,7,2,3,,10,21,3,,,23.1,7.6,,,,Normal,19,"Dim Positive (CD13, MPO) | Dim Partial positive (CD34) | Variable partial positive (CD117)",5.2,138.2,positive,19,positive,,,,"FLT3-ITD (ITD, c.l815_1816ins30; p.F605_P606insl0 (MAF 49%))|IDH1 (c.395G>A; p.R132H (MAF 45%))|NPM1 (c.863_864insTCTG; p.W288fs (MAF 43%))"
17-00210,validation,Dead,51,BA3133D,BA3133R,2747,4428,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,,1,,,61,FALSE,FALSE,TRUE,FALSE,FALSE,y,Skin cancer,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,61,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Vidaza,1,Induction,Unknown,Standard Chemotherapy,-1,Standard Chemotherapy,Vidaza,Induction,-1,Dead,51,Dead-Disease,0,25,26,0,11.5,9.7,7.1,43.4,0.1,23,33,3.6,0.8,M2,22,7,"45,XY,del(5)(q13q33),-7,add(8)(q24.3),add(9)(q34),add(10)(q23),del(17)(p13)  ,add(18)(q23)[3]/47-49,sl,+2-4mar[cp12]/44,sl,-2,add(3)(p21),t(6;11)(p22;q1  4),-add(8)(q24.3),add(8)(p22),-9,add(9)(q33),-10,-13,add(21)(q21),+2mar[8] ",855,116.4,"TP53 (17p13.1):  83% of cells were missing a signal for TP53, consistent with the 17p deletion seen on metaphase analysis.  | RUNX1 (21q22):  15.5% of cells were missing a signal for RUNX1.  No  evidence for RUNX1/RUNX1T1 fusion.  | MECOM (3q26.2):  33% of cells had six (6) signals for MECOM. On available  metaphases, the extra MECOM signals hybridized to the small marker  chromosomes.  No evidence for MECOM/RPN1 fusion. ",166,"CD13, CD33, CD34, CD38, CD58, CD71, CD117,  CD123, HLA-DR + ",6.7,19.22,negative,0,negative,RUNX1 (p.X170_splice; 26.1%),,TP53 (p.Q167*; 91.3%),BCOR (p.Q1658H; MAF 100%)|RUNX1 (Splice Site; MAF 17%)|SF3B1 (p.K666M; MAF 47%)|SRSF2 (p.R180G; MAF 54%)|TP53 (p.Q167; MAF 65%)
17-00230,validation,Alive,785,BA3451D,BA3451R,2780,4438,Waves3+4,Waves3+4,yes,yes,yes,yes,Female,Female,White,UNKNOWN,,1,,,47,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,47,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,HiDAC,Consolidation,95,Alive,1181,Alive,0,85,70,0.4,0.4,27.1,63.8,5.3,0.1,14,15,2.8,1.39,M5,19.8,6.5,"46,XX[20]",355,97.5,Normal,48,"CD4, CD11b, CD13, CD33, variable CD14, CD38,  dim CD56, CD58, bright CD64, dim CD123, HLA-DR, and partial MPO +",7.7,58.66,negative,0,positive,,,,KRAS (p.G13D; MAF 36%)|NPM1 (p.W288fs*12; MAF 44%)|TET2 (p.Q897*; MAF 39%)
17-00252,validation,Alive,777,BA3212D,BA3212R,2727,4443,Waves3+4,Waves3+4,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,,1,,,0,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,0,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Cytarabine, Daunorubicin, and Etoposide|Busulfan, Cyclophosphamide|Etoposide, Cytarabine",5,Consolidation|Induction|Intensification|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)",Re-induction,4,Dead,855,Dead-Disease,0,,82,0,,23.1,63.1,5.8,0.6,55,179,3.2,0.26,M0,15.5,5.6,"46,XX,der(1)t(1;9)(p36.1;q22),t(5;17)(p13;q21),der(5;9)(p10;p10),+8[12]/47,  sl,+20[7]64~69<3n>,XXX,+1,der(1)t(1;9)(p36.1;q22)x2,+5,t(5;17)(p13;q21)x2,+  6,-9,-11,+21[cp3] ",8707,85.2,"EGR-1/ D5S23, D5S721: 175/200 cells had a 1 red/ 2 green signal  pattern, indicating a deleted 5q. Five cells had a 2 red/ 4 green signal pattern consistent with the  two normal chromosomes 5 and the two derivative chromosomes (5;9),  resulting in loss of 5q, present in the near-triploid clone. | RUNX1T1/ RUNX1: 155/200 cells had a 3 chromosome 8 signals,  consistent with the trisomy 8 observed in the metaphase karyotype.  Four cells had 4 chromosome 21 signals (in addition to trisomy 8),  consistent with the tetrasomy 21 observed in the near-triploid clone. No evid for RUNX1T1/RUNX1 fusion. | ETV6/ RUNX1:   5/200 cells (2.5%) had a 4 red/ 3 green signal pattern,  consistent with the near-triploid clone with trisomy 8 and tetrasomy 21.  There was no evidence for ETV6/ RUNX1 fusion. ",28,"CD4, CD7, partial CD13, CD33, CD71, partial CD117, CD123 and dim HLA-DR-positive ",5.7,133.39,negative,0,negative,,,,NRAS (p.G12D; MAF 29%)|NRAS (p.Q61K; MAF 6%)
17-00262,validation,Dead,23,BA3271D,BA3271R,2792,4449,Waves3+4,Waves3+4,yes,yes,yes,yes,Female,Female,White,HISPANIC,,1,,,62,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,62,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Unknown,Standard Chemotherapy,6,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,6,Dead,23,Dead-Disease,0,81,43,7.5,,20.6,16.8,8.4,0.8,21,33,2.3,2.79,M5,26.5,8.6,"46,XX[20]",487,106.4,Normal,73,"dim CD4, dim CD7, CD13, CD33, CD38, CD58, CD117, CD123, HLA-DR, and dim partial MPO (Myeloid Blast Population) | CD4, CD11b, CD13, dim CD14, dim CD15, CD16, CD33, CD38, CD58, CD63, CD123, HLA-DR  (Promonocyte/Monocyte Blast Population)",6.5,28.53,positive,0.666666666666667,positive,,,,FLT3-ITD (ITD; MAF 45%)|IDH2 (p.R140Q; MAF 38%)|NPM1 (p.W288fs*12; MAF 41%)
17-00264,validation,Dead,5,BA3152D,BA3152R,2758,4450,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,,1,,,74,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,74,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,Azacitidine,1,Supportive/Palliative Care,,,,Standard Chemotherapy,Azacitidine,Supportive/Palliative Care,3,Dead,5,Dead-Disease,0,42,4,0,9.1,3.8,44.7,38.6,0.5,27,23,2.3,1.64,M5,23.8,7.7,"43~44,XY,der(5)t(5;15)(q22;q11.2),add(6)(p23),-15,-16,-17,add(18)(q21),add(  19)(q13.1),-21,+mar1,+mar2[cp20]",387,93.3,"Approximately 95% of cells had abnormal signal patterns consistent with the metaphase karyotype and reflecting deleted 5q, monosomy 16, monosomy 17, and monosomy 21. ",93,"partial CD11b, CD13, partial CD14, CD33, CD34, partial CD64, CD117, HLA-DR and dim MPO (+)",6,29.15,negative,0,negative,,,TP53 (p.Y220C; 90.9%),TP53 (p.Y220C;  MAF 91%)
17-00276,validation,Alive,721,BA3095D,BA3095R,2626,4453,Waves3+4,Waves3+4,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,,1,,,27,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML without maturation,27,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),7,"Ruxolitinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Busulfan, Cyclophosphamide|Ibrutinib",5,Consolidation|Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor,Refractory,Standard Chemotherapy,6,Targeted Therapy - Kinase Inhibitor(s),Ruxolitinib,Maintenance,-1,Alive,1512,Alive,0,61,82,0,0,11.5,0.9,1.8,1.9,17,33,3.5,0.64,M1,20.5,7.1,"47,XX,+8[19]/46,XX[1]",440,96.2,RUNX1T1 (8q21.3):   93% of cells had three signals for RUNX1T1 (8q21.3)  consistent with trisomy 8 as seen on metaphase analysis.,53,"dim CD7, CD13, CD33, dimCD34, dimCD64, dim CD117, CD123, and dim HLA-DR+ ",5.9,24.3,positive,0.818181818181818,negative,,,,FLT3-ITD (MAF 50% )
17-00287,validation,Dead,14,BA3251D,BA3251R,2815,4456,Waves3+4,Waves3+4,yes,yes,yes,yes,Female,Female,White,,,5,,,75,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",75,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"Venetoclax (ABT-199), Azacitidine",1,Induction,Unknown,Standard Chemotherapy,4,Standard Chemotherapy,"Venetoclax (ABT-199), Azacitidine",Induction,4,Dead,14,Dead-Disease,0,80.5,60,0,,16,22,1,,61,75,3.7,,,33.7,11.1,"46,XX[20]",,,Normal,35,"Positive (CD38, CD13, CD33, CD117, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD11b, CD14, CD15, CD34, CD64, TdT, Glyc A) | DIM (CD45, CD71)",6.5,142.8,positive,0.5625,negative,,,,FLT3-ITD (c.1829_1830ins51; p.N609_L610ins17; MAF 19%)|IDH2 (c.419G>A; p.R140Q; MAF 48%)|RUNX1 (c.1041G>A; p.M347I; MAF 50%)
17-00300,validation,Dead,24,BA3362D,BA3362R,2655,4461,Waves3+4,Waves3+4,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,,1,,,72,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,72,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"3+7 (Cytarabine, Daunorubicin)",1,Induction,Unknown,Standard Chemotherapy,-1,Standard Chemotherapy,"3+7 (Cytarabine, Daunorubicin)",Induction,-1,Dead,24,Dead-Disease,0,85,75,0,0,14.8,7.8,1.7,0.5,31,63,3.4,0.89,M5,23.7,7.7,"46,XX,der(1)t(1;1)(p36.3;q21),t(8;16)(p11.2;p13.3),add(15)(q24)[20]",4853,96.7,"In 95/100 cells (95%), three  signals for chromosome 1q25 were observed, and only two signals for 1p36  were observed, consistent with gain of 1q by der(1)t(1;1)",144,"CD4, CD11b, partial CD13, CD33, CD56, bright CD64, partial CD117, CD123, HLA-DR and partial MPO-positive",6.6,95.49,negative,0,negative,,,TP53 (p.R175H; 55.0%),FLT3 (p.D835E; MAF 42%)|TP53 (p.R175H; MAF 43%)
17-00304,validation,Dead,633,BA3400D,BA3400R,2292,2254,Waves3+4,Waves3+4,no,no,no,no,Female,Female,Unknown,,,2,,,52,TRUE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,54,616,Relapse,Relapse,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)",3,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,7,Standard Chemotherapy,"MEC (Cytarabine, Etoposide, Mitoxantrone)",Salvage,-1,Dead,633,Dead-Disease,,,,,,,,,,,,,,M1,,,"46,XX[20]",,,"nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",,,,,negative,0,positive,,,,
17-00322,validation,Alive,900,BA3187D,BA3187R,2823,4468,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,White,,,8,,CBFB-MYH11,76,TRUE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,78,0,Relapse,Relapse,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine",3,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,Decitabine,Salvage,81,Alive,901,Alive,,10,,,,,,,,,,,,M4,42.5,14.6,"46,XY,inv(16)(p13.1q22.1) [16]/46,idem,del(7)(q32)[ 4]",,97.7,POSITIVE for CBFB gene locus rearrangement (separated by chromosome 16 inversion),47,,,13.3,negative,0,negative,,,,
17-00325,validation,Alive,119,BA3098D,BA3098R,2630,4470,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,White,,,3,,CBFB-MYH11,44,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,44,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)",Allogeneic - Matched Unrelated Donor,-1,Alive,119,Alive,,74.8,83,,,,,,,,,,,,,,"46,XY,der(7)t(7;11)(q22;q13), inv(16)(p13.1q22)[15]/46,XY[5]",,,"7cen (D7Z1), 7q31 (D7S486): deletion present | 11q23 (KMT2A; also known as MLL): gain present | 16q22 (CBFB): rearrangement present",23,,,102.09,negative,0,negative,,,,KIT (p.Tyr418_Arg420delinsArgTrpGly; MAF 10%)
17-00328,validation,Dead,289,BA3261D,BA3261R,2633,4472,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Female,White,NON-HISPANIC,,1,bi,,61,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated CEBPA,61,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,5,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Matched Unrelated Donor,-1,Dead,289,Dead-Treatment,0,40,25,0,0,27,0,46,0,30,14,3.9,0.84,M2,22.8,8.1,"45,X,-Y,del(11)(q12)[20]",,98.3,"95/100 cells (95%) had a single signal, consistent with the deleted 11q in the metaphase karyotype. There was no evidence for MLL rearrangement.",35,"CD7, partial CD13, dim CD33, CD34, CD28, CD58, CD71, CD117, HLA-DR and MPO ",6.9,4.17,negative,0,negative,,ASXL1 (p.A752Lfs*20; 43.9%),,"ASXL1 (p.A752fs*20; MAF 46%)|CEBPA (D105Vfs*64; MAF 45%)|CEBPA (H236Rfs*78; MAF 35%)|EP300 (p.R1627W ; MAF 46%)|IDH2 (p.R140Q, MAF 50%)|KMT2D (p.P647Q; MAF 43%)"
17-00337,validation,Dead,310,BA3203D,BA3203R,2767,4475,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,Unknown,HISPANIC,,6,,,62,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",62,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|HiDAC|3+7 (Cytarabine, Daunorubicin)",3,Allogeneic - Sibling|Consolidation|Induction,Refractory,Standard Chemotherapy,7,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Sibling,6,Dead,310,Dead-Disease,,35,39,1,,36,2,9,,83,69,2.8,0.99,,,7,,,102.9,The translocations commonly seen in AML are not detected. 3 copies of RUNX1T1 gene at 8q22 are detected in 56% of cells. Loss of RUNX1 and RARA genes at 21q22 and 17q21 are detected in about 58% of cells Gain of MLL gene at 11q23 are detected in 82% of cells. (Cytogenetics),50,"THESE ARE POSITIVE FOR HLA-DR, CD117, CD34, CD33 AND CD13. POSITIVE FOR HLA-DR, CD117, CD34, CD33 AND CD13. (Bone Marrow Immunnophenotype)",,44.8,negative,0,negative,,,TP53 (p.P153Afs*28; 75.8%),
17-00346,validation,Dead,283,BA3174D,BA3174R,2652,4479,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,,8,,,61,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,61,0,Residual Disease|Post-Chemotherapy,Residual,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,4,"Vidaza|7+3 (Cytarabine, Idarubicin)|Cytarabine, OXi4503|Velcade",3,Salvage|Induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,Velcade,Salvage,41,Dead,283,Dead-Disease,,14,,,,,,,,,,,,,26,9.2,"46,XY,del(5)(q13q33)[1]/4 7,idem,+21[14]/46,idem,id ic(21)(p12)[cp4]/47,idem, +21,idic(21)[1]",,81.5,POSITIVE for chromosome 5q copy number loss,34,,,6.5,negative,0,negative,RUNX1 (p.R107H; 59.2%),ASXL1 (p.E635Rfs*15; 24.3%),,
17-00360,validation,Alive,263,BA3299D,BA3299R,2608,4482,Waves3+4,Waves3+4,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,,6,,,47,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,47,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Busulfan, Fludarabine|HiDAC|3+7 (Cytarabine, Daunorubicin)",3,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Busulfan, Fludarabine",Allogeneic - Sibling,11,Alive,263,Alive,,70,,2.3,,18.3,72.7,6.2,,17,17,3.1,0.62,,,9.5,"46,XX[20]",,97.7,"An apparently NORMAL KARYOTYPE was observed in all 20 mitotic cells analyzed. Specifically, there was no significant numerical chromosomal abnormality and no clonal structural aberration of any chromosome detectable within the limits of resolution.  (Cytogenetics)",237,"positive for CD117, HLADR, CD33, CD11b, CD64 and MPO (partial).  (Bone Marrow Immunophenotyping)",,66.7,negative,0,positive,,,,
17-00423,validation,Alive,233,BA3347D,BA3347R,2708,4487,Waves3+4,Waves3+4,yes,yes,yes,yes,Female,Female,White,,,5,,,68,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,68,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"Venetoclax (ABT-199), Azacitidine",1,Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"Venetoclax (ABT-199), Azacitidine",Induction,-1,Alive,233,Alive,0,85,30,3,,35,21,11,,16,15,2.8,,M5,32.4,10.3,"46,XX[20] ",,,Normal,131,"Neagtive (CD10, CD19, CD16, CD14, CD34, CD117) | Bright Positive (CD64)",5.2,22,negative,0,positive,,,,DNMT3A (c.2311T>C; p.R771X; MAF 40%)|NPM1 (c.863_864insTCTG; p.W288fs; MAF 38%)|TET2 (c.2827C>T; p.Q943X; MAF 80%)
17-00436,validation,Dead,360,BA3235D,BA3235R,2194,4240,Waves3+4,Waves3+4,no,no,no,no,Female,Female,Multiracial,HISPANIC,,1,,,46,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,47,168,Residual Disease|Post-Chemotherapy|Post-Transplant,Residual,Peripheral Blood,y,y,y,y,y,y,4,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s),7,"Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Methotrexate",6,Allogeneic - Sibling|Consolidation|Induction|Experimental|CNS|Re-induction,Complete Response i,Standard Chemotherapy,-1,Targeted Therapy - Kinase Inhibitor(s),Dasatinib,Experimental,-1,Dead,360,Dead-Disease,,,,,,,,,,,,,,,,,"46,XX,t(10;16)(q22;q24)[cp12]/46,sl,t(1;4)(q41;q33),t(7;9)(p15;q32)[5]/46,sl,t(X;1)(q23;q44)[2]/46,sl,der(1)t(1;2)(p32;q32)t(1;15)(q23;q24),der(2)t(1;2)(p32;q32),der(15)t(1;15)(q23;q24)[1]",,,,,,,,positive,15.6666666666667,positive,,,,FLT3-ITD (ITD; MAF 60%)
17-00438,validation,Alive,733,BA3126D,BA3126R,2686,4491,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,,1,,KMT2A_re,66,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,66,2,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,5,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Mismatched Unrelated Donor,-1,Alive,1580,Alive,0,61,,0,1.5,3.6,87.8,7.1,0.2,22,39,1.7,1.52,M5,24.4,7.8,"46,XY[20]",607,87.8,MLL: 86% of cells had a split signal pattern consistent with MLL rearrangement.,14,"CD11b, CD13, CD14, CD33, bright CD64, HLA-DR and partial MPO-positive ",5,67.35,negative,0,negative,,,,FLT3 (p.D835Y; MAF 35%)
17-00442,validation,Dead,864,BA3089D,BA3089R,2219,2538,Waves3+4,Waves3+4,no,no,no,no,Male,Male,White,NON-HISPANIC,,1,,,67,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,68,429,Post-Chemotherapy|Residual Disease,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other,5,"AG-120|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC",5,Consolidation|Salvage|Induction|Experimental|Allogeneic - Mismatched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Mismatched Unrelated Donor,-1,Dead,864,Dead-Other,0,75,68,1.7,0,17.4,0.9,12.2,0,21,22,3.4,0.9,M4,40.6,13.6,"46,XY[20] ",,95.8,Normal,91,"CD7, CD13, CD33, CD38, CD58, CD117, CD123, partial MPO+ ",6.4,20.31,negative,0,positive,,,,"DNMT3A (p.R882H; MAF 46%)|FLT3 (p.V592D; MAF 39%)|IDH1 (p.R132H, MAF 39%)|IDH2 (p.R140Q; MAF 39%)|NPM1 (p.W288fs*12; MAF 41%)|NRAS (p.Q61P; MAF 40%)|SETBP1 (p.K459E; MAF 40%)"
17-00444,validation,Dead,93,BA3114D,BA3114R,2631,4513,Waves3+4,Waves3+4,no,no,no,no,Female,Female,White,NON-HISPANIC,,8,mono,,75,FALSE,FALSE,TRUE,FALSE,FALSE,y,Endometrial cancer|Lobular carcinoma in situ,y,n,n,n,y,y,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,75,0,Post-Chemotherapy,Remission,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)",1,Induction,Unknown,Standard Chemotherapy,4,Standard Chemotherapy,"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)",Induction,4,Dead,93,Dead-Disease,,,,,,,,,,,,,,,,,"46,XX[20]",,,Normal (Clonal aberrations were not identified in metaphase cells examined by conventional cytogenetic techniques* or for any loci examined by FISH methods.),,,,,negative,0,positive,,,,CEBPA (biallelic)|NPM1|PTPN11|TET2
17-00446,validation,Dead,24,BA3418D,BA3418R,2824,4515,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,Asian,NON-HISPANIC,,8,,GATA2-MECOM,72,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,72,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Refractory,Standard Chemotherapy,7,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,7,Dead,24,Dead-Disease,,50,,,,,,,,,,,,,29.3,10.3,"45-46,X,-Y,t(3;3)(q21;q26 .2),del(4)(q12),-5,del(6) (q21),del(9)(q22),del(11) (p11.2),ins(15;5)(q12;p15 .2p15.2),add(16)(q22),-17,-20,-21,-22,+mar1-5[c p18]/ 46,XY[2]",,85.5,,40,,,2.2,negative,0,negative,,,,
17-00464,validation,Alive,345,BA3423D,BA3423R,2605,4533,Waves3+4,Waves3+4,yes,yes,yes,yes,Female,Female,,HISPANIC,,6,,,49,FALSE,FALSE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,50,0,Residual Disease|Post-Chemotherapy,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Unknown,Standard Chemotherapy,28,Standard Chemotherapy,HiDAC,Consolidation,114,Alive,345,Alive,,90,96,,,2,1,2,,43,32,3.7,0.67,,,8.7,,,84.8,,78,"Positive for CD34, CD117, HLADR, CD33 and CD13.  (Bone Marrow Immunophentyping)",,19,negative,0,positive,,,,FLT3-TKD
17-00467,validation,Dead,412,BA3171D,BA3171R,2719,4535,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,,1,,,55,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,55,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine|Busulfan, Cyclophosphamide",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,9,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Matched Unrelated Donor,-1,Dead,402,Dead-Treatment,0,60,,0,6.8,19.7,20.5,15.4,1.5,,,,,M4,29.8,9.6,"43,XY,dic(5;12)(q11.2;p13),der(7)t(7;13)(q11.2;q12),i(8)(q10),+9,dup(11)(q2  3q23),-13,-15,-16,der(17)t(15;17)(q22;q23),-21,+mar[20]/46,XY[5] ",,101.4,"RUNX1T1/RUNX1:  86/100 cells (86%) reflecting the isochromosome 8q and the monosomy 21.  No evidence for RUNX1T1/RUNX1fusion | EGR-1/ D5S23, D5S721:  89/100 cells (89%) consistent with missing 5q in the dicentric 5;12 | PML/RARA:  Signal patterns were within normal limits with no evidence for  PML/RARA fusion.  One metaphase cell shows the PML (15q22) signal on the derivative 17, consistent with the metaphase karyotype | BCR/ABL/ASS:  72/100 cells (72%) consistent the trisomy 9 in the metaphase karyotype.  No evidence  for BCR/ABL fusion.  | D7S486/ CEP 7:  79/100 cells (79%) consistent with missing 7q in the derivative 7 | DEK/NUP:  79/100 cells (79%) reflecting the trisomy 9 in the metaphase karyotype.  No evidence for  DEK/NUP fusion. | MLL:  61/100 cells (61%) had three intact MLL signals. One metaphase cell  shows two signals on the duplicated 11q.  There was no evidence for MLL rearrangement.",21,"CD11c, CD13, CD33, CD34, CD38, CD56, CD64, CD117, HLA-DR; negative TdT, CD19 and CD10 (from bmbx 5/3/17)",,17.99,negative,0,negative,,,TP53 (p.X125_splice; 75.0%),KRAS (p.G12D; MAF 35%)|TP53 (Splice site (5' splice site mutation in intron 4); MAF 69%)
17-00478,validation,Alive,211,BA3277D,BA3277R,2818,4539,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,,5,,,65,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,65,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"Venetoclax (ABT-199), Azacitidine",1,Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,"Venetoclax (ABT-199), Azacitidine",Induction,-1,Alive,211,Alive,0,66.5,37,2,,24,6,31,,23,25,2.6,,M4,26.3,8.1,"46,XY[20] ",,,Normal,101,"positive (CD38 dim, CD33 dim, CD45 dim, CD117 var, MPO var) | negative (CD10, CD19, CD20, CD22, CD23, Surf Kappa, Surf Lambda, FMC7, CD3, CD5, CD7, CD56, CD13, CD14, CD15, CD34) | PP (CD11b VAR, CD64 VAR, HLA-DR VAR)",6,8.6,negative,0,positive,,,,IDH2 (c. 419G>A; p.R140Q; MAF 47%)|NPM1 (C.863_864insTCTG; p.W288fs; MAF 34%)|SRSF2 (c. 284C>A; p.P95H; MAF 47%)
17-00485,validation,Alive,717,BA3157D,BA3157R,2614,4544,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,,1,,,60,FALSE,FALSE,FALSE,FALSE,FALSE,y,Basal Cell Carcinoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,60,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"HiDAC|3+7 (Cytarabine, Daunorubicin)|Busulfan, Cyclophosphamide",3,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Sibling,-1,Alive,1425,Alive,0,87,83,0,0,13.4,0.8,8.3,0.3,125,74,2.3,0.79,M1,26.3,9.2,"46,XY,del(9)(q13q22)[20]",823,89.5,Normal,146,"CD13, CD33, variable CD34, CD38, CD58, CD117,  CD123, HLA-DR, variable MPO",6.1,23.32,negative,0,positive,,,,NPM1 (p.W288fs*12; MAF 41%)|NRAS (p.G13D; MAF 41%)|SF3B1 (p.T663I; MAF 50%)
17-00491,validation,Alive,215,BA3433D,BA3433R,2681,4545,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,,,,5,,,63,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,63,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,2,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin) plus Midostaurin",2,Allogeneic - Sibling|Induction,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Sibling,-1,Alive,215,Alive,0,92,96,0,,3,0,1,,30,16,3.3,,M0,24.8,8.5,"46,XY[20]",,,Normal,51,"negative (CD19, CD22, CD7, CD11b, CD13, CD14, CD15, CD34, CD64, HLA-DR) | Dim (CD38, CD45) | Positive (CD56, CD33, CD117, MPO)",6.5,52.1,negative,0,positive,,,,FLT3 (c.1818_1819ins26; p.P606_R607insCREYEYDLKWEFP; MAF 7%)|NPM1 (c.863_864insTCTG; p.W288fs; MAF 45%)|TET2 (C.3379C>t; p.Q1127X; MAF 44%)
17-00499,validation,Dead,316,BA3374D,BA3374R,2617,4548,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,,1,,KMT2A_re,21,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,21,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Intrathecal,6,"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC|Venetoclax (ABT-199), Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Methotrexate",3,Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,4,Standard Chemotherapy,"Venetoclax (ABT-199), Azacitidine",Salvage,26,Dead,316,Dead-Disease,0,91,90,0,0,27.3,0,2.7,0,70,152,2.2,1.35,M5,19.9,6.8,"47~49,XY,+8[cp13]/46,XY[7]",2767,96.6,RUNX1T1/CEP8: 140/200 cells (70%) reflect the trisomy 8 in the metaphase karyotype; 20 cells (10%) reflect extra centromere signals only. It is possible the G-banded cell with two small markers reflects a small clone containing extra copies of a derivative chromosome 8. | MLL: 88/100 cells (88%) had a variant. A green signal appears on the short arm of a chromosome 10 with a red/small green signal retained on the chromosome 11q. It is unclear whether the material translocated disrupts MLL.,54,"CD4, partial CD11b, CD13, CD33, dim CD22, CD34, variable CD56, variable CD64, CD117, HLA-DR, dim PAX5+",5.5,55.69,negative,0,negative,,,,KRAS (p.G13R; MAF 37%)|U2AF1 (p.S34F; MAF 39%)
17-00514,validation,Alive,162,BA3167D,BA3167R,2704,4557,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,,2,,MLLT3-KMT2A,38,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with t(9;11)(p22;q23); MLLT3-MLL,38,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,HiDAC,Consolidation,-1,Alive,162,Alive,,94,55,,,,,,,,,,,,,,"46,XY,t(9;11)(p22;q23),inv(9)(p11q12)",,,,,,,25.29,negative,0,negative,,,,BCOR (D1006fs*16)|FLT3-D835|MLL (MLL-MLLT3 (AF9) Fusion)
17-00551,validation,Dead,37,BA3226D,BA3226R,2734,4573,Waves3+4,Waves3+4,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,,1,,,75,FALSE,FALSE,FALSE,FALSE,FALSE,y,Breast Cancer,y,y,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,75,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,37,Dead-Disease,0,73,79,0,0,11.4,1.8,7.9,0.4,42,41,2.8,0.66,M2,22.9,7.5,"46,XX[20]",,97.9,Normal,45,"dim CD11b, CD13, CD33, partial CD34, partial CD38, dim CD45, partial CD64, CD58, partial CD117, CD123 and partial MPO positive",6.9,88.2,positive,0.96078431372549,positive,,,,FLT3-ITD (MAF 44%)
17-00556,validation,Alive,181,BA3421D,BA3421R,2659,4575,Waves3+4,Waves3+4,yes,yes,yes,yes,Female,Female,White,,,5,,,52,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,52,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),3,"7+3 (Cytarabine, Idarubicin) plus Midostaurin|Midostaurin|Busulfan, Cyclophosphamide",3,Allogeneic - Sibling|Induction|Maintenance,Complete Response,Standard Chemotherapy,-1,Targeted Therapy - Kinase Inhibitor(s),Midostaurin,Maintenance,13,Alive,181,Alive,,,,,,,,,,,,,,,,,,,,Normal/Negative Rearrangement,,,,,positive,0.724137931034483,positive,,,,"DNMT3A (MAF 47%)|FLT3-ITD (2 on separate alleles: p.E604_F605insYDLKWE, MAF 19%; p.L601_K602ins18, MAF 9%)|NPM1 (MAF 44%)"
17-00613,validation,Dead,370,BA3232D,BA3232R,2714,4592,Waves3+4,Waves3+4,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,,1,,,36,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,36,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,4,Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Other,6,"Azacitidine, Sorafenib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Busulfan, Cyclophosphamide|Cytarabine, Methotrexate",5,Allogeneic - Sibling|Induction|Experimental|Re-induction|Maintenance,Complete Response,Standard Chemotherapy,-1,Targeted Therapy - Other,SY-1425 (Tamibarotene) plus Daratumumab,Experimental,28,Dead,370,Dead-Disease,0,30,40,0,9.6,13.9,0.9,36.5,0.1,14,25,3.5,0.77,M4,13.3,4.6,"46,XX[20]",,100,Normal,58,"dim CD7, partial CD11b, variable CD13, CD33, CD64,  CD117, dim CD123, dim HLA-DR and partial MPO positive",6.6,59.05,positive,0.265822784810127,positive,,,,BCOR (p.V89D; MAF 54%)|DNMT3A (p.R882H; MAF 51%)|FLT3-ITD (MAF 15%)|NPM1 (p.W288fs*12; MAF 48%)|NRAS (p.G12S; MAF 20%)
17-00634,validation,Alive,177,BA3289D,BA3289R,2677,4603,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,White,,,5,,,61,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,61,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s),3,"7+3 (Cytarabine, Idarubicin)|Midostaurin|Fludarabine, Cyclophosphamide, Thiotepa, TBI",3,Induction|Double Umbilical Cord Blood Transplant (DUCBT)|Supportive/Palliative Care,Complete Response,Standard Chemotherapy,-1,Bone Marrow Transplant,"Fludarabine, Cyclophosphamide, Thiotepa, TBI",Double Umbilical Cord Blood Transplant (DUCBT),-1,Alive,177,Alive,,65,,,,,,,,,,,,M0,,,,,,Normal,179,,,111.5,positive,0.587301587301587,negative,,,,DNMT3A|FLT3-ITD|TET2
17-00641,validation,Dead,1003,BA3145D,BA3145R,2523,1813,Waves3+4,Waves3+4,no,no,no,no,Male,Male,White,NON-HISPANIC,,2,,DEK-NUP214,74,FALSE,FALSE,FALSE,FALSE,FALSE,y,Prostate Cancer,y,y,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,77,979,Post-Chemotherapy|Residual Disease,Residual,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Targeted Therapy - Other,3,"Crenolanib|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Azacitidine, Pracinostat",2,Induction|Maintenance,Complete Response,Standard Chemotherapy,-1,Targeted Therapy - Other,Crenolanib,Maintenance,433,Dead,1003,Dead-Disease,,,,,,,,,,,,,,,,,"47,XY,t(6;9)(p23;q34),+8[13]/48,idem,+13[4]/46,XY[3]",,,"DEK-NUP214 fusion; MAF unavailable (DEK-NUP214 fusion; MAF unavailable) | nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[198], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[17/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]",,,,,positive,,negative,,ASXL1 (p.G645Vfs*58; 10.5%),,DNMT3A (F827fs*4)|FLT3-ITD
17-00676,validation,Dead,1,BA3449D,BA3449R,2609,4627,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,,8,,GATA2-MECOM,55,FALSE,FALSE,TRUE,FALSE,FALSE,n,,y,n,y,y,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1,55,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,2,Vidaza|Decitabine,2,Salvage|Supportive/Palliative Care,,,,Standard Chemotherapy,Decitabine,Salvage,-1,Dead,1,Dead-Disease,,80,67,,,,,,,,,,,,30.1,10.4,"49,XY,dup(1)(p22.1p32.1), inv(3)(q21.3q26.2),+8,+12 ,+21[20]",,83.7,POSITIVE for RUNX1T1 and RUNX1 copy number gains,31,,,43.7,negative,0,negative,RUNX1 (p.R76Pfs*62; 66.7%),,,
17-00678,validation,Alive,721,BA3384D,BA3384R,2736,4624,Waves3+4,Waves3+4,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,,1,,KMT2A_re,39,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute myelomonocytic leukaemia,39,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,4,DLI|Standard Chemotherapy|Bone Marrow Transplant|Other,7,"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Radiation|Busulfan, Cyclophosphamide",5,Consolidation|Unknown|Induction|Maintenance|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,7,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1,Alive,1512,Alive,0,>90,90,0,0,9.7,28.3,0,0,,,2.4,0.57,M4,20.5,6.7,"47,XX,del(11)(q23),+21[20]",540,109.6,"MLL:  97/100 cells (97%) had a 0 red/ 1 green/ 1 yellow signal pattern,  partially deleting the MLL region of 11q23 and consistent with the deleted 11q in the metaphase karyotype. | RUNX1T1/RUNX1:  95/100 cells (95%) had a 2 red/ 3 green signal pattern, consistent with the trisomy 21 in the metaphase karyotype. There was no evidence for RUNX1T1/RUNX1fusion.",12,"partial CD11b, dim CD13, CD33, partial CD34, variable CD64, CD117, CD123, HLA-DR+ ",,173.2,negative,0,negative,RUNX1 (p.P49T; MAF 69%),,,MLL (Possible subclone with partial tandem duplication)|RUNX1 (p.P49T; MAF 69%)
17-00685,validation,Dead,62,BA3163D,BA3163R,2638,4629,Waves3+4,Waves3+4,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,,1,,MLLT3-KMT2A,43,FALSE,FALSE,FALSE,FALSE,FALSE,y,Breast Cancer,y,y,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,43,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,Azacitidine|Mitoxantrone,2,Induction|Supportive/Palliative Care,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,Mitoxantrone,Supportive/Palliative Care,0,Dead,62,Dead-Disease,0,80,55,0.9,2.5,8.5,61,25.4,0.3,198,685,2.7,1.18,M5,34.2,11.4,"46,XX,t(9;11)(p22;q23)[15]/47,idem,+8[2]/46,XX[3]",5919,99.1,"MLL:  57/100 cells (57%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting MLL (11q23) rearrangement, consistent with the 9;11  translocation observed in the metaphase karyotype. | RUNX1T1/RUNX1:  6/200 cells (3%) had a 3 red/ 2 green signal pattern,  reflecting an extra RUNX1T1 (8q21.3) signal, consistent with the trisomy 8  clone observed in the metaphase karyotype. | CEP 8:  5/200 cells (2.5%) had three signals, reflecting an extra  chromosome 8 centromere signal, consistent with the trisomy 8 clone observed in the metaphase karyotype.",120,"dim CD4, CD11b, CD13, partial CD14, CD33,  CD38, variable CD56, CD58, CD64, dim CD71, dim CD123, and HLA-DR+",5,91.72,negative,0,negative,,,,DNMT3A (Splice site mutation (invariant splice donor at end of exon 14; likely pathogenic); MAF 20%)
17-00687,validation,Alive,0,BA3158D,BA3158R,2646,4631,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,,,,3,,RUNX1-RUNX1T1,68,FALSE,FALSE,FALSE,FALSE,FALSE,y,Non-Hodgkins Lymphoma,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,68,0,Initial Acute Leukemia Diagnosis|Post-Chemotherapy,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,,,,,,,,,,,,,,Unknown,0,,,90.8,,,,,,,,,,,,,,,"46,XY,t(8;21)(q22;q22)[8]46,sl,del(9)(q13q22)[4]/47,sdl,+21[2]/47,sl,+21[4]/46,XY[2] ",,,"This analysis showed evidence of t(8;21)(q22;q22) (RUNX1T1-RUNX1 translocation) in 196/200 (98.0 percent) cells scored. Of these cells, 20/200 (10.0 percent) showed the translocation accompanied by an additional copy of the RUNX1 locus. ",,,,27.1,negative,0,negative,,,,
17-00690,validation,Alive,527,BA3436D,BA3436R,2755,4633,Waves3+4,Waves3+4,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,,1,mono,,23,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,23,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,5,"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|FLAG-IDA, Gemtuzumab|Busulfan, Cyclophosphamide",4,Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Matched Unrelated Donor,-1,Alive,1510,Alive,0.9,80,,0,0,11.6,0,10.7,0.3,17,7,3,0.68,M1,26.7,8.9,"46,XX[8]",145,90.8,Normal,54,"CD13, CD33, partial CD34, CD38, CD58, dim CD71, CD117,  CD123, and cMPO+ ",6.9,29.58,negative,0,positive,,,,CEBPA (p.A199fs*114; MAF 50%)|EZH2 (p.R288*; MAF46%)|GATA2 (p.A372T; MAF 31%)|NPM1 (p.W288fs*12; MAF 50%)
17-00694,validation,Dead,256,BA3154D,BA3154R,2768,4635,Waves3+4,Waves3+4,yes,yes,yes,yes,Female,Female,White,,,7,,,29,FALSE,FALSE,FALSE,FALSE,FALSE,y,Breast Cancer,y,n,n,n,n,n,n,n,ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE,"Mixed phenotype acute leukaemia, B/myeloid, NOS",Adverse,ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE,"Mixed phenotype acute leukaemia, B/myeloid, NOS",29,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,256,Dead-Other,,95,,,,,,,,,,,,,,,"30~35<1n>,XX,+1,+2,+6,+10,+11,+12,+18,+19,+21,+22[cp6]/46XX[20]",,,Negative for 9;22 and MLL,,"positive for dim CD2 (aberrant), CD11b (aberrant), CD13, CD33, CD34, CD38, CD117, HLA-DR, and dim nTdT (aberrant)",,,negative,0,negative,,,TP53 (p.V122Dfs*26; 87.5%),CREBBP|NF1|TP53
17-00741,validation,Alive,99,BA3162D,BA3162R,2740,4641,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,White,,,2,,CBFB-MYH11,20,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,Favorable,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,20,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"7+3 (Cytarabine, Idarubicin)|HiDAC",2,Consolidation|Induction,Complete Response,Standard Chemotherapy,-1,Standard Chemotherapy,HiDAC,Consolidation,-1,Alive,99,Alive,,50,,,,,,,,,,,,,,,"46,XY,inv(16)(p13.1q22)[20]",,,Evidence of a CBFB [inv(16)] gene rearrangement in 98% of the cells.,16,"CD2(-), CD4(-), CD5(-), CD7(-), CD8(-),CD10(-), CD11b(dim +), CD13(dim +),CD14(dim +), CD15(dim+CD16(-), CD20(-), CD22(-), CD25(dim +), CD33(dim +), CD34(+), CD38(+), CD36(subset +), CD56(-), CD64(subset +), CD79a +)(-), CD123(dim +), MPO(dim +), TdT(-), and surface kappa lambda light chain(-).,",,68.59,negative,0,positive,,,,KIT (Y418_R420>RW; MAF 10.2%)|NRAS (G12s; MAF45.4%)
17-00755,validation,Dead,22,BA3352D,BA3352R,2699,4654,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,White,,,2,,,73,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,73,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,Refractory,Standard Chemotherapy,-1,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,-1,Dead,22,Dead-Disease,,90,94,,,,,,,,,,,,,,"46,XY[20]",,,Normal,,"CD34(-), CD13(predominantly -), CD33(+), CD38(partial +), CD45(dim +), CD56(variably +), CD64(partial dim +), CD117(+),HLA-DR(-), MPO(+), TdT(-), other myeloid and lymphoid antigens(predominantly -).",,64.4,positive,1.22222222222222,positive,,,,
17-00770,validation,Dead,5,BA3169D,BA3169R,2662,4664,Waves3+4,Waves3+4,yes,yes,yes,yes,Female,Female,White,,,5,,KMT2A_re,88,FALSE,FALSE,FALSE,FALSE,FALSE,y,Uterine Sarcoma,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Therapy-related myeloid neoplasms,88,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,5,Dead-Disease,,80,24,,,,,,,,,,,,,,"47,XX,+8[4]/47,sl,add(10)(q22)[10]/89~94,sdlx2[cp3]/55,sl,+X,+6,+8,+ 8,+9,+13,+21,+22[2]/46,XX[1]",,,MLL (KMT2A) rearrangement in 94% of 200 cells | gain of 8q22 sequence in 94% of 200 cells,,"positive for CD11b, dim CD7, CD13, CD14, CD33, CD38, CD15, CD45, CD56, CD64 and HLA-DR",,23.4,negative,0,positive,,,,
17-00776,validation,Dead,272,BA3255D,BA3255R,2725,4666,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,,1,,,55,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with mutated NPM1,55,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,4,"7+3 (Cytarabine, Idarubicin)|HiDAC + Midostaurin|Decitabine, Sorafenib |Busulfan, Cyclophosphamide",4,Allogeneic - Sibling|Consolidation|Salvage|Induction,Complete Response,Standard Chemotherapy,6,Standard Chemotherapy,"Decitabine, Sorafenib ",Salvage,61,Dead,272,Dead-Disease,0,90,80,0,2.6,9.6,22.6,5.2,0.4,21,25,3,0.9,M0,22.3,7.4,"46,XY[20] ",1037,85.8,Normal,234,"dim partial CD4, dim partial CD7, dim CD11b, CD13, CD33,  partial CD34, CD38, CD58, dim CD71, CD117, CD123 and HLA-DR+ ",7.7,118.21,positive,3,positive,,,,DNMT3A (Splice site (start of intron 18; likely pathogenic); MAF 47%)|FLT3-ITD (p.E598delinsDYVDFREYE; MAF 60%)|NPM1 (p.W290fs*10; MAF 45%)|WT1 (p.D464N; MAF 46%)
17-00779,validation,Dead,65,BA3438D,BA3438R,2834,4673,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,,1,,KMT2A_re,53,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,53,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Standard Chemotherapy,2,"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)",2,Induction|Re-induction,Refractory,Standard Chemotherapy,6,Standard Chemotherapy,"5+2 (Cytarabine, Idarubicin)",Re-induction,4,Dead,65,Dead-Disease,3.5,95,,1.7,,69.8,0.9,15.5,4.5,30,24,3.3,0.87,M1,25.1,8.4,"47,XY,der(5)t(5;17)(q12;q12),+8,+15,der(15)t(11;15)(q22;q24)dup(11)(q25q22)  ,del(16)(q22q24),-17,der(20;21)(p10;q10),+mar[16]/46,idem,der(10)t(10;11)(q  25;q23)t(5;11)(q12;q25),-mar[3]/46,XY[1] ",399,88.4,"EGR1:  90% of cells were missing a signal for EGR1 (5q31), consistent with  the der(5) seen on metaphase analysis.  | MLL (11q23):   97% of cells had two normal intact signals and a many other  intact signals per cells, suggesting amplification.  (On available metaphase  cells, there was clustering of amplified fused signals on two chromosomes:  in the first clone, amplified signals clustered on the der(15) and on the  marker chromosome; in the second clone, amplified signals clustered on the  der(15) and on the der(10).) | CBFB (16q22):   94% of cells were missing a signal for CBFB, consistent  with del(16q) as seen on metaphase. | RUNX1/RUNX1T1+CEP8: 92% of cells had three signals for chromosome 8 probes (CEP8 and RUNX1T1) and only one signal for RUNX1 (21q22), consistent with trisomy 8. Results with the RUNX1 probe on chromosome 21 suggest that the interpretation of the chrom results as der(20;21) may be more complicated.",23,"CD4, dim CD20, dim CD11b, CD13, CD33, CD34, CD38, CD58,  variable CD64, partial dim CD117, MPO",6.8,3.81,negative,0,negative,,,TP53 (p.R248Q; 80.3%),MLL |TP53 (p.R248Q; MAF 82%)
17-00843,validation,Alive,52,BA3341D,BA3341R,2628,4682,Waves3+4,Waves3+4,yes,yes,yes,yes,Female,Female,White,,,2,,,62,FALSE,TRUE,FALSE,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",62,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Targeted Therapy - Other,1,Enasidenib,1,Induction,Refractory,Targeted Therapy - Other,-1,Targeted Therapy - Other,Enasidenib,Induction,-1,Alive,52,Alive,,48,26,,,,,,,,,,,,,,"46,XX,del(7)(q22q32)[cp4]/46,XX[16]",,,Evidence of deletion of the BCR (22q11.2) gene in 7% of the cells examined.,,,,,negative,0,negative,,,,DNMT3A|IDH2 (p.172Arg>Lys)|KMT2A
17-00851,validation,Alive,562,BA3448D,BA3448R,2752,4688,Waves3+4,Waves3+4,yes,yes,yes,yes,Female,Female,White,NON-HISPANIC,,1,,KMT2A_re,27,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with minimal differentiation,27,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|7+3 (Cytarabine, Idarubicin)|HiDAC",3,Allogeneic - Sibling|Consolidation|Induction,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501),Allogeneic - Sibling,-1,Alive,1455,Alive,0,90,85,0,0,30.2,0,0,0,23,16,2.2,0.81,M0,25.5,8.3,"46,XX,t(6;11)(q27;q23)[25] ",496,91.1,"MLL:  92/100 cells (92%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting MLL rearrangement and consistent with the 6;11  translocation observed in a companion bone marrow G-banded chromosome  study. One metaphase cell showed the 6;11 rearrangement.",16,"CD13 , CD33 , partial CD34 , CD38 , CD58 , CD64 , CD71 , CD117 , CD123 and HLA-DR positive",5.5,22.95,negative,0,negative,,,,KRAS (p.G12D; MAF 16%)|MLL (PTD)
17-00862,validation,Alive,30,BA3406D,BA3406R,2796,4691,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,,,,3,,,33,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",33,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,1,Standard Chemotherapy,1,"7+3 (Cytarabine, Idarubicin)",1,Induction,UNKNOWN,Standard Chemotherapy,6,Standard Chemotherapy,"7+3 (Cytarabine, Idarubicin)",Induction,6,Alive,30,Alive,,69,28,,,,,,,,,,,,,,"46, XY[20]",,,Normal,70,,,4.52,positive,0.492537313432836,negative,,,,BCOR (p.G1n1626; MAF 62.2%)|FLT3-ITD (p.Glu598_Tyr599ins9)|WT1 (p.Arg370fs; MAF 27.7%)
17-00867,validation,Dead,319,BA3308D,BA3308R,2772,4692,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,,1,,,78,FALSE,FALSE,TRUE,FALSE,FALSE,n,,n,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,78,0,Post-Chemotherapy|Residual Disease,Residual,Bone Marrow Aspirate,y,y,y,y,y,y,2,Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s),4,AG-221|Imatinib|Midostaurin|Interferon,3,Salvage|Maintenance|Supportive/Palliative Care,,,,Targeted Therapy - Kinase Inhibitor(s),AG-221,Salvage,191,Dead,319,Dead-Disease,,,,,,,,,,,,,,,,,"47,XY,del(6)(q13),+8[8]/47,idem,-8,+13[2]/46,XY,del(13)(q14q22),del(20)(q11.2)[6]/46,XY[4] ",,,"RUNX1T1:  22/200 cells (11%) had a 3 red/ 2 green signal  pattern, reflecting an extra RUNX1T1 (8q21.3) signal, consistent with the  trisomy 8 clone observed in the metaphase karyotype | RUNX1: 18/200 cells (9%) had a 2  red/ 3 green signal pattern, reflecting an extra RUNX1 (21q22) signal.  The  extra chromosome 21 material was not apparent in the G-banded karyotype.  There was no evidence for RUNX1T1/RUNX1 fusion. | CEP8:  29/200 (14.5%) cells  scored with the CEP 8 probe had three signals, consistent with trisomy 8.  | D20S108/20p subtel:  6/200 cells (3%) had a 1 red/ 2 green signal pattern,  consistent with the deleted 20q in the metaphase karyotype. ",,,,,negative,0,negative,RUNX1 (p.R162S; 84.5%),ASXL1 (p.G646Wfs*12; 34.3%),TP53 (p.X187_splice; 9.3%),IDH2 (p.R140Q; MAF 45%)|KRAS (p.Q61R; MAF 5%)|NOTCH1 (p.P2412L; MAF 57%)|RUNX1 (p.R162S; MAF 74%)|SRSF2 (p.P95H; MAF 54%)|TP53 (Splice site; MAF 9%)
17-00878,validation,Dead,980,BA3186D,BA3186R,2743,4701,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,White,NON-HISPANIC,,1,,,68,TRUE,FALSE,TRUE,FALSE,FALSE,n,,y,n,n,n,n,n,y,y,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,NonInitial,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,AML with myelodysplasia-related changes,70,0,Relapse|Post-Chemotherapy|Post-Transplant,Relapse,Peripheral Blood,y,y,y,y,y,y,3,Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care,3,"Fludarabine, Melphalan|Azacitidine|MiDAC",3,Symptom Control|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor,,,,Bone Marrow Transplant,"Fludarabine, Melphalan",Allogeneic - Matched Unrelated Donor,-1,Dead,980,Dead-Disease,0,79,56,0,0,14.6,4.5,8.2,2.6,31,58,2.9,0.69,,33.5,11.8,"45,XY,add(3)(p22),-7,t(8;22)(q11.2;q11.2),add(11)(q23),-13,-15,-16,  der(17)t(7;17)(q11.2;p11.2),+3mar[cp3]/44~46,sl+der(8)t(8;21)(q11.2;q11.2),  -18[cp15]/44,sl,-add(3)(p22),+10,+13,+15,-18,-3mar[2] ",3293,92.5,"MLL:  97/100 cells (97%) had the variant abnormal 0 red/ 1 green/1 yellow  signal pattern, reflecting MLL (11q23) rearrangement and previously  observed.  | TP53/CEP 17:  99/100 cells (99%) had a 1 red/ 2 green signal pattern,  reflecting TP53 deletion, previously observed and consistent with the  derivative 17 in the metaphase karyotype. | RUNX1T1/RUNX1:  93/100 cells (93%) had a 2-3 red/ 3-4 green signal pattern,  reflecting an extra copies of RUNX1T1 and RUNX1.  There was no evidence for  RUNX1T1/RUNX1 fusion.  | CBFB:  96/100 cells (96%) had a single intact signal, reflecting CBFB  (16q22) loss and consistent with the monosomy 16 in the metaphase  karyotype.  | D7S486/ CEP 7:  99/100 cells (99%) had a 2 red/ 1 green signal pattern,  indicating loss of a chromosome 7 centromere signal with 7q material  attached to the derivative 17 in the metaphase karyotype.  | CEP 8:  66/100 cells (66%) had three signals, consistent with the clone  having an extra copy of the derivative 8. ",28,"dim CD4, dim CD7, dim CD33, CD34, dim CD56, CD58, dim  CD123, CD117 and HLA-DR positive",,49.48,negative,0,negative,,,TP53 (p.R248W; 71.9%),JAK2 (p.V617F; MAF 88%)|SF3B1 (p.G740V; MAF 41%)|TET2 (p.E692fs*8; MAF 40%)|TP53 (p.R248W; MAF 78%)
17-00881,validation,Alive,47,BA3334D,BA3334R,2640,4703,Waves3+4,Waves3+4,yes,yes,yes,yes,Female,Female,White,,,2,,,76,FALSE,TRUE,FALSE,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",76,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Bone Marrow Aspirate,y,y,y,y,y,y,1,Targeted Therapy - Other,1,Entospletinib,1,Experimental,,,,Targeted Therapy - Other,Entospletinib,Experimental,-1,Alive,47,Alive,,,,,,,,,,,,,,,,,,,,Normal,,,,,negative,0,negative,,ASXL1 (p.C687Yfs*30; 45.2%),,ASXL1|FLT3 (N841K)|SRSF2|STAG2
17-00901,validation,Alive,553,BA3094D,BA3094R,2660,4712,Waves3+4,Waves3+4,yes,yes,yes,yes,Male,Male,White,UNKNOWN,,1,,KMT2A_re,23,FALSE,TRUE,FALSE,FALSE,FALSE,n,,y,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,Adverse,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,Acute monoblastic and monocytic leukaemia ,23,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,2,Standard Chemotherapy|Bone Marrow Transplant,3,"7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide",3,Consolidation|Induction|Allogeneic - Matched Unrelated Donor,Complete Response,Standard Chemotherapy,6,Bone Marrow Transplant,"Busulfan, Cyclophosphamide",Allogeneic - Matched Unrelated Donor,-1,Alive,1386,Alive,0,95,85,0,0,12.4,0.9,1.8,0,68,83,2.8,0.78,M5,25.5,8.6,"46,XY,der(10)t(10;11)(p13;q23),der(11)t(10;11)(p13;q23)inv(11)(q13q23)[20]",2144,87.9,"MLL:  60% of cells had a split signal pattern consistent with MLL rearrangement. On available metaphase cells, there was a distal signal on chromosome 10p and the proximal signal was close to the chromosome 11 centromere, consistent with t(10;11) and inv(11), as seen on chromosome analysis.",56,"CD4, variable CD13, CD33, CD38, variable CD56, CD58,  CD64, dim CD71, dim CD117, dim CD123 and HLA-DR+ ",7.7,98.29,negative,0,negative,,,,NRAS (p.G12A; MAF 4%)|NRAS (p.Q61H; MAF 30%)
17-00915,validation,Dead,16,BA3216D,BA3216R,2632,4722,Waves3+4,Waves3+4,yes,yes,yes,yes,Female,Female,White,,,5,mono,,73,FALSE,TRUE,FALSE,FALSE,FALSE,n,,n,n,n,n,n,n,n,n,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",Intermediate,ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS,"Acute myeloid leukaemia, NOS",73,0,Initial Acute Leukemia Diagnosis,Initial Diagnosis,Peripheral Blood,y,y,y,y,y,y,0,,0,,0,,,,,NONE,NONE,NONE,,Dead,16,Dead-Disease,,85,79,,,,,,,,,,,,,,,,,,44,,,123.2,positive,0.428571428571429,negative,,,,FLT3-ITD (suspicious for D835 as well)
